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Advanced prostate cancer (PrC) is the second leading cause of death from cancer in US 
males. Advanced PrC cells are initially androgen-sensitive and thus androgen ablation therapy 
causes tumors to undergo regression and fall into a remission phase where residual cells remain 
dormant while androgen levels remain very low. Unfortunately, this phase usually lasts 3 to 5 
years prior to tumor relapse, where the tumor cells re-grow in the absence of androgens. This 
form of the disease is aggressive and invariably fatal.   
In this study, we investigated the effects of a combination of herbal extracts on various 
stages of PrC, androgen-dependent and castrate-resistant, using CWR22 and CWR22Rv1 cells, 
respectively. Zyflamend, a commercially available product consisting of 10 different herbal 
extracts, had been shown to reduce pre-malignant forms of PrC in clinical trials. We expanded 
these earlier experiments by using Zyflamend in a model of advanced PrC. Our initial results 
indicated that Zyflamend could repress androgen-sensitive and castrate-resistant (androgen-
insensitive) prostate tumor growth.  Using a cell model for castrate-resistant PrC, Zyflamend 
inhibited the growth of CWR22Rv1 cells by increasing the expression of the cell cycle inhibitors 
p21 and p27. These effects were mediated via hyperacetylation of histone 3 through the 
suppression of class I and II histone deacetylases (HDACs) and an induction of CBP/p300 
histone acetyl transferase activity. The latter effect was mediated by the upregulation/activation 
of Erk-1/-2 and Elk-1.  Zyflamend also inhibited androgen receptor expression, its downstream 
gene target, prostate specific antigen (PSA), and increased cell death by inducing apoptosis as 
indicated by caspase 3 activity and PARP cleavage. The reduction of androgen receptor was 




combination inhibits castrate-resistant prostate cancer cell growth epigenetically and by 
coordinately affecting androgen receptor signaling pathways involved in cell growth/death.  
In an androgen-dependent PrC tumor xenograft model, Zyflamend reduced the growth of 
CWR22-derived tumors and enhanced the responsiveness of tumor cells to hormone ablation. 
Zyflamend potentiated the regression of PrC cells and their sensitivity to androgen deprivation. 
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Prostate cancer is the most commonly diagnosed solid malignancy and in the last few 
years the incidence of prostate cancer has risen dramatically and become the second leading 
cause of cancer-related deaths in men in the United States and most developed countries (1-3).  
Progression of prostate cancer is a long process, and it often needs decades to develop 
into a clinically relevant disease. Prostatic intraepithelial neoplasia (PIN) is characterized by 
increased cellular irregularity and abnormal tissue morphology. Development of PIN takes 
~twenty years, with another 10 years to progress to cancer (4). The incidence of prostate cancer 
increases dramatically from the fifth decade of life (5.3-14%) to the ninth decade (40-80%). The 
disease is diagnosed by monitoring the blood levels of prostate specific antigen (PSA) and with a 
tissue biopsy (5). At the early stages, the tumor is considered “low-grade” (Gleason grade 1-3). 
After three to fifteen years, early stages of the disease will progress to more advanced forms 
(Gleason grade 4-5) (6), eventually metastasizing to secondary sites, such as bone. 
Metastatic prostate cancer can be defined by four phases.  The first phase is androgen-
dependent growth. In this stage, cancer cells are sensitive to the male hormone known as 
androgen and therapy often involves the removal of testosterone. Hormone ablation therapy by 
blocking the androgens/ androgen receptor activation leads to the regression of tumor. The 
second phase is characterized by regression following hormone deprivation. Following 
regression, the disease is considered to be in remission and this stabilization phase (Phase III) 
typically last between 3-5 years. During this time, blood PSA, a protein produced by prostate 
epithelial cells, is regularly measured to monitor the disease progression.  The fourth phase is the 




androgens. The relapsed tumor is remarkably aggressive and death occurs within one to two 
years (Figure 1.1). 
Epidemiologic studies suggest that multiple factors, including high fat diet, family history, 
age and high serum androgens, affect the incidence of prostatic cancer and its mortality (7, 2, 8). 
In this study, we are interested in the effects of dietary compounds on the advanced prostate 
cancer progression by blocking cell proliferation using androgen-dependent and androgen-
independent prostate cancer cell lines. The dietary compounds used in this study are a mixture of 
herbal extracts, Zyflamend®; some of the herbal extracts have been shown to have anti-cancer 
properties in vitro and in vivo studies (9-15). Therefore, a combination of these herbal extracts 
might have a universal effect on inhibiting cancer cell growth through multiple pathways.   
 
 




1.1  Actions of androgen 
In the eighteenth century, John Hunter was the first to reveal testicular function, and one 
hundred years later, Arnold Bechter reported the relationship between the behavior and 
physiological castration to a substance secreted by the testis into the plasma. In 1889, Charles 
Edouard Brown-Séquard isolated the extract derived from dog and guinea pig testis. Forty-five 
years later, Leopold Ruzicka and colleagues isolated the testicular hormone and named it 
testosterone. One year later, testosterone was artificially synthesized by Butenandt and Hanish 
(16). Nowadays, testosterone is one of many compounds in a group of male steroid hormones 
called androgens, including androstenedione, dehydroepiandrosterone and testosterone.  
Androgens are important steroid hormones in males playing many physiological roles, 
including differentiation and maturation of the male sexual organs and contributing to male 
secondary sex characteristics (17).  Androstenedione is produced in the adrenal glands and 
converted into testosterone in testis Leydig cells and peripheral tissue and it can be metabolized 
to estradiol by the action of aromatase. Dehydroepiandrosterone is produced in the adrenal 
cortexand is also synthesized de novo in brain (18). It is metabolized to androstenedione and 
androstenediol prior to their conversion to testosterone. Testosterone biosynthesis in testicular 
Leydig cells declines with age and these changes are related to increased expression of  
cyclooxygenase-2 and the decrease expression  of steroidogenic acute regulatory protein (19) 
(20). The production of testosterone is regulated by feedback of luteinizing hormone (LH) and 
luteinizing hormone-releasing hormone (LHRH) of the gonad-hypothalamus-pituitary axis. 
Testosterone, the major circulating androgen in humans, diffuses into cells and is converted to 




androgen receptor (AR) or a nuclear receptor (estrogen receptor) and further binds to hormone 
responsive elements such as androgen responsive elements and/or estrogen responsive elements 
to activate related gene transcription and stimulation of insulin growth factor- I (IGF-I) 
expression (21), and stimulating proliferation of  prostate cancer epithelial cells (17). 
In addition to androgen receptor, it is found that testosterone binding to a sexual hormone 
binding globulin (SHBG) or an androgen binding proteins (ABP) (22). A complex of testosterone 
and binding proteins bind to membrane testosterone
 
binding sites and this association initiates a 
rapid action (seconds~minutes) involving endocytosis (23), and the actin cytoskeleton, ion-
channels (TRPM8 (24)) and transporters affecting intracellular Ca
2+
 fluxes (25). This rapid 
association recruits heterotrimeric guanine nucleotide-binding proteins (G-proteins) and 
stimulates the downstreat signal transduction including PI3K, Ras and Src pathways (26-27).  
In summary, the action of androgen signaling can be divided into two groups, direct 
steroid action, and indirect steroid action, described as the “Mannheim classification” (28). In the 
direct steroid action, membrane vesicles, fluidity and permeability as well as rapid responses 
would be changed without cell membrane receptors. In the indirect steroid action, the action of 
the steroids, requiring steroid receptors such as intracellular androgen receptors and SHBG 
receptors, mediate the activation of cAMP/PKA and induce AR and AR-related genes expression 
such as prostatic specific antigen (PSA) (29), and enhance phosphorylation of AR (30-31) and 
activation of Ras/Raf-1/Erk (32) and Ras/PI3K (33).  
Whether androgen functions through an intracellular receptor (AR)-mediated pathway or 
through a rapid response-signal transduction pathway, they promote prostate cancer cell 




1.2  Hormone ablation therapy in androgen-dependent advanced prostate cancer   
Androgen-dependent prostate cancer cells require the presence of androgens for growth. 
In 1941, Huggins and Hodges observed that malignant tumors arising from the prostate gland 
were partially responsive to the withdrawal of androgens and this led to the hormonal 
management of prostate cancer. This finding provided the solid basis for advanced prostate 
cancer treatment (34). Androgen deprivation therapy (ADT) is considered one of the first-line of 
treatments for men with high-grade, clinically localized prostate cancer who undergo 
radiotherapy (35) or metastatic prostate cancer (36). There are various methods to achieve 
testosterone ablation. Primary hormone ablation therapy includes maximal androgen deprivation 
(MAD) (also known as maximal androgen blockage, MAB). Maximal androgen deprivation 
refers to a combination of androgen suppression (AS) and anti-androgen therapy using 
luteinizing hormone-releasing hormone (LHRH) agonists to achieve medical castration and non-
steroidal anti-androgens, such as flutamide, to inhibit tumor growth and increase 5-year survival 
rates (37).  
Following primary therapy, the patients are monitored by measuring PSA levels as an 
indicator of tumor growth. If chemical relapse should occur (increasing PSA levels), patients 
could receive secondary hormone therapy. Secondary hormone ablation therapy 1) inhibits the 
production of adrenal androgens using corticosteroids, ketoconazole or liarozole and 
aminoglutethimide; 2) involves androgen receptor blockade using steroidal anti-androgens, such 
as cyproterone acetate, or non-steroidal anti-androgens, such as flutamide; 3) or involves 
estrogen therapy, using transdermal estradiol (38). Castrate-resistant prostate cancer (CRPC) is 




independent /hormone refractory and eventually fatal. 
1.3  Androgen-independent prostate cancer 
Approximately 90% of advanced prostate cancer patients response to hormone 
ablation therapy (HAT); however, most still suffer tumor relapse within 5 years (42-43). 
Relapsed tumor cells can survive in the absence of androgens resulting in tumors that are 
unresponsive to treatment with an invariably fatal outcome. The mechanism of resistance to 
androgen withdrawal is being investigated. One of the mechanisms targets androgen 
signaling. During androgen deprivation, the loss of androgen appears to be a form of stress 
that may transform cells to derive from androgen-dependence to androgen-independent 
growth (44). There are several pathways leading to androgen-independent prostate cancer 
(in the absence of androgens). These pathways have been reviewed by Pienta KJ  et al. (45) 
and Feldman BJ et al (46) and are summarized below.   
1.3.1 The hypersensitive pathway 
To survive in an environment of low levels of androgens, prostate cancer cells develop 
castration-resistance, as opposed to androgen independence, by increasing expression and 
sensitivity of androgen receptors, and by increasing 5α-reductase activity (47-48) to compensate 
for the low levels of androgens. Following hormone ablation therapy, 30% of recurrent prostate 
cancers have amplified androgen receptor gene expression with no amplification in primary 
tumor (49). In addition to an induction of androgen receptor, androgen receptor sensitivity  is 
increased (lowering threshold) along with an increase in receptor stability (50), increasing the 




levels decrease by 90%, but the level in prostate tissue is only reduced by 60% in compensation 
for the decline of testosterone in the circulation (47). The genes involved in steroid biosynthesis, 
such as HMG-CoA synthase, squalene synthetase, squalene mono-oxygenase, and lanosterol 
synthase have been found to be increased in recurrent human prostate carcinoma (51). 
1.3.2 The promiscuous pathway 
Most of the prostate cancer cells that are androgen-independent have been found to 
express androgen receptor. Some of prostate tumor cells develop amplified androgen signaling 
by increasing androgen receptor expression, androgen receptor sensitivity and local androgen 
production; other prostate tumor cells develop mutations on androgen receptors associated with 
alterations of co-regulators (52-53). Forty-four mutations of the androgen receptor have been 
identified, and twenty of those mutations had gain of function. Five of the twenty gain of 
function mutants had promiscuous activity that enhanced the activation of androgen receptor by 
non-androgenic steroid and anti-androgen molecules (52). The enhancement of androgen 
receptor promiscuous pathways can also be achieved through an induction of co-regulators such 
as cAMP response element-binding protein (CREB)-binding protein (CBP). The increasing 
androgen receptor activity and co-regulators promotes cancer cell survival against anti-androgen 
molecules (54).  
1.3.3 The outlaw pathway 
Androgen receptor signaling can be activated by outlaw receptors in a ligand-independent 
mechanism. IGF-1/IGF-1R has been shown to activate androgen receptor in the absence of 




mutant androgen receptors are unable to bind DNA but can potentiate membrane tyrosine kinase 
signaling, such as activation of the Src-Erk1/2 pathway and induction of IGF-1R expression (56). 
Epidermal growth factor (EGF) has been found to activate the androgen receptor (55) and 
cytokines, including IL-6, has been shown to induce androgen synthesis (57). 
1.4  The animal models of prostate cancer research 
The development of prostate cancer takes many decades and the disease is very diverse in 
humans. This is a limitation in studying prostate cancer.. Therefore, identifying a suitable animal 
model would be a helpful tool to study this disease. The development of animal models of 
prostate cancer is important for the investigation of improved therapeutic strategies and to 
identify underlying molecular mechanisms in the event of effective intervention. Over the last 30 
years, many rodent models have been developed, mimicking different physiological stages of 
prostate cancer progression. There are rodent models that study the disease as it forms 
spontaneously, or where prostate cancer is induced and xenograft models where human prostate 
cancer cells are grown subcutaneously in immune-compromised mice. Other models study pre-
malignant forms of the disease (prostatic intraepithelial neoplasia, PIN), carcinomas, and 
metastasized tumors, in addition to models that are sensitive and insensitive to androgens (Table 
1.1). These models show that 1) androgens are necessary for most prostatic carcinomas, 2) most 
advanced prostatic carcinomas eventually develop androgen-independence, and 3) advanced 
prostatic carcinomas metastasize to regional lymph nodes or distant organs such as bones and 
liver (58).  However, it should be recognized that no single model can represent the diversity of 




1.4.1 Rodent models 
There are two major categories of rodent models when studying prostate cancer; one is 
the spontaneous rodent model and the other is the induced rodent model. Of the spontaneous 
rodent models, the Dunning rat model (59) is the most common and widely used model in 
nutritional studies (60). This model has identified some critical genes importatnt in the prostate, 
such as CD44. The Dunning R-3337 is derived from Dunning rat model and develops well 
differentiated adenocarcinomas. Sublines of Dunning R-3337 have a variety of characteristics of 
the disease being either highly metastatic or involving AR deficiency (61). ACI/Seg and Lobund-
Wister rat models have also been used for nutritional studies for the progression of the disease. 
ACI/Seg rat model has a long lifespan with an age-related incidence of cancer, but the tumor 
does not metastasize. The Lobund-Wister rat model develops prostate adenocarcinomas that 
metastasize to the lung. This model has androgen-dependent properties in early stages of the 
disease but becomes androgen-independent thereaftere. In a N-methyl-N-nitrosourea 
(MNU)/testosterone propionate (TP) system, prostate adenocarcinomas can be induced by MNU, 
followed by a promotion with TP (62). Fisher F334 and Noble rats are rodent models whose 
prostate tumors are induced by carcinogens. The tumors formed in these two models are 
androgen dependent and non-invasive.  
On the other hand, transgenic mouse models have the advantage of studying the effects of 
targeted genes on initiation, promotion, and progression of prostate cancer, providing a useful 
tool for therapeutics. For example, the TRAMP (transgenic adenocarcinoma mouse prostate) 
model has been used to study of the effects of post castration, oncogenes, and the role of IGF 




cells of the rat prostate. PB is regulated by androgens, showing a similar PSA expression pattern 
as that of humans. The TRAMP model has a high incidence for the development of prostatic 
adenocarcinomas, with no metastasis. To study the progression from low grade PIN to high grade 
PIN, and development to invasive adenocarcinoma, C3(1)/SV40 transgenic mouse model 
containing a well characterized androgen-driven prostatic steroid binding protein (PSBP). This 
C3(1)/SV40 transgenic mouse model supports the idea that PIN is a precursor of carcinomas of 
the prostate (63).   
Knockout mouse models provide an advantage when studying targeted gene alterations 
on prostate cancer progression. In patients with early stages of prostate cancer, deletions of Pten 
and Nkx3.1 have been identified (64-65) and thus a heterozygous of Pten and Nkx3.1 double 




mice develop invasive 
adenocarcinomas accompanied by metastasis to lymph nodes after one year. After treatment of 
high-grade PIN with androgen ablation in these the mice, the prostate cancer cells exhibit 
androgen-independent properties (66-67) mimicking relapsed patients on hormone ablation 
therapy.  
1.4.2 Xenograft model 
The above models are based on rodent prostatic tumor cells, not human prostatic tumor 
cells. In order to study human prostate cancer in rodent models, athymic nude mouse xenograft 
models have been developed using cell lines derived from human prostate cancer. These human 
cells are derived from the tumors of prostate cancer patients and are transplanted into immune-
deficient mice. A xenograph model using androgen-sensitive PC-82 cells (established in 1977) 




cell lines, PC-133 and PC-135, were established. (68). Since then, there are more than 25 
xenograft models of human prostate cancer (61). In 1993, Pretlow‟s group from Case Western 
Reserve reported the initial use of the CWR22 prostate cancer cell line (69). This human cell line 
was derived from a primary tumor and is highly androgen dependent. When grown in a 
xenograph model, tumor regression occurs following androgen deprivation. Relapses to an 
androgen-independent line, CWR22R occurs in 30-50% of the animals within 3-10 months of 
castration (69). Microarray analysis has been identified changes (cutoff >2.5 fold) between 
CWR22-derived androgen-dependent tumors, and the CWR22R-derived androgen-independent 
tumors. Thirteen genes that increased were associated with thyroid hormone receptor signaling 
and cell surface receptors; 44 genes were decreased (70). In addition, mutations of hAR signaling 
of the CWR22 cell line has been reported with a mutation in the ligand-binding domain of the 
hAR gene which can be transcriptionally activated by testosterone, dihydroxytestosterone (DHT), 
dehydroepiandrosterone (DHEA), estradiol, progesterone, and the anti-androgen 
hydroxylflutamide (71). This AR mutation is found in relapsed prostate cancer patients, and in 
the CWR cell line series of androgen-independent xenograft models (CWR22, CWR22R, and 
CWR91). As such, these models have been used for the evaluation of drug therapy (72). 
Other xenograft models can be generated using various cell lines, such as androgen-
dependent LNCaP cell line and androgen-independent PC3 and DU145 cell lines. These models 
are widely used to study the androgen dependent and androgen-independent stages of prostate 










Features of cancer 
Spontaneous rodent model 
ACI/Seg rat >33 mo No ND 




>26 mo lung AD in early 
stage; then 
AID 
High grade PIN 
Dunning rat 2 mo lung AID rapid growth and rapid 
metastasis 
Induced rodent model 
Lobund-Wister 
(Pollard) rat 
10.5 mo lung, liver AD in early 
stage; then 
AID 
three types of cancer develop: 
moderately to poor 
differentiated prostatic 
adenocarcinoma, 
hepatocellular carcinoma, and 
lung carcinoma 
Fisher F334 rat 20 wk No AD when 
DMAB 
followed 





Noble 44 wk rare AD 100% of rats develop PIN and 
then CaP by testosterone 
treatment for 16 wk and for 44 
wk, respectively 




AD 10% incidence of metastasis in 
one yr 
ND: no determined; NE: neuroendocrine; AD: AR dependent; AID: AR independent; WT: 











Features of cancer 
Transgenic mouse model 
Probasin- SV40 T 
antigen (TRAMP) 






variable progressive disease restricted 






 10-22 wk No AD invasive adenocarcinoma 







AID progressive prostate disease 
with epithelial and NE feature 
C3(1)-SV40 T 
antigen 
8-28 wk rare ND invasive adenocarcinoma 
C3(1)-polyomavirus 
middle T 
11 wk No ND invasive adenocarcinomas 
Cryptdin-SV40 T 
antigen 




AID NE-derived progressive 
prostate disease  
Pten, Nkx3.1 mutant 
mice 









CaP cell lines 
Origin AD/AI AR PSA 
CWR22 prostate AD mutant positive 
LAPC-3 prostate AID WT positive 
LAPC-9 bone AD WT positive 
LuCaP 23.1 lymph 
node 
AD N/A positive 
LuCaP 23.12 liver AD N/A positive 
MDA Pca-31 liver N/A positive positive 
PC-82 prostate AD WT positive 
PC-329 prostate AD WT positive 




1.5  The cell model of prostate cancer research 
To study the underlining mechanisms of prostate cancer progression, cell models have 
been developed that mimic various stages of prostate epithelial cells, normal and neoplastic, 
including those cells that are androgen-dependent and androgen-independent (Table 1.2). 
Different cell lines are thought to represent different characteristics of the disease. For example, 
a mutation of the androgen receptor has been found in LNCaP cells and this mutation results in 
the substitution of alanine for threonine at position 877 (T877A) (75). The same mutation was 
observed in metastatic tumor tissues from six out of twenty-four patients (76) and was also 
observed in bone marrow metastatic tissues from 5 out of sixteen patients receiving combined 
androgen blockage and flutamide (77), indicating this mutant form of the androgen receptor is 
common in patients. Therefore, LNCaP cells can potentialy become androgen independent. The 
use of LNCaP cells to mimic the transition of androgen dependence to androgen independence 
has been widely used to study the signaling mechanisms and genotypes during prostate cancer 
progression after androgen deprivation.  
MDA PCa 2b is an androgen dependent cell line that was derived from a tumor that 
metastasized to bone. MDA PCa 2b cells have an androgen receptor mutation (T887A and 
L701H) and this mutation reduces the binding affinity of androgen. Although  MDA PCa 2b cells 
are  less sensitive to androgens, they can still respond to androgens and produce PSA (78).  
Similarly, androgen receptor mutation was also found in CWR22 cells at position 874 
(substitution of tyrosine for histidine) in the ligand binding domain at c-terminus. This mutation 




PC3 and DU145 cells are the most common cell lines used to study the mechanisms of 
androgen-independent cell/tumor growth. However, these two cell lines do not express an 
androgen receptor and do not produce PSA, two key components associated with advanced and 
metastatic prostate cancer. It is believed that expression/activation of androgen receptor plays an 
important role in the resistance to hormone ablation therapy and contributes to the transformation 
of androgen-dependent to androgen-independent cell growth. Therefore, the use of these two cell 
lines are unable to address the role of the androgen receptor in the disease.  
CWR22Rv1 cells are derived from relapsed CWR22 cells and are castrate-resistant cells. 
CW22Rv1 cells can survive in the absence of androgen but can still respond to androgen 
stimulation. Androgen receptor is expressed by CWR22Rv1 cells and PSA is produced in the 
presence of androgen. CWR22Rv1 cells express two isoforms of androgen receptor; one is a 
114-kDa protein and other one is a 75~80-kDa protein. The two isoforms have been identified. 
The 114-kDa protein has a duplication of exon 3 encoding zinc finger domain of the androgen 
receptor DNA-binding site, while the truncated protein lacks the ligand-binding domain (LBD) 
in COOH-terminus, referred to as ARΔLBD (80), these two isoforms do not exist in parental 
CWR22 cells. The in-frame androgen receptor regulates endogenous androgen-dependent gene 
expression and the truncated androgen receptor promotes cell proliferation in a ligand-
independent manner. The two isoforms of androgen receptor is constitutively expressed and are 
active following hormone deprivation. Because of these characteristics of androgen receptors 
expressed in CWR22Rv1 cells, CWR22Rv1 cells have advantages when studying the 
progression of prostate cancer during the refractory state and can serve as a model to understand 




such, CWR22Rv1 cells were the cell model of choice for the in vitro and in vivo studies in this 












immortalized prostate cells 
RWPE-1 CRL-11609 normal No epithelial  + AD  + 
RWPE-2 CRL-11610 normal Yes epithelial  + AD  + 
PWR-1E CRL-11611 normal No epithelial  + AD  + 
PZ-HPV-7 CRL-2221 normal No epithelial  + AID  - 
WPE1-NA22 CRL-2849 normal Yes epithelial  + AD  + 
WPE1-NB14 CRL-2850 normal Yes epithelial  + AD  + 
WPE1-NB11 CRL-2851 normal Yes epithelial  + AD  + 
WPE1-NB26 CRL-2852 normal Yes epithelial  + AD  + 
RWPE2-W99 CRL-2853 normal Yes epithelial  + AD  + 
WPMY-1 CRL-2854 normal No stroma  + AD  + 
WPE-stem CRL-2887 normal No peripheral zone  + AID  + 
WPE-int CRL-2888 normal No peripheral zone  + AD  + 
WPE1-NB26-64 CRL-2889 normal Yes peripheral zone  + AD  + 
WPE1-NB26-65 CRL-2890 normal Yes peripheral zone  + AD  + 
prostate cancer cells 
LNCaP CRL-1740 carcinoma Yes left 
supraclavicular 
lymph node 
 + AD  + 
CA-HPV-10 CRL-2220 adenocarcinoma No epithelial  + AD  + 
MDA PCa 2b CRL-2422 adenocarcinoma Yes bone  + AD  + 
VCaP CRL-2876 cancer Yes vertebral 
metastasis 
 + AD  + 
NCI-H660 CRL-5813 small cell carcinoma lymph node AN
PR 
AID N/A 
        
PC-3 CRL-1435 adenocarcinoma Yes bone  - AID  - 
DU-145 HTB-81 carcinoma Yes brain  - AID  - 
22Rv1 CRL-2505 carcinoma Yes epithelial  + AID  + 





1.6  Cellular mechanisms of prostate cancer 
The progression of prostate cancer is a long process and the mechanism is complicated. 
The mechanisms involved in tumorigenesis include promotion of cell growth, metastasis and 
angiogenesis, as well as inhibition of cell death. The regulation of proliferative mechanisms is 
influenced by the surrounding environment, such as factors in circulation, i.e., cytokines and 
growth factors, such as IGF-1 and androgens, and the influence of nearby tissues, i.e. fibroblast, 
and other stimuli, i.e. hypoxia. These mechanisms are discussed as below.   
1.6.1 Cell growth 
Cancer progression is associated with the deregulation of cell growth and cell death. 
In cancer cells, the signal transduction of cell proliferation is up-regulated. For example, 
cell cycle promoting regulators such as cyclin dependent kinases (CDKs) are induced and 
cell cycle suppressors such as the retinoblastoma (Rb) family and p53 are inhibited, thereby 
continuing cell division. In addition, cell death signal pathways are inhibited and thus 
cancer cells escape apoptosis, and the growth of cancer cells is promoted. To support tumor 
cell growth, formation of new blood vessels provide sufficient nutrients and oxygen for 
survival and channel cells from local areas to more distance sites, i.e. bone, in most prostate 
cancer patients (81).    
1.6.1.1  Cell cycle arrest 
Cell growth and division is tightly regulated by cell cycle progression. Cell cycle 
stages are defined as Gap 0 (G0), Gap 1 (G1), Synthesis (S), Gap 2 (G2) and Mitosis (M) 




cell division is halted and for transition to the G1 phase. In the G1 phase, the cell is enlarged 
and the production of mRNA and protein is increased in preparation for DNA synthesis.  
There is an important cell cycle mechanism regulated during this period which is G1 
checkpoint. G1 checkpoint, a point of transition of the G1 and S phases, decides whether the 
cell continues to the S phase or remains resting in the G0 phase. In tumor cell progression, 
the G1 checkpoint is a critical regulatory stage. G1 checkpoint is negatively regulated by 
cyclin dependent kinase inhibitors (CDKIs) including Cip/Waf family (p21, p27 and p57) 
and INK4 family (p15, p16, p18, p19) and by tumor suppressor genes such as retinoblastoma 
(Rb) and p53. Members of the Cip/Waf family bind cyclin/cyclin dependent kinase 
complexes and disrupt the catalytic activity of CDKs (CDK4/6 and CDK2) on cyclins 
(cyclin D and cyclin E). Disruption of CDKs inhibits DNA polymerase, thymidine kinase 
and hydrofolate reductase, all required for DNA synthesis in the S phase. The Rb family is 
another major regulator of the G1 phase through the Rb/E2F pathway. E2F is a transcription 
factor that binds the promoter region of many genes, such as DNA polymerase subunits, cyclin A 
and cyclin E, allowing the initiation of DNA synthesis and progression to the S phase. E2F is 
inhibited by Rb to form a Rb/E2F complex in the cytosol; however, E2F is released from the 
complex when Rb becomes hyper-phosphorylated by the cdk–cyclin complex (82). In prostate 
cancer patients, most of the CDKIs, p21, p27 and p16 and Rb, are repressed by genetic and 
epigenetic regulation (83).  
The second checkpoint of the cell cycle is at S phase where the cells replicate DNA.  
The S phase checkpoint is regulated through ataxia telangiectasia mutated (ATM)/ATM and 
Rad3-related (ATR)-checkpoint1 (chk1)-cell-division-cycle 5A (cdc25A) (ATM/ATR-chk1-




chromosomes protein 1 (SMC1) (ATM-Nbs1-SMC1) pathways. DNA damage stimulates 
phosphorylation of Ser/Thr kinases, checkpoint kinases 1 and 2 (chk1 and chk2), by ATM or 
ATR. Activated chk1/2 phosphorylates the serine sites of cdc25A phosphatase, the inactive 
form, thereby reducing the activity of cyclin E and Cdk2. The inactive cyclin E/Cdk2 is  
incapable of phosphorylating Cdc45, disrupting DNA replication (84). ATM-Nbs1-SMC1 
also regulates the S phase checkpoint. This pathway is induced by ionizing radiation. ATM 
phosphorylates SMC1 at S957 and S966 sites, which recruits a phosphorylated Nbs1 as an 
adaptor (85). The ATM-Nbs1-SMC1 pathway is distinct from the ATM/ATR-chk1-cdc25A 
branch, but it is still required for the activation of the S phase checkpoint.  
The third checkpoint is G2/M checkpoint initiating the DNA repair before entering 
into the mitosis. Activation of the G2/M checkpoint is induced by ATM/ATR-chk1-cdc25A. 
cdc25A phosphatase is inactivated by chk1/2 and binding to 14-3-3 proteins. The 14-3-
3/cdc25A complex translocates into the cytoplasm followed by degradation. Therefore, the 
downstream complex, cdk1/cyclin B1, cannot be activated and the structure of chromosome 
remains tight, arresting the cell cycle (86).  
Checkpoints deregulate cell cycle progression and allow unlimited cell proliferation. 
Most cancer treatments focus on enhancing the function of the checkpoints through 
radiation therapy or deprivation of hormones or chemotherapies, thereby inducing DNA 
damage and activating ATM/ATR pathways, as well as inducing expression of cell cycle 





1.6.1.2  Cell apoptosis 
Cell apoptosis was termed “programmed cell death” (PCD), which is a form of cell 
suicide. The mechanisms of programmed cell death have been identified and include 
autophagy, paraptosis, mitotic catastrophe and apoptosis (87). Apoptosis is more specifically 
defined as a progress of cell death mediated by caspases through intrinsic and extrinsic 
pathways. Apoptosis occurs following the removal of growth factors or growth stimulating 
hormones, i.e. fibroblast growth factor or androgens, and the exposure of cytotoxic 
chemicals or pro-apoptotic ligands, such as TRAIL (TNF-related apoptosis-inducing ligand), 
activating the caspase cascade.  
Caspase cascade includes intrinsic or extrinsic pathways (88). The intrinsic pathway, 
also called the mitochondrial pathway, and is initiated by intracellular stress, DNA damage. 
Double-strand DNA damage stimulates ATM (ataxia-telangiectasia-mutanted) activation and 
induces the expression of the tumor suppressor gene p53. p53 is an important negative 
regulator of the cell cycle and promotes the expression of pro-apoptotic proteins (e.g. puma, 
Bax, apaf-1, FasL and DR5) (89). Puma (p53 upregulated modulator of apoptosis, a member 
of pro-apoptotic Bcl-2 family) inhibits the association of anti-apoptotic protein Bcl-2, Bcl-x 
and pro-apoptotic protein Bax and Bak. Therefore, free Bax and Bak translocate to the outer 
membrane of the mitochondria, enhancing the release of cytochrome c and Smac/DIABLO 
(Second Mitochondria-derived Activator of Caspases/Direct IAP Binding Protein with Low PI) 
into the cytoplasm (90). Cytochrome c, Apaf-1 and pro-caspase 9 form an apoptosome, a 
complex of proteins formed in the process of apoptoisis. In the apoptosome, pro-caspase 9 




6 and 7 and IAPs (inhibitors of apoptosis). Smac/DIABLO inhibits IAPs through physical 
interaction, and therefore negatively affects caspase activity (91). Active effectors (caspase 
3, 6 and 9) initiate the death substrates, PARP and Gas2 (92), resulting in apoptosis. 
The extrinsic pathway is induced by apoptosis-induced ligands, such as FasL/CD95L 
and TRAIL, binding to the pro-apoptotic membrane receptors and decoy receptors. Once 
activated, the death domain of the receptor recruits the adapter molecules such, as FADD (Fas-
associated death domain) and the initiators, pro-caspases 8 and 10, forming a DISC (death-
inducing signaling complex). By proteolytic processing, initiator caspase 8 and 10 is active and 
activates caspase 9 following the activation of caspase 3, 6 and 7. Initiator caspase 8 and 10 
cleave Bid to form tBid (truncated Bid). tBid associated with Bax and Bak forms a channel on 
the mitochondrial outer membrane (MOM) and increases MOM permeabilization, releasing pro-
apoptotic proteins, such as cytochrome c. Intrinsic apoptosis is initiated (90, 93).  
1.6.2 Metastasis 
Metastasis is a process whereby cancer cells relocate to the secondary sites, such as 
lymph nodes, lung or bone. In this process, it is involved in angiogenesis, migration and 
invasion. While the tumor mass is increasing, angiogenic molecules are generated by the 
tumor cells and stromal cells to stimulate new vessel formation. The tumor cells change 
their morphology and secrete proteinases to pass through the surrounding barrier and enter 






1.6.2.1  Angiogenesis 
Angiogenesis is a process of new blood vessel formation. In tumors, new vessel 
formation provides a mechanism to supply sufficient nutrients, oxygen and pro-
tumorigenetic factors to the cancer cells and to remove waste form the cell cluster. In 
addition, new vessel formation is critical for tumor metastasis. During tumorigenesis, 
angiogenesis occurs in different stages of tumor development, including premalignant 
lesions and malignancy, and allows tumor progression, thereby increasing tumor mass. This 
process is initiated by angiogenic molecules generated by the cancer cells and also by the 
stroma under environmental stimuli, such as hypoxia. Angiogenic molecules include 
vascular endothelial factor (VEGF), platelet-derived growth factor (PDFG), placental growth 
factor (PlGF), angiopoietin-1 (ANG1) and basic fibroblast growth factor (bFGF). VEGF is 
one of the most ubiquitous molecules for angiogenesis and released not only from the cancer 
cells, but also by fibroblasts and inflammatory cells such as macrophages. VEGF has an 
important role in new vessel formation by promoting the growth of vascular endothelial 
cells (ECs) and is also a survival factor for ECs by preventing cell death (94). The 
expression of VEGF is upregulated by various growth factors, including insulin-like growth 
factor-1 (IGF-1), PDGF and bFGF, suggesting that the release of VEGF is coordinately 
regulated by local hypoxia and growth factors in the microenvironment (95).    
In prostate cancer, VEGF and endoglin (a protein that is involved in vascular 
remodeling) expression were detected in 50 radical prostatectomy specimens, categorized by 
Gleason score. VEGF correlated significantly with angiolymphatic invasion and Gleason score 




stage, and preoperative prostate-specific antigen level (P < 0.05). Expressions of VEGF and 
endoglin were correlated with shorter survival times (96). In addition, serum levels of VEGF 
were significantly higher in the metastatic prostate cancer patients compared to patients with 
localized tumors (97). These results indicated that the pro-angiogenic molecule, VEGF, was 
associated with prostate cancer cell metastasis and progression.  
One of the activators of VEGF is hypoxia-inducible factor 1α (HIF-1α). HIF-1α is a 
transcription factor and is induced by hypoxia while the tumor mass is increasing. Under a low 
oxygen environment, the repressor of HIF-1α, von Hippel-Lindau (VHL), is released from the 
HIF-1α-VLH complex (98), resulting in activation of HIF-1α, allowing it to bind to genes such 
as VEGF. Overexpression of HIF-1α was observed  in prostate malignancy and non-malignant 
prostate tissues compared with the normal prostate (99). This is consistent with elevated 
expression of VEGF in prostate cancer and increases in the degree of neovascularization with 
tumor stage.    
1.6.2.2  Migration and Invasion 
The translocation of tumor cells as a result of the formation of new vessels, angiogenesis, 
requires the ability to pass through a multilayer barrier composed of pericytes, base membrane, 
fibroblast and endothelial cells, and is referred to as migration and invasion. Tumor cells 
elongate polarize and stiffen while interacting with the surrounding environment, such as 
extracellular matrix (ECM) substrates, i.e., collagen, elastin and fibronectin. Tumor cells, 
macrophages and fibroblast can secrete ECM-degrading proteases, including urokinase-type 




MMP9, and MMP12 (100), resulting in ECM degradation and providing space for cell invasion 
into the underlying tissue and migration  into the circulation.  
Tumor cells in the circulation would be attracted by certain growth factors and move to 
the secondary site.This interaction between tumor cells and target tissues are hypothesized as 
“seed and soil”. Briefly, “seed and soil” hypothesis was first published in 1889 by English 
surgeon Stephen Paget where tumor cells are the seed and the target tissues are the soil. He 
analyzed more than 900 autopsy records and found that tumor cells metastasize to specific 
organs (101). His observations suggested that sites of metastasis are determined by both the 
characteristics of those tumor cells and the microenvironment of the host tissue (102). In prostate 
cancer, 90% of patients with hematogeneous metastases develop bone metastasis (81), 
suggesting that bone marrow-derived cells (VEGF receptor-1 and -2 positive progenitor cells) 
and bone-specific matrix in the tumor microenvironment promotes and attracts metastasis to 
bone (103). This interaction between local prostate cancer cells and bone marrow is consistent 
with the “seed and soil” hypothesis (104). In addition, several growth factors such as IGF-1 
produced by bone marrow cells promote prostate cancer growth and survival through a 
stimulation of the IGF-1/IGF-1R survival signal pathway.  
1.6.3 IGF AXIS 
Insulin-like growth factors (IGFs) are polypeptide growth factors secreted from many 
tissues with functional homolgy to insulin. There are two types of IGFs, IGF-I and IGF-II, 
sharing 62% homolgy in their amino acid sequence (105) and tightly regulated in the circulation 
by insulin-like growth factor binding proteins (IGFBPs). Both IGF-I and IGF-II bind to IGF-I 




identical α-subunits and two β-subunits. IGF-IR can resemble the insulin receptor forming a 
hemireceptor and binds to IGF-I, but not insulin (106). IGF-I/IGF-IR binding presents a similar 
signal transduction pathway as the insulin signaling cascade. Over 99% of the circulating IGFs 
are bound to IGFBPs, with a majority forming a complex with IGFBP-3 and the acid-labile 
subunit (ALS). The binding of IGF-I to this complex prolongs its half-life in the serum. IGFs 
have a greater binding affinity with IGFBPs than IGF-I receptors, therefore regulating bioactivity 
of IGF and signaling at the cellular level via affinity competition (107). However, the function of 
IGFBP is very controversial. In the CWR22 human prostate cancer xenograft model, it has been 
shown that IGFBP-5 was regulated by androgen receptor (AR), whereby the interaction of AR 
with IGFBP-5/IGF was associated with tumor growth (108). On the other hand, PSA, an 
androgen-related gene, induced IGFBP-5 degradation, enhancing IGF/IGF-IR interaction and 
IGF-1R phosphorylation., Activation of the IGF-1R signaling pathway promotes malignancy 
progression (109). IGF-IIR, on the other hand, has no tyrosine kinase activity and selectively 
binds to IGF-II. This process results in the degradation of IGF-II and controls circulating levels.    
1.6.3.1 IGF-IR signal in cell proliferation 
IGF-I/IGF-IR signaling also modulates cell cycle regulation. Activation of PI3K/AKT by 
IGF-I/IGF-IR signaling phosphorylates p70 S6K and elF-4E. Phospho-elF-4E associates with 
ribosome and thus accumulated ribosome becomes a sufficient translational machinery to ensure 
the rapid processing of transcripts through the cycle (110). Activation of IGF-I/IGF-IR increases 
the release of E2F from retinoblastoma (Rb). It also increases synthesis of cyclin D1, cyclin E 
and CDK4 through MAPK (Erk) activation (111) (112), and reduces the expression of the cell 




cycle from G1 to S phase.  The production of cyclins A and cdc2 are induced by IGF-I/IGF-IR 
signaling and thereby enhance cell cycle progression from the G2-M phase (114). Taken together, 
IGF-I/IGF-IR activation promotes cell cycle at several phases, mainly through AI3K/AKT and 
MAPK pathways, and thereby inducing cell proliferation.     
1.6.3.2 IGF-IR signal in apoptosis 
Downstream of IGF-I/IGF-IR signaling cascades are AKT and MAPK intracellular 
signaling. The IGF-1R activation leads to autophosphorylation on tyrosines 1131, 1135 and 1136 
in the kinase domain, followed by phosphorylation of juxtamembrane tyrosines and carboxy-
terminal serines and subsequent phosphorylation of insulin receptor substrate (IRS) proteins 
(115). Signal transduction proceeds through IRS with the activation of PI3K/AKT and MAP 
kinases and involves phosphorylation of downstream substrates including the members of Bcl-2 
family, Bad and forkhead transcription factors (i.e., FKHRL1), and caspases (107, 116). 
Phosphorylated Bad binding to 14-3-3 proteins relocates into cytosol and neutralizes the pro-
apoptotic function of Bad (117-118).  In addition, AKT activation inhibits the caspase cascade by 
phosphorylation of caspase 9 and caspase 3 (119). IFG-IR is frequently overexpressed in 
carcinomas of breast, lung, colon, and prostate (120) and overexpression of IGF-IR reduces p53-
mediated apoptosis through a p53-Mdm2 feedback loop (121). In addition, IGF-IR signaling 
inhibits apoptosis signal-regulating kinase 1 (ASK1) which is a MAP kinase kinase kinase 
(MAPKKK) that is required for c-Jun N-terminal kinase (JNK) and p38 activation in response to 
Fas and tumor necrosis factor (TNF) receptor stimulation in the extrinsic apoptotic pathway. 
IGF-IR forms a complex with ASK1 and suppresses ASK-1-mediated stimulation of JNK/p38 




of multiple anti-apoptotic pathways may explain the efficacy of the IGF-IR in protecting cells 
from apoptosis. 
1.6.3.3 IGF-IR signaling in cell angiogenesis and metastasis  
Angiogenesis (neovascularization) is a process by which new blood vessels are formed 
from current blood vessels. This process is critically important for the growth and development 
of tumors. As tumors enlarge, centrally located cells require sufficient oxygen and nutrients for 
viability and the removal the waste during metabolism.  In addition, it creates a new path for 
cells to migrate to more distance organs. IGF-IR has been shown to increase VEGF expression 
through an induction of hypoxia-inducible factor 1α (HIF-1α) via PI3K and MAPK pathways 
(123), and therefore promotes endothelial cell proliferation. IGF-IR also cooperates with 
integrins, αvβ3, and activates PI3K and MAPK signals in promoting angiogenesis and cell 
metastasis (124-126). Angiogenesis is an obligate requirement for tumor cell invasion, migration,, 
and metastasis.  
Along with promoting angiogenesis, IGF-IR signaling contributes to the metastatic 
process by affecting cell behavior, adherence, motility, and invasive ability. Cell-cell interaction 
is tightly regulated by adhesion molecules such as E-cadherin, β-catenin and integrins. Activation 
of PI3K/AKT via IGF-IR signaling has been shown to reduce epithelial markers, E-cadherin and 
β-catenin, and therefore promote IGF-IR-induced cell motility (127). The reduction of cell 
adhesion breaks down intracellular adherent junctions and changes cell behavior from an 
epithelial cell type to a mesenchymal cell type. This process is called “epithelial-mesenchymal 
transtion” (EMT). This is a classical transition when tumor cells are transformed to undergo 




and thus promoting a degradation of the sorrounding extracellular matrix (ECM) (128), and 
establishing a proper microenvironment for cell migration and invasion. MMPs have to be 
activated by a proteolytic process and IGF-IR/PI3K/AKT promotes MMP protein activation by 
increasing a proteolytic activator. MMP-14 is one of the proteolytic activators of MMP-2 (129). 
MMP-2, MMP-7 and MMP-9 have been shown to free IGF via proteolytic cleavage of IGFBP3 
(130-131), increasing IGF bioactivity and constitutively activating IGF-IR signaling.    
1.6.3.4 Epidemiological studies of IGF/IGF-IR axis in prostate cancer 
There is a positive correlation between the  IGF signaling axis and prostate cancer. The 
risk for prostate cancer was more than 4 fold higher in men with the highest circulating levels of 
IGF-I (highest quartile) compared to the men in the lowest quartile (132). In addition, plasma 
levels of IGF-I and IGFBP3 were the predictors of advanced prostate cancer (133). In a nested 
case–control study within the Northern Sweden Health and Disease Cohort Study, subjects with 
prostate cancer had significantly higher mean levels of IGF-I and IGFBP-3 compared to controls 
(134). Furthermore, a higher ratio of IGF-I:IGFBP3 was associated with increased risk for 
benign prostatic hyperplasia (BPH) (a potentially preneoplastic condition), while high serum 
IGFBP3 levels were associated with decreased BPH risk (135). In addition, IGF-I levels and 
IGF-IR expression increased significantly as the prostatic tissue transitioned from BPH to PIN to 
malignancy, demonstrating a high correlation between the IGF axis and prostate tissue 
morphology and tumor grade (136). These observations were supported by data showing stroma 
adjacent to Gleason grade ≥7 tumors had higher expression of IGF-IR than the lower grade 
tumors and benign epithelium (137). Chen et al. analyzed 96 studies and over 110,000 subjects 




cancer risk (138). They found increased levels of IGF-I significantly increased cancer risk by 
15%, whereas increased IGFBP3 levels significantly decreased the risk of advanced prostate 
cancer by 56%. Taken together, circulation of IGF and IGFBP as well as the expression of IGF-
IR may serve as biomarkers for prostate cancer development.  
Controversially, some evidence showed that the IGF axis disrupts hormone ablation 
therapy on prostate cancer patients. Before hormone ablation therapy, the IGF-I level was 
correlated with bone metabolic disorder, but there was no relationship after hormone ablation 
therapy (p=0.565). This result indicated that IGF axis may be inactivated during hormone 
ablation therapy (139). The role of IGF-1/IGF-1R axis should be clarified.  
1.6.4 HDACs mechanisms 
Histone deacetylases (HDACs) are a family of proteins that are involved in cancer 
development and have been a target for cancer therapy. There are several members in the HDAC 
family and can be classified as class I, class II, class III and class IV. The class III subgroup is 
also called known as sirtuins and depend on nicotinamide adenine dinucleotide (NAD1) for their 
catalytic activity, exhibiting catalytic activities similar to ADP-ribosyltransferases or ADP-
cyclases. Some of the Class III members lack deacetylase activity.  
Histone deacetylases of class I, class II and class IV are zinc-dependent amidohydrolases 
and represent the classical activity of deacetylases. The function of HDACs is activated through 
a zinc-based catalytic mechanism. At the transcription level, HDACs cleave acetyl groups from 
lysine residues on histones, particularly histone H3 and H4. The removal of acetyl group 




histones are involved in chromatin assembly (140), DNA repair and recombination (141). 
Therefore, accumulation of epigenetic changes results in the alteration of gene expression. 
Histones are not the only substrates of HDACs, and growing evidence suggests that 
HDACs function on the non-histone proteins such as p53 (142) and IRS-I (143). In addition, 
non-protein molecules such as polyamines or metabolic intermediates might also be substrates of 
HDACs (144).  
Both acetyaltion and deacetylation have different effects on proteins. First, acetylation or 
deacetylation on select lysine residues can affect protein stability by site competition for 
ubiquitylation (145), protein-protein interaction (changes in configuration), and protein 
localization. For example, deacetylated Ku70, a nuclear DNA-damage-response protein, 
complexes with Bax, a pro-apoptotic protein, protecting cells from apoptosis.  Bax dissociates 
from acetylated Ku70 and translocates into mitochondria to activate intrinsic apoptosis (146).   
Activity of classical HDACs is inhibited by zinc chelators, mainly thiols or hydroxamic 
acid derivatives like TSA (trichostatin A) and SAHA (suberoylanilide hydroxamic acid, INN: 
Vorinostat) (147). An increasing number of studies show that inhibition of HDACs suppress 
tumorigenesis by increasing cell death and inhibit cell proliferation by altering the acetylation 
status of chromatin and other non-histone proteins (Figure 1.2). Inhibitors of class I, class II and 
class IV HDACs have been identified. Most of them are derived from the natural compounds and 
some of them are artificially synthesized. These HDAC inhibitors have been used in the phase I, 
phase II and phase III clinical trials on hematological malignancies and various solid tumors 
(148-149). The combination of HDAC inhibitors with other anticancer agents associated with 










1.6.4.1 HDAC inhibitors in apoptosis 
Inhibitors of HDACs have been found to have pro-apoptotic properties through either 
intrinsic or extrinsic apoptosis. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand 
(TRAIL), death receptor 4 and 5 (Dc4 and Dc5), along with Fas-associated death domain (FADD) 
initiate extrinsic apoptosis downstream by activating caspase 8 and caspase 10. Activation of 
caspase 8 and caspase 10 cleave pro-caspase 3 and Bid, which engages the intrinsic apoptotic 
pathway in the mitochondria. The involvement of TRAIL associated with HDAC inhibitor, 
SAHA, results in cell death by activation of the caspase cascade and induction of mitochondrial-
mediated cascade (150).  HDAC inhibitors and TRAIL synergize to induce caspase 3 activation, 
internucleosomal DNA fragmentation, and promote mitochondrial damage (151). HDAC 
inhibitors, sodium butyrate and TSA, had similar effects on prostate cancer cells. Inhibition of 
HDACs decreased protein kinase casein kinase (PKCK) 2 activity, leading to caspase 2 
activation and partial cleavage of caspase 8, sensitizing tumor cells to TRAIL-mediated cell 
death (152). Most of the studies investigated show that HDAC inhibitors are associated with 
TRAIL to synergize extrinsic and intrinsic apoptosis. 
1.6.4.2 HDAC inhibitors in cell proliferation 
Cell growth is tightly regulated via cell cycle, and growth is attenuated or terminated as a 
result of cell cycle arrest. The cell cycle can be blocked by cell cycle inhibitors, such as the 
cip/kip family and the INK4a/ARF (Inhibitor of Kinase 4/Alternative Reading Frame) family, 
each of which is involved in regulating different phases of cell cycle. HDAC inhibitors have 




 in vitro (153-157) and in vivo 




variety cell types through a p53-independent mechanism. This involves Sp1 binding sites in the 
p21 promoter region (159-160). In G1/S phase, retinoblastoma (Rb) forms a repressor containing 
HDAC and the hSWI/SNF, a member of E2F family. This complex inhibits transcription of genes 









 are both induced by HDAC inhibitors (162). In addition, p21
WAF1/Cip1
 
inhibits the association of phospho-Rb and E2F, thereby reducing the activity of E2F on cyclin E 
and CDK2, resulting in G1/S arrest.  
1.6.4.3 HDAC inhibitors in angiogenesis and metastasis  
The potential ability of HDAC inhibitors on tumor cell migration and invasion have been 
validated in vitro. Cell adhesion molecules such as E-cadherin, β-catenin and integrins have been 
reported to be regulated by HDAC inhibitors. TSA up-regulates integrins a4, b2 and b6 in 
Hep3B cells, inhibiting cell migration (163). HDAC inhibitors markedly induced growth 
response gene-1 (Egr-1), a Cys2-His2-typed zinc-finger transcription factor, and restored tight 
junctions (TJs) in cancer cells. These results suggest that HDAC inhibitors increase cell-cell 
adhesion. In addition, proteins that negatively regulate metastasis, such as thrombospondin- 1 
(TSP-1), claudin-3 and E-cadherin were up regulated by HDAC inhibition and proteins that 
positively regulate metastasis, such as IGF-1R and snail (an EMT promoter), were reduced in 
human hepatocarcinoma cells (164). HIF-1α and VEGF were suppressed by TSA through an 
inhibition of the PI3K-AKT/PKC/HDAC pathway (165). Inhibition of these angiogenic factors 
inhibits endothelial cell migration, proliferation and angiogenesis (166-167). The same events 
have been demonstrated in other models by using bovine aortic endothelial cells and chick 




violaceum, blocked hypoxia-induced proliferation, invasion, migration, adhesion, tube formation 
and neovasculariztion (168).   
1.6.4.4 HDAC and HDAC inhibitors in prostate cancer 
Androgen receptor is an important transcription factor for cell growth and cell survival 
whether in hormone-sensitive or in castrated-resistant prostate cancer. There is increasing 
evidence demonstrating that AR is regulated by HDAC inhibitors. The effects of HDAC 
inhibitors have been determined in AR-dependent and AR-independent prostate cancer cell lines 
such as LNCaP, PC3 and CWR22Rv1 cells either in vitro or in vivo models. Valproic acid, an 
HDAC inhibitor that has been used clinically, reduced LNCaP cell proliferation by 14% when 
provided at physiological doses (0.45 mM) and abolished the growth promoting response of 
androgens by reducing AR expression (169). Similarly, valproic acid reduced PC3 cells 
proliferation by 40%, and the effects in both cell lines were associated with an increase of E-Cad 
(169).  
Inhibition of HDACs with a variety of inhibitors or through siRNA technology 
suppresses transcriptional activity of the AR by inhibiting the assembly of co-activator/RNA 
polymerase II complex to target genes. In addition, HDAC inhibition can also reduce AR protein 
levels (170). In a CWR22Rv1 castrate-resistant prostate cancer xenograft model, LBH589 
blocked tumor growth by 75% compared to control and reduced PSA gene expression (170). In 
contrast, Lee et al. reported that extracts of allspice reduced LNCaP cell growth by reducing 
histone acetyltransferase and histone acetylation through the inhibition of CBP/p300 (a protein 
complex with histone acetyltransferase activity). This reduction in histone acetyltransferase 




expression (171). Collectively, it is suggested that high activity of HDACs causes epigenetic 
alterations (reductions in histone acetylation) and these changes are associated with an induction 
of malignancy.   
There are two important features of HDAC inhibitors for use in the clinical setting. 
HDAC inhibitors are cytotoxic against tumor cells, but normal cells appear to be unaffected; and 
HDAC inhibitors have multiple activities affecting multiple molecular pathways. For example, 
they increase p21 expression via epigenetic regulation, and p53 through non-histone protein 
acetylation. Overall, HDAC inhibitors repress cancer cell proliferation, cell survival, metastasis 
and angiogenesis and induce cell apoptosis through transcriptional and post-translational 
modulation (172). 
Despite what we know about HDAC inhibitors, the functions of HDAC isoforms in 
human tumors are not clear. Analysis of 192 samples of prostate carcinomas, revealed strong 
expression patterns of the class I family of HDACs, where 70%, 74% and 95% of the tumor 
samples had strong signals from HDAC1, HDAC2 and HDAC3, respectively.  The expression of 
these HDACs was associated with tumor cell proliferation, and HDAC1 and HDAC2 
expressions were significantly correlated with Gleason score. High expressions of HDAC1, 2 
and 3 were accompanied by an earlier PSA-relapse after radical prostatectomy, showing an 
increase castrate-resistance (173). Therefore, HDACs might be a suitable target for treatment in 
prostate cancer. FK228 (romidepsin) has been approved by US Food and Drug Administration 
(FDA) for the treatment of cutaneous T-cell lymphoma (CTCL) and it has been used in a phase II 
clinical trial of progressing, metastatic, castration-resistant prostate cancer (CRPC), although 




HDAC inhibitor (vorinostat) and chemotherapy (doxorubicin) showed an antitumor effect 
without additional toxicity associated with chemotherapy alone (175). The combination of 
HDAC inhibitor SAHA (139) and radiation has been shown to enhance radiation-induced 
cytotoxicity in DU145 cells (androgen-independent prostate cancer cell line) (176), and this 
result provides a rationale for a combination therapy in further clinical trials.  
1.7 Dietary components, phytochemicals, and prostate cancer 
1.7.1 Anti-cancer properties of phytochemicals 
Phytochemicals are non-nutritive components typically found in plants that have been 
shown to have multiple anti-carcinogentic and anti-mutagenic properties. These compounds  are 
commonly used in the prevention and treatment of cancer/tumorigenesis using  experimental 
models  in vitro and in vivo, and in human clinical trials. The mechanisms of action of these 
phytochemicals involve  multiple signaling pathways including suppression of PI3 kinase and 
MAP kinase pathways and inactivation of transcriptional factor such as nuclear factor k B 
(NFkB), resulting in cell cycle arrest and apoptosis. 
1.7.1.1 Epidemiological and clinical evidences for an association between 
phytochemicals and prostate cancer 
Prostate cancer is currently the most commonly diagnosed solid malignancy and has 
become the second leading cause of cancer-related deaths in men in most Western developed 
countries (3) and the use of phytochemicals in prostate cancer might be one of the more 
promising treatments. There is increasing evidence demonstrating dietary components, such as 




vegetables, fruits and medicinal herbs are rich in phytochemicals. Some studies indicated that the 
increased intakes of vegetables and fruits can lower the incidence and/or progression of prostate 
cancer. In an earlier multi-ethnic case-control study involving African-Americans, whites, 
Japanese, and Chinese from the United States and Canada, intakes of legumes, yellow-orange 
and cruciferous vegetables were inversely related to prostate cancer risk, but not tomatoes or 
fruits (177).  Carotinoids, including lycopene-rich vegetables, reduced incidence and advanced 
forms of prostate cancer in a prospective cohort study and these effects were also observed in a 
phase II clinical trial (178-179). Allium vegetables, including garlic, scallions, onions, chives 
and leaks also decreased the risk of prostate cancer (180). In addition to vegetables and fruits, 
consumptions of food containing soy and isoflavones reduced the risk of cancer in a case-control 
study involving Chinese (181). 
In addition to foods, common and medicinal herbs, including green tea, turmeric, etc., 
have been shown to have beneficial effects on reducing prostate cancer progression and 
incidence. Green tea has been used in China for thousands of years and green tea and its 
bioactive components reduce prostate cancer progression in different phases of the disease. In a 
proof-of-principle clinical trial, sixty individuals with high-grade prostate intraepithelial 
neoplasia (HGPIN) were randomly treated with green tea catechins (600 mg/day) or a placebo 
for a year. Only one individual was diagnosed with a malignancy in the group receiving 
catechins, while nine individuals in the placebo group developed prostate cancer (182). In a 
short-term study involving twenty-six men with positive prostate biopsies  who were 
administered tea-derived polyphenols (1.3 g/day) , a majority of subjects had significant 
reductions in serum levels of hepatocyte growth factor (HGF), VEGF, IGF-I/ IGFBP-3 ratio, and 




anticancer properties.  
1.7.1.2  The anti-carcinogenetic mechanisms of phytochemicals 
Carcinogenesis is a multiple step process involving tumor initiation, promotion, and 
progression. Phytochemicals that are present in plants sources have been reported to possess anti-
carcinogenic activities through multiple pathways (Table 2.1). Basically, these phytochemicals 
are classified into two categories: blocking agents and suppressing agents. Blocking agents 
prevent carcinogen formation from precursors and prevent carcinogens from reacting in the 
tissues. Suppressing agents inhibit, delay or reverse the expression of malignancy after exposure 
to carcinogens (184-185). Some phytochemicals inhibit pro-carcinogenic activity to electrophilic 
species or interaction with DNA and stimulate the detoxification of carcinogens. Other 
phytochemicals suppress the latter steps of cancer (promotion and progression) and some 
phytochemicals can act as both blocking and suppressing agents (186).  
Phytochemicals, such as epigallocatechin-3-gallate (EGCG) and curcumin, have been 
shown to coordinately regulate the expression of xenobiotic metabolizing enzyme genes (phase I, 
II and III) and antioxidative stress genes (187-189), preventing tumor initiation by reducing pro-
carcinogens, reactive intermediates or their activated metabolites and enhancing the cellular 
defense system (187-188). In addition, phytochemicals have been shown to generate reactive 
oxygen species (ROS) to disrupt the mitochondrial membrane potential and activate the intrinsic 
apoptotic cascade. Phytochemicals, such as berberine, can increase the production of ROS by 





Phytochemicals also act as suppressing agents and function on tumor promotion and 
progression by coordinately regulating various signaling pathways, including growth factor 
receptors pathways, stress-activated protein kinases pathways, nuclear factors signaling and the 
regulation of the cell cycle and cell death. 
1.7.1.2.1 Modulation of growth-factor receptors pathways by phytochemicals 
Increasing evidence indicates growth factors and/or growth factor receptors are over 
expressed in tumor cells and contribute to cell proliferation and survival signals. Phytochemicals 
have been shown to reduce growth factor expression and down regulate the expression and 
activity of growth factor receptors. Curcumin was the first phytochemical found to inhibit 
tyrosine phosphorylation of epidermal growth factor receptor (EGFR) (190-191) and human 
epidermal growth factor receptor 2 (Her2/neu) (192). It was also found that curcumin sensitized 
prostate cancer cells to apoptosis induced by TRAIL by activating c-Jun N-terminal kinase 
(JNK), inhibiting IκBα/NFκB activation, and suppressing AKT signaling pathways (193-196), 
resulting in activation of the caspase cascade, and thus cell death (197). The ability of curcumin 
to sensitize cells to TRAIL was demonstrated in a xenograft model using TRAIL-resistant 
LNCaP prostate cancer cells. Mice were provided TRAIL (15 mg/kg) in the presence or absence 
of curcumin (30 mg/kg body weight). Compared to TRAIL alone, curcumin sensitized LNCaP 
cells and by reducing VEGF, VEGFR2, NFκB-induced COX2, MMP2 and MMP9 while 
inducing death receptor 4 and 5,  p21 and p27  (198).  
Additionally, the proliferative EGFR-dependent Erk1/2 signaling pathway can be 
inhibited by EGCG (199). EGCG also inhibited IGF-1-induced cell growth in androgen-




VEGF/VEGFR axis by suppressing the expression of hypoxia-inducible factor (HIF)-1α, 
reducing angiogenesis (202). The reductions in growth-factor receptors pathways were also 
observed in other phytochemicals such as resveratrol (15), gingerol (203), baicalein (14), 
berberine (204).  
1.7.1.2.2 Modulation of stress-activated pathways by phytochemicals 
Extracellular stresses activate several pathways including stress-activated protein kinases 
and p53 expression. Stress-activated protein kinases include JNKs and p38 mitogen-activated 
protein kinase (MAPK). They are activated in response to the extracellular stimuli, such as UV, 
DNA-damage agents or pro-inflammatory factors. These kinases function as either pro-apoptotic 
protein kinases or anti-apoptotic kinases (205). Curcumin has been shown to have multiple 
anticancer properties including induction of JNK and p38 MAPK,  cytochrome c release from 
mitochondria and activation of caspases 3,  8 and  9 in androgen-independent PC3 prostate 
cancer cells (10). Similar results were observed when PC3 cell were treated with a variety of 
flavonoids ( kaempferol, apigenin, genistein and naringenin). Inductions in phospho-JNK, 
phospho-Erk and increases in activator protein 1 (AP-1), a downstream transcription factor of 
JNK, was observed in PC3 cells (206). Transcription factor AP-1 plays an important role in 
carcinogenesis and regulates a variety of its target genes, such as EGFR, cyclin D1, Bcl-2 and 
MMPs (207-210).  In androgen-dependent LNCaP prostate cancer cells, protoapigenone, a 
natural derivative of the flavanoid apigenin, showed similar effects on JNK and p38 MAPK 
activations (211). These studies indicate that the treatments of flavonoids can result in activation 





In addition to AP-1 activation through JNK or p38 MAPK signaling, NFκB is a rapid-
activated stress-responsive transcription factor, inducing the transcription of various genes 
encoding cytokines, membrane proteins, other transcription factor, inhibitors of apoptosis and 
pro-inflammatory factors (212). NFκB activation is initiated through a removal of inhibitory 
protein (IκB) from the NFκB/IκB complex by a variety of stimuli including TNFα, LPS, UV or 
IR and DNA damage (213). In cervical cancer cells, curcumin reduced TNFα-induced NFκB 
activation and reduced cyclooxygenase 2 (COX-2) expression through a blockage of IκBα 
phosphorylation, increasing degradation (214). In addition, Curcumin has anti-inflammatory 
property by reducing leukocytes recruitment mediated by TNFα-induced NFκB activation (215). 
Resveratrol has also been shown to reduce NFκB expression by targeting protein NAD(P)H 
dehydrogenase and quinone 2 (NQO2) in CWR22Rv1 prostate cancer cells (216). Resveratrol 
also inhibited TNFα-induced Erk and JNK activation and reduced p65 phosphorylation and 
nuclear translocation (217). Other phytochemicals including EGCG (218), genistein (219), [6]-
gingerol (11), capsaicin (220) and caffeic acid phenethyl ester (CAPE) (221) have the similar 
inhibitory effects on NFκB activation induced by UV light, TNFα, 12-O-tetradecanoylphorbol-
13-acetate (TPA) or phorbol 12-myristate 13-acetate (PMA). 
Tumor suppressor gene, p53, inhibits tumorigenesis in responding to cellular genotoxic 
stresses, such as UV, IR or non-genotoxic stress, such as phytochemicals (222). Activation of p53 
induces cell cycle arrest and cell apoptosis resulting in reducing cancer cell growth. Lack of p53 
is associated with an increase of tumorigenesis, allowing an accumulation of mutations in 
damaged cells and blocking the apoptotic responding to genotoxic stress. Phytochemicals, 
EGCG, genistein, quercetin, indole-3-carbinol, curcumin and resveratrol, have been shown to 




LNCaP and androgen-independent PC3, DU145 and CWR22Rv1 prostate cancer cells (223-228). 
Activation and induction of p53 by phytochemicals such as resveratrol and caffeine are regulated 
by MAP kinases on p53 phosphorylation at serine 15, which stabilize and activate p53 (229-231). 
Resveratrol inhibits the growth of LNCaP prostate cancer cell by activating p53-responsive 
genes such as p21
WAF1/CIP1
, p300/CBP and Apaf-1 (232). Additionally, in LNCaP cells, cell 
apoptosis is promoted and the cell growth is inhibited by EGCG treatment along with induction 
of p53, reduction of NFκB, and suppression of Bcl-2 (233). Activation and phosphorylation of 
p53 can be induced through ataxia teleangetasia mutated and ATM-related kinase (ATM/ATR) 
pathway by genistein and enhances the sequence-binding specificity of p53 on target DNA (228). 
While p53 is up-regulated and activated by phytochemicals, activated p53 promotes cell cycle 
arrest and cell death, thus inhibiting tumorigenesis. 
1.7.1.2.3 Induction of cell cycle arrest and apoptosis by phytochemicals 
The majority of phytochemicals reduce tumor cell proliferation by inducing cell cycle 
arrest and increasing cell death. Cell cycle mediators and cell death promoters are modulated by 
phytochemical in a variety of cancer cell lines (234). Resveratrol is one of the more widely 
studied phytochemicals.  When LNCaP, DU-145, PC-3, and JCA-1 human prostate cancer cells 
were treated with resveratrol, G1/S transition phase of the cell cycle was inhibited and cell 
apoptosis was induced (235). The inhibition effects of resveratrol on cancer cell growth have 
been found in other cells including breast, colon, pancreas, and squamous cell carcinoma etc. 
Resveratrol increased cell cycle inhibitors, p21 and p27, and tumor suppressor gene, p53, along 
with reductions in cell cycle promoter, cyclin D1 and cyclin E, anti-apoptotic proteins, Bcl-2 and 




cell cycle regulators, cyclin/ cyclin-dependent kinase, thus blocking cell cycle transition.  In 
addition, it has been shown that resveratrol enhances apoptosis induced by TRAIL through 
induction of cellular inhibitor-of-apoptosis proteins (cIAPs) and Bax expression (237, 13, 238), 
and reduction of AKT phosphorylation (239) in androgen-dependent and androgen-independent 
prostate cancer cells.  
In  animal models, green tea and its bioactive compounds, catechins, have been shown to 
inhibit tumor cell growth. In a CWR22Rv1 athymic nude mouse model, green tea polyphenols 
(GTP) and EGCG attenuated tumor growth by extending the length of time to reach final tumor 
size by 38% and 108%, respectively.   Reduced Bcl-2 expression and increases in active caspase 
3, cleaved PARP and Bax expression indicated EGCG and GTP inhibited prostate cancer cell 
growth by increasing apoptosis (240). The mechanisms of EGCG on prostate cancer cell growth 
have been investigated using PC3 and LNCaP cells. EGCG induces cell cycle arrest by 
increasing p53-dependent p21 expression and promotes cell death by reducing pro-proliferative 






Table 1.3 Summary of molecular targets by curcumin and EGCG in prostate cancer animal and 
cell models 
phytochemicals doses Molecular targets Animal models/ 
cell types 
Ref. 
Curcumin 5-50 μM ↓ EGFR LNCaP; PC3 (190) 
 
 10 μM No changes on  Her2/neu, PARP, STAT3 
DNA binding activity 
PC3 , DU145 (242) 
 
 
 10-50 μM ↓ IκBα/NFκB;   
↓ p-AKT, Bcl-2, Bcl-xL, XIAP; 
↑ caspase 









 5-30 μM ↓p-AKT 
↓Bcl-2, Bcl-X 
↑ROS 
↑p53, Bax, Bak, PUMA, Noxa,  Bim, Cyt 
c, Smac/DIABLO, Omi/HtrA2, caspase 
3; 









 30 mg/kg ↓ VEGF, VEGFR-2, MMP2, MMP9, 
COX2, p65; 
↓ cyclin D1, Bcl-2, Ki67; 













Table 1.3 Continued. 
phytochemicals doses Molecular targets Animal models/ 
cell types 
Ref. 
























 20-80 μM ↓ NFκB; 
↑p53, p21
WAF-1
, Bax, caspase 3, 8, 9 
LNCaP (241, 233) 
 
 
 1 mg/ day ↓ PSA, tumor size; 
↓ VEGF, Bcl-2; 










1.7.1.3  Epigenetic anti-cancer effects of phytochemicals 
Phytochemicals have been shown to regulate gene expression epigenetically via DNA 
methylation and histone acetylation and methylation. Methylation on CpG site in DNA by DNA 
methyltransferases (DNMTs) is an epigenetic silencing mechanism on tumor suppressor genes 
during tumorigenesis, and removal of methyl groups from the CpG islands allows binding of 
transcriptional proteins. This removal can be induced by phytochemicals such as EGCG, 
curcumin and others. In addition, histone modification is another key feature of epigenetic 
regulation through acetylation and methylation. These modifications on histones allow the 
loosing of the chromatin structure resulting in the recruitment of transcriptional factors on DNA, 
thus increasing gene expression.  A number of phytochemicals have been shown to modify 
histones, enhancing the expression of tumor suppressor genes, such as p21. It has been 
demonstrated that the epigenetic regulation by diet is inherited in mice (243), indicating that 
dietary factors are able to influence gene expression.  
1.7.1.3.1 DNA methylation 
One of the epigenetic changes in prostate cancer is DNA methylation. More than 30 
genes have been identified to have abnormal methylation on DNA promoters including the genes 
related to the cell cycle, hormone response, and DNA repair (244). For example, gluthathione-S-
transferase pi (GSTP1) is involved in detoxification and protects DNA from reactive 
electrophilic intermediates. Hypermethylation results in gene silencing and this phenomenon has 
been found in LNCaP, C4–2B, PC-3, DU-145, LAPC-4, and VCaP human prostate cancer cells. 
This observation is supported in metastatic prostate cancer tissues compared to normal tissue 




expression of GSTP1 (246). DNA methyltransferase 1 functions by adding methyl groups on the 
DNA promoter region, resulting in DNA silencing. The activity of  DNMT1 in LNCaP, MDA, 
PCa 2b and DU145 human prostate cancer cell lines were suppressed by EGCG (247). EGCG 
binds to catalytic residues on DNMT1 through hydrogen bonding and blocks the active site of 
DNMT1, reducing DNMT1 activity (248). In addition to the inhibitory effect of EGCG on 
DNMT1 kinetic activity, the DNMT1 inhibitor, S-adenosyl-L-homocysteine (SAH), is increased 
by EGCG by an enzymatic methylation reaction (249). These results explain the epigenetic 
regulation mechanisms of EGCG in vitro. However, the underling mechanisms of EGCG via 
mediation of DNMTs on tumor suppressor genes have not been illustrated in prostate cancer 
patients yet. 
1.7.1.3.2 Histones acetylation and methylation 
Histone acetylation and methylation are the principle regulators of epigenetic regulation 
of gene expression involving histones. The actions of acetylation and methylation on specific 
lysine or arginine residues in histones H3 and H4 are reversible processes that are modulated by 
histone acetyltransferases (81), HDACs and histone methyltransferases (HMTs) (250). Histone 
deacetylases are the new target for cancer chemotherapy, including prostate cancer, with elevated 
expressions of HDAC1, 2 and 3 (173). The use of HDAC inhibitors, such as TSA, has been 
shown to inhibit HDAC expression and activity and induce the cell cycle inhibitor, p21. This 
results in cell cycle arrest and cell death (using in vitro models) (160), and thus HDACs 
inhibitors are a therapeutic target for the inhibition of tumor progression. Important to this 
discussion is the fact that phytochemicals appear to act as HDAC inhibitors, arresting tumor cell 




broccoli, and has been shown to inhibit HDACs in vitro, in vivo and in tissues from human 
subjects (251). For example, consumption of broccoli sprouts (68 g), containing 105 mg of the 
isothiocyanate sulforaphane, reduced plasma HDAC activity in human subjects after 3 hours 
(252). In a xenograph mouse model using PC3 human prostate cancer cells, sulforaphane (443 
mg/kg diet for 21 days) reduced tumor growth, inhibited HDAC activity, and increased 
acetylation of histones H3 and H4 (252).  
Regulation of histone acetylation is a balance between the removal and incorporation of 
acetyl groups mediated by HDACs and histone acetyltransferases.  Induction of histone 
acetyltransferases counter balances the actions of HDACs. Ideally, if hyperacetylation of 
histones were the overall goal, then it would be most desirable to use a product that inhibits 
HDAC function and enhances histone acetyltransferase activity. The classical HDAC inhibitor 
TSA has been shown to increase acetylation of CBP/p300 and thus increase its acetyltransferase 
activity (253-254). The mechanism of activation is through MAP kinase signaling (255). 
Curcumin has been shown to increase this pathway via MAP kinase phoshporylation with 
concomitant induction of p21 expression, negatively regulating the cell cycle (256). This effect 
of curcumin to inhibit tumor cell growth is supported by similar results in LNCaP prostate cancer 
cells. Curcumin inhibited ntunor growth and induced the acetylation of histones H3 and H4 (227).  
In addition to histone acetylation, methylation on specific lysine or arginine residues in 
histones H3 and H4 by HMTs is another process either to activate or to repress gene expression. 
When compared to post-treatment (radiotherapy + hormone therapy) plasma levels of circulating 
histone H3 lysine 27 trimethylation (H3K27me3) from organ confined (n=22), locally advanced 




the patients with metastatic PCa was lower than patients with localized or locally advanced 
prostate cancer (257), indicating that histone methylation is associated with progression of the 
disease. This result is consistent with a finding that JMJD3 (defined as a histone demethylase) is 
upregulated in advanced and metastatic prostate cancer patients (258). JMJD3 and H3K27me3 
might be used as biomarkers of advanced of prostate cancer.  
1.7.2 The use of phytochemicals in combination on prostate cancer 
Consumption of whole fruits, vegetables and whole grain is strongly associated with a 
reduction of prostate cancer risk (180, 177, 259). The effective bioactive compounds in the fruits, 
vegetables and whole grains have been identified. The molecular mechanisms of these bioactive 
compounds on tumorigenesis are well studied using experimental models in vitro and in vivo 
(260, 198, 240, 185). However, it is believed that single nutrients or phytochemicals when used 
at physiological concentrations, do not have the same effects as the whole fruits, vegetables and 
whole grains as reported in epidemiological studies. In a 12- year randomized, double-blind, 
placebo-controlled trial of beta-carotene (50 mg/d on alternate days), Hennekens et al. found that 
the participants receiving beta-carotene had significantly higher beta-carotene concentrations  in 
plasma than those given placebo, but there were no significant differences in the number of cases 
of lung cancer, or with other cancers, including colon/rectum, prostate , stomach, pancreas, brain,  
or with various types of cancers, such as melanoma, leukemia, or lymphoma (261). These results 
suggest that a single compound might as bioactive against tumorigenesis as compared to the food 
it is found in. One of the possible strategies is the use of combinations of bioactive compounds, 
whereby combinations may act synergistically to inhibit tumor growth. For example, when tea 




reduction in serum PSA levels, but this effect was not observed with isolated catechins (183). In 
a CWR22Rv1 athymic nude mouse model, green tea polyphenols attenuated tumor growth 
compared to mice receiving one of its bioactive components, EGCG (240). A combination of soy 
phytochemicals (5 g/kg diet) and tea (15 g tea leave/L drinking water) for 10 weeks showed a 
synergistic inhibition on prostate tumor growth, metastasis and angiogenesis in LNCaP prostate 
cancer xenograft mice (262). The same effects have been observed in other cancers, such as lung 
and colon in mouse models (263-264). These synergistic effects of a combination of 
phytochemicals may explain the efficacy of fruits and vegetables. 
1.7.2.1 An example of the use of phytochemicals in combination, Zyflamend®  
Zyflamend® is a multi-herb extract with anticancer properties. Extracts from each herb 
contain a variety of bioactive phytochemicals (i.e., berberine, curcumin, epigallocatechin gallate, 
resveratrol, etc), with known efficacy.  The individual chemistries have been shown to increase 
cell death and suppress cell proliferation via a variety of mechanisms (10, 265, 12, 203, 202, 14-
15). Therefore, their unique combination could result in additive or synergistic effects at 
relatively low concentration. Zyflamend® appears to provide clinical improvement to patients 
diagnosed with HGPIN, an early  preneoplastic form of the disease. In a phase I clinical study, it 
was reported that 48% of HGPIN patients had a 25-50% reduction in PSA levels and a reduction 
in NFκB expression after a 18-month Zyflamend® (2.3g/d) (266-267). Using In vitro studies, 
Zyflamend® reduced the growth of androgen-dependent LNCaP cells and this reduction was 
associated with an elevated expression of p21 and apoptosis (as indicated an induction of PARP 
cleavage and caspase 3 activity). Androgen receptor expression was also reduced by 




G2/M phase in the cell cycle. The reduction of Rb was related to inhibition of 12-lipoxygenase 
(269). These anticancer properties of Zyflamend® were also observed in other cell models, 
including human non-small cell lung carcinoma (H1299), human myelogenous leukemia (KBM-
5), and human multiple myeloma (U266) cells (suppressing osteoclastogenesis). Zyflamend® 
induced cell cycle arrest and apoptotic and anti-angiogenetic gene expression by repressing 
NFκB and its downstream genes, such as Bcl-2, Bcl-xL, FADD-like interleukin-1β converting 
enzyme /caspase-8 inhibitory protein (270). However, the anticarcinogenic properties of 
Zyflamend® on various stages of advance prostate cancer stages and the progression of the 
disease from androgen-dependent to castrate-resistant growth in conjunction with hormone 
deprivation has yet to be explored.  Because of the diversity of chemo-preventive phytonutrients 
in Zyflamend®, the use of Zyflamend® as an adjuvant to standard therapies, such as hormone 
ablation therapy, seems promising.  
1.8 Summary 
Prostate cancer is a complicated disease involving multiple mechanisms and using a 
therapy that has a specific target may not be as effective as a strategy that takes advantage of the 
complexity associated with foods and herbs, thereby simultaneously affecting many signaling 
pathways. 
In this study, we decided to use a mixture of the extracts of ten individual herbs, 
Zyflamend®, many of which having anticancer properties. We chose only to use human 
equivalent does when provided in a diet, and concentrations we believed to be physiologically 
relevant (in vitro). This was important to insure some translatability.  We chose a human prostate 




of human prostate cancer. We would like to discover if this mixture can reduce prostate cancer 
growth and delay progression in a model of advance prostate cancer in the presence or absence 
of androgens.  
1. Determine the effects of Zyflamend® on androgen-dependent tumor growth in vivo. 
2. Determine the effects of Zyflamend® on tumor regression in conjunction with 
hormone deprivation in vivo. 
3. Determine the effects of Zyflamend® on castrate resistant tumor growth in vivo and 
in vitro. 






1. Baade PD, Youlden DR, Krnjacki LJ. International epidemiology of prostate cancer: 
geographical distribution and secular trends. Mol Nutr Food Res. 2009;53:171-84. 
2. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer 
incidence and mortality. Int J Cancer. 2000;85:60-7. 
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA 
Cancer J Clin. 2008;58:71-96. 
4. Bostwick DG. Prostatic intraepithelial neoplasia (PIN): current concepts. J Cell Biochem 
Suppl. 1992;16H:10-9. 
5. Sakr WA. Prostatic intraepithelial neoplasia: A marker for high-risk groups and a 
potential target for chemoprevention. Eur Urol. 1999;35:474-8. 
6. Whittemore AS, Keller JB, Betensky R. Low-grade, latent prostate cancer volume: 
predictor of clinical cancer incidence? J Natl Cancer Inst. 1991;83:1231-5. 
7. Boyle P, Severi G. Epidemiology of prostate cancer chemoprevention. Eur Urol. 
1999;35:370-6. 
8. Luo W, Birkett NJ, Ugnat AM, Mao Y. Cancer incidence patterns among Chinese 
immigrant populations in Alberta. J Immigr Health. 2004;6:41-8. 
9. Garg R, Ingle A, Maru G. Dietary turmeric modulates DMBA-induced p21ras, MAP 
kinases and AP-1/NF-kappaB pathway to alter cellular responses during hamster buccal pouch 
carcinogenesis. Toxicol Appl Pharmacol. 2008;232:428-39. 
10. Hilchie AL, Furlong SJ, Sutton K, Richardson A, Robichaud MR, Giacomantonio CA, 
Ridgway ND, Hoskin DW. Curcumin-induced apoptosis in PC3 prostate carcinoma cells is 




Nutr Cancer. 2010;62:379-89. 
11. Kim SO, Kundu JK, Shin YK, Park JH, Cho MH, Kim TY, Surh YJ. [6]-Gingerol inhibits 
COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappaB in phorbol 
ester-stimulated mouse skin. Oncogene. 2005;24:2558-67. 
12. Meeran SM, Katiyar S, Katiyar SK. Berberine-induced apoptosis in human prostate 
cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol. 
2008;229:33-43. 
13. Shankar S, Chen Q, Siddiqui I, Sarva K, Srivastava RK. Sensitization of TRAIL-resistant 
LNCaP cells by resveratrol (3, 4', 5 tri-hydroxystilbene): molecular mechanisms and therapeutic 
potential. J Mol Signal. 2007;2:7. 
14. Taniguchi H, Yoshida T, Horinaka M, Yasuda T, Goda AE, Konishi M, Wakada M, 
Kataoka K, Yoshikawa T, Sakai T. Baicalein overcomes tumor necrosis factor-related apoptosis-
inducing ligand resistance via two different cell-specific pathways in cancer cells but not in 
normal cells. Cancer Res. 2008;68:8918-27. 
15. Vanamala J, Reddivari L, Radhakrishnan S, Tarver C. Resveratrol suppresses IGF-1 
induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-
1R/Wnt and activation of p53 signaling pathways. BMC Cancer. 2010;10:238. 
16. So AI, Hurtado-Coll A, Gleave ME. Androgens and prostate cancer. World J Urol. 
2003;21:325-37. 
17. Rosner W, Hryb DJ, Khan MS, Nakhla AM, Romas NA. Sex hormone-binding globulin 
mediates steroid hormone signal transduction at the plasma membrane. J Steroid Biochem Mol 
Biol. 1999;69:481-5. 





19. Wang C, Catlin DH, Starcevic B, Heber D, Ambler C, Berman N, Lucas G, Leung A, 
Schramm K, Lee PW, Hull L, Swerdloff RS. Low-fat high-fiber diet decreased serum and urine 
androgens in men. J Clin Endocrinol Metab. 2005;90:3550-9. 
20. Wang X, Shen CL, Dyson MT, Eimerl S, Orly J, Hutson JC, Stocco DM. 
Cyclooxygenase-2 regulation of the age-related decline in testosterone biosynthesis. 
Endocrinology. 2005;146:4202-8. 
21. Wu Y, Zhao W, Zhao J, Pan J, Wu Q, Zhang Y, Bauman WA, Cardozo CP. Identification 
of androgen response elements in the insulin-like growth factor I upstream promoter. 
Endocrinology. 2007;148:2984-93. 
22. Heinlein CA, Chang C. The roles of androgen receptors and androgen-binding proteins in 
nongenomic androgen actions. Mol Endocrinol. 2002;16:2181-7. 
23. Mata LR, David-Ferreira JF. Testosterone interferes with the kinetics of endocytosis in 
the hamster seminal vesicle. Biol Cell. 1990;68:195-203. 
24. Zhang L, Barritt GJ. Evidence that TRPM8 is an androgen-dependent Ca2+ channel 
required for the survival of prostate cancer cells. Cancer Res. 2004;64:8365-73. 
25. Kampa M, Papakonstanti EA, Hatzoglou A, Stathopoulos EN, Stournaras C, Castanas E. 
The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors 
that increase PSA secretion and modify actin cytoskeleton. FASEB J. 2002;16:1429-31. 
26. Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP. Caveolin-1 interacts with androgen 
receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem. 
2001;276:13442-51. 




proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol 
Chem. 1998;273:5419-22. 
28. Falkenstein E, Norman AW, Wehling M. Mannheim classification of nongenomically 
initiated (rapid) steroid action(s). J Clin Endocrinol Metab. 2000;85:2072-5. 
29. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression 
via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. 
J Biol Chem. 1999;274:7777-83. 
30. Desiniotis A, Schafer G, Klocker H, Eder IE. Enhanced antiproliferative and proapoptotic 
effects on prostate cancer cells by simultaneously inhibiting androgen receptor and cAMP-
dependent protein kinase A. Int J Cancer. 2009. 
31. van Laar JH, Berrevoets CA, Trapman J, Zegers ND, Brinkmann AO. Hormone-
dependent androgen receptor phosphorylation is accompanied by receptor transformation in 
human lymph node carcinoma of the prostate cells. J Biol Chem. 1991;266:3734-8. 
32. Sumanasekera WK, Zhao L, Ivanova M, Morgan DD, Noisin EL, Keynton RS, Klinge 
CM. Effect of estradiol and dihydrotestosterone on hypergravity-induced MAPK signaling and 
occludin expression in human umbilical vein endothelial cells. Cell Tissue Res. 2006;324:243-53. 
33. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, Hung MC. HER-2/neu 
promotes androgen-independent survival and growth of prostate cancer cells through the AKT 
pathway. Cancer Res. 2000;60:6841-5. 
34. Shaffer DR, Scher HI. Prostate cancer: a dynamic illness with shifting targets. Lancet 
Oncol. 2003;4:407-14. 
35. Roach M, 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, Rotman M, Jones 




whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined 
androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol. 2003;21:1904-11. 
36. Schulze H, Senge T. Influence of different types of antiandrogens on luteinizing 
hormone-releasing hormone analogue-induced testosterone surge in patients with metastatic 
carcinoma of the prostate. J Urol. 1990;144:934-41. 
37. Mukha RP, Kumar S, Kekre NS. Maximal androgen blockade for advanced prostate 
cancer. Indian J Urol. 2010;26:133-8. 
38. Ockrim JL, Lalani el N, Kakkar AK, Abel PD. Transdermal estradiol therapy for prostate 
cancer reduces thrombophilic activation and protects against thromboembolism. J Urol. 
2005;174:527-33; discussion 32-3. 
39. Lepor H. Comparison of single-agent androgen suppression for advanced prostate cancer. 
Rev Urol. 2005;7 Suppl 5:S3-S12. 
40. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced 
prostate cancer. Rev Urol. 2007;9 Suppl 1:S3-8. 
41. Small EJ, Ryan CJ. The case for secondary hormonal therapies in the chemotherapy age. 
J Urol. 2006;176:S66-71. 
42. Raghavan D, Koczwara B, Javle M. Evolving strategies of cytotoxic chemotherapy for 
advanced prostate cancer. Eur J Cancer. 1997;33:566-74. 
43. Rashid MH, Chaudhary UB. Intermittent androgen deprivation therapy for prostate 
cancer. Oncologist. 2004;9:295-301. 
44. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk 
SP. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. 




45. Pienta KJ, Bradley D. Mechanisms underlying the development of androgen-independent 
prostate cancer. Clin Cancer Res. 2006;12:1665-71. 
46. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat 
Rev Cancer. 2001;1:34-45. 
47. Labrie F, Dupont A, Belanger A, St-Arnaud R, Giguere M, Lacourciere Y, Emond J, 
Monfette G. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr 
Rev. 1986;7:67-74. 
48. Makridakis N, Ross RK, Pike MC, Chang L, Stanczyk FZ, Kolonel LN, Shi CY, Yu MC, 
Henderson BE, Reichardt JK. A prevalent missense substitution that modulates activity of 
prostatic steroid 5alpha-reductase. Cancer Res. 1997;57:1020-2. 
49. Palmberg C, Koivisto P, Hyytinen E, Isola J, Visakorpi T, Kallioniemi OP, Tammela T. 
Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the 
nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response 
to maximal androgen blockade. Eur Urol. 1997;31:216-9. 
50. Gregory CW, Johnson RT, Jr., Mohler JL, French FS, Wilson EM. Androgen receptor 
stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. 
Cancer Res. 2001;61:2892-8. 
51. Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J, Zhang L, Ryan C, Smith S, 
Scher H, Scardino P, Reuter V, Gerald WL. Gene expression analysis of human prostate 
carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of 
therapy resistance. Am J Pathol. 2004;164:217-27. 
52. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW. Functional analysis of 44 mutant 




53. Zhao XY, Malloy PJ, Krishnan AV, Swami S, Navone NM, Peehl DM, Feldman D. 
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a 
mutated androgen receptor. Nat Med. 2000;6:703-6. 
54. Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, 
Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z. The transcriptional co-activator cAMP 
response element-binding protein-binding protein is expressed in prostate cancer and enhances 
androgen- and anti-androgen-induced androgen receptor function. Am J Pathol. 2003;162:233-41. 
55. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, 
Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth 
factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 1994;54:5474-8. 
56. Pandini G, Genua M, Frasca F, Vigneri R, Belfiore A. Sex steroids upregulate the IGF-1R 
in prostate cancer cells through a nongenotropic pathway. Ann N Y Acad Sci. 2009;1155:263-7. 
57. Chun JY, Nadiminty N, Dutt S, Lou W, Yang JC, Kung HJ, Evans CP, Gao AC. 
Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clin Cancer Res. 
2009;15:4815-22. 
58. Lucia MS, Bostwick DG, Bosland M, Cockett AT, Knapp DW, Leav I, Pollard M, Rinker-
Schaeffer C, Shirai T, Watkins BA. Workgroup I: rodent models of prostate cancer. Prostate. 
1998;36:49-55. 
59. Dunning WF. Prostate Cancer in the Rat. Natl Cancer Inst Monogr. 1963;12:351-69. 
60. Lamb DJ, Zhang L. Challenges in prostate cancer research: animal models for nutritional 
studies of chemoprevention and disease progression. J Nutr. 2005;135:3009S-15S. 





62. Pollard M. The Lobund-Wistar rat model of prostate cancer. J Cell Biochem Suppl. 
1992;16H:84-8. 
63. Sharma P, Schreiber-Agus N. Mouse models of prostate cancer. Oncogene. 
1999;18:5349-55. 
64. Bethel CR, Faith D, Li X, Guan B, Hicks JL, Lan F, Jenkins RB, Bieberich CJ, De Marzo 
AM. Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial 
neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion. 
Cancer Res. 2006;66:10683-90. 
65. Koksal IT, Dirice E, Yasar D, Sanlioglu AD, Ciftcioglu A, Gulkesen KH, Ozes NO, 
Baykara M, Luleci G, Sanlioglu S. The assessment of PTEN tumor suppressor gene in 
combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. 
Urol Oncol. 2004;22:307-12. 
66. Abate-Shen C, Banach-Petrosky WA, Sun X, Economides KD, Desai N, Gregg JP, 
Borowsky AD, Cardiff RD, Shen MM. Nkx3.1; Pten mutant mice develop invasive prostate 
adenocarcinoma and lymph node metastases. Cancer Res. 2003;63:3886-90. 
67. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev. 
2000;14:2410-34. 
68. van Weerden WM, Romijn JC. Use of nude mouse xenograft models in prostate cancer 
research. Prostate. 2000;43:263-71. 
69. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, 
Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: the 
first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains 




70. Amler LC, Agus DB, LeDuc C, Sapinoso ML, Fox WD, Kern S, Lee D, Wang V, Leysens 
M, Higgins B, Martin J, Gerald W, Dracopoli N, Cordon-Cardo C, Scher HI, Hampton GM. 
Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-
independent prostate cancer xenograft model CWR22-R1. Cancer Res. 2000;60:6134-41. 
71. Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere 
White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS. Dehydroepiandrosterone 
activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer 
xenograft CWR22 and LNCaP cells. Mol Endocrinol. 1997;11:450-9. 
72. Chen CT, Gan Y, Au JL, Wientjes MG. Androgen-dependent and -independent human 
prostate xenograft tumors as models for drug activity evaluation. Cancer Res. 1998;58:2777-83. 
73. Gao H, Ouyang X, Banach-Petrosky WA, Gerald WL, Shen MM, Abate-Shen C. 
Combinatorial activities of AKT and B-Raf/Erk signaling in a mouse model of androgen-
independent prostate cancer. Proc Natl Acad Sci U S A. 2006;103:14477-82. 
74. Kim MJ, Cardiff RD, Desai N, Banach-Petrosky WA, Parsons R, Shen MM, Abate-Shen 
C. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate 
carcinogenesis. Proc Natl Acad Sci U S A. 2002;99:2884-9. 
75. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, 
Brinkmann AO, Mulder E. The androgen receptor in LNCaP cells contains a mutation in the 
ligand binding domain which affects steroid binding characteristics and response to 
antiandrogens. J Steroid Biochem Mol Biol. 1992;41:665-9. 
76. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, 
Srivastava S. Frequent detection of codon 877 mutation in the androgen receptor gene in 




77. Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP. Selection 
for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res. 
1999;59:2511-5. 
78. Zhao XY, Boyle B, Krishnan AV, Navone NM, Peehl DM, Feldman D. Two mutations 
identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J 
Urol. 1999;162:2192-9. 
79. McDonald S, Brive L, Agus DB, Scher HI, Ely KR. Ligand responsiveness in human 
prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 
tumors. Cancer Res. 2000;60:2317-22. 
80. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ. 
Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer 
xenograft and cell line. Cancer Res. 2002;62:6606-14. 
81. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch 
MJ. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol. 
2000;31:578-83. 
82. Sun A, Bagella L, Tutton S, Romano G, Giordano A. From G0 to S phase: a view of the 
roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway. J Cell Biochem. 
2007;102:1400-4. 
83. Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E, Shimada K. Heterogeneous 
methylation and deletion patterns of the INK4a/ARF locus within prostate carcinomas. Am J 
Pathol. 2002;160:1207-14. 
84. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of 




85. Yazdi PT, Wang Y, Zhao S, Patel N, Lee EY, Qin J. SMC1 is a downstream effector in the 
ATM/NBS1 branch of the human S-phase checkpoint. Genes Dev. 2002;16:571-82. 
86. Krempler A, Deckbar D, Jeggo PA, Lobrich M. An imperfect G2M checkpoint 
contributes to chromosome instability following irradiation of S and G2 phase cells. Cell Cycle. 
2007;6:1682-6. 
87. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin 
Cancer Res. 2005;11:3155-62. 
88. Ashkenazi A, Herbst RS. To kill a tumor cell: the potential of proapoptotic receptor 
agonists. J Clin Invest. 2008;118:1979-90. 
89. Hoffman B, Liebermann DA. Apoptotic signaling by c-MYC. Oncogene. 2008;27:6462-
72. 
90. Adrain C, Creagh EM, Martin SJ. Apoptosis-associated release of Smac/DIABLO from 
mitochondria requires active caspases and is blocked by Bcl-2. EMBO J. 2001;20:6627-36. 
91. Wu G, Chai J, Suber TL, Wu JW, Du C, Wang X, Shi Y. Structural basis of IAP 
recognition by Smac/DIABLO. Nature. 2000;408:1008-12. 
92. Benetti R, Del Sal G, Monte M, Paroni G, Brancolini C, Schneider C. The death substrate 
Gas2 binds m-calpain and increases susceptibility to p53-dependent apoptosis. EMBO J. 
2001;20:2702-14. 
93. Jourdain A, Martinou JC. Mitochondrial outer-membrane permeabilization and 
remodelling in apoptosis. Int J Biochem Cell Biol. 2009;41:1884-9. 
94. Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular 
regression and permeability changes in established human tumor xenografts induced by an anti-





95. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 
1997;18:4-25. 
96. El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R, Saad RS. 
Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic 
adenocarcinoma. Am J Clin Pathol. 2007;127:572-9. 
97. Duque JL, Loughlin KR, Adam RM, Kantoff PW, Zurakowski D, Freeman MR. Plasma 
levels of vascular endothelial growth factor are increased in patients with metastatic prostate 
cancer. Urology. 1999;54:523-7. 
98. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A, 
Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ. Targeting of 
HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl 
hydroxylation. Science. 2001;292:468-72. 
99. Du Z, Fujiyama C, Chen Y, Masaki Z. Expression of hypoxia-inducible factor 1alpha in 
human normal, benign, and malignant prostate tissue. Chin Med J (Engl). 2003;116:1936-9. 
100. Schmid MC, Varner JA. Myeloid cell trafficking and tumor angiogenesis. Cancer Lett. 
2007;250:1-8. 
101. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. 
Nat Rev Cancer. 2003;3:453-8. 
102. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of 
B16 melanoma. Cancer Res. 1980;40:2281-7. 
103. Lorusso G, Ruegg C. The tumor microenvironment and its contribution to tumor 




104. Kaplan RN, Rafii S, Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res. 
2006;66:11089-93. 
105. Sara VR, Hall K. Insulin-like growth factors and their binding proteins. Physiol Rev. 
1990;70:591-614. 
106. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological 
actions. Endocr Rev. 1995;16:3-34. 
107. Grimberg A. Mechanisms by which IGF-I may promote cancer. Cancer Biol Ther. 
2003;2:630-5. 
108. Gregory CW, Kim D, Ye P, D'Ercole AJ, Pretlow TG, Mohler JL, French FS. Androgen 
receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a 
human prostate cancer xenograft. Endocrinology. 1999;140:2372-81. 
109. Maeda H, Yonou H, Yano K, Ishii G, Saito S, Ochiai A. Prostate-specific antigen 
enhances bioavailability of insulin-like growth factor by degrading insulin-like growth factor 
binding protein 5. Biochem Biophys Res Commun. 2009;381:311-6. 
110. Dupont J, Pierre A, Froment P, Moreau C. The insulin-like growth factor axis in cell 
cycle progression. Horm Metab Res. 2003;35:740-50. 
111. Rosenthal SM, Cheng ZQ. Opposing early and late effects of insulin-like growth factor I 
on differentiation and the cell cycle regulatory retinoblastoma protein in skeletal myoblasts. Proc 
Natl Acad Sci U S A. 1995;92:10307-11. 
112. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J. Cyclin D1 expression is 
regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J 
Biol Chem. 1996;271:20608-16. 




point control of the fibroblast cell cycle. Science. 1996;272:877-80. 
114. Shen WH, Yin Y, Broussard SR, McCusker RH, Freund GG, Dantzer R, Kelley KW. 
Tumor necrosis factor alpha inhibits cyclin A expression and retinoblastoma 
hyperphosphorylation triggered by insulin-like growth factor-I induction of new E2F-1 synthesis. 
J Biol Chem. 2004;279:7438-46. 
115. Baserga R, Hongo A, Rubini M, Prisco M, Valentinis B. The IGF-I receptor in cell 
growth, transformation and apoptosis. Biochim Biophys Acta. 1997;1332:F105-26. 
116. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 
2008;8:915-28. 
117. Peruzzi F, Prisco M, Dews M, Salomoni P, Grassilli E, Romano G, Calabretta B, Baserga 
R. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from 
apoptosis. Mol Cell Biol. 1999;19:7203-15. 
118. Rapp UR, Fischer A, Rennefahrt UE, Hekman M, Albert S. BAD association with 
membranes is regulated by Raf kinases and association with 14-3-3 proteins. Adv Enzyme Regul. 
2007;47:281-5. 
119. Goyal A, Wang Y, Graham MM, Doseff AI, Bhatt NY, Marsh CB. Monocyte survival 
factors induce AKT activation and suppress caspase-3. Am J Respir Cell Mol Biol. 2002;26:224-
30. 
120. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and 
progression. J Natl Cancer Inst. 2000;92:1472-89. 
121. Xiong L, Kou F, Yang Y, Wu J. A novel role for IGF-1R in p53-mediated apoptosis 





122. Galvan V, Logvinova A, Sperandio S, Ichijo H, Bredesen DE. Type 1 insulin-like growth 
factor receptor (IGF-IR) signaling inhibits apoptosis signal-regulating kinase 1 (ASK1). J Biol 
Chem. 2003;278:13325-32. 
123. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 
1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, 
which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer 
cells. J Biol Chem. 2002;277:38205-11. 
124. Bahr C, Groner B. The IGF-1 receptor and its contributions to metastatic tumor growth-
novel approaches to the inhibition of IGF-1R function. Growth Factors. 2005;23:1-14. 
125. Clemmons DR, Maile LA. Interaction between insulin-like growth factor-I receptor and 
alphaVbeta3 integrin linked signaling pathways: cellular responses to changes in multiple 
signaling inputs. Mol Endocrinol. 2005;19:1-11. 
126. Saegusa J, Yamaji S, Ieguchi K, Wu CY, Lam KS, Liu FT, Takada YK, Takada Y. The 
direct binding of insulin-like growth factor-1 (IGF-1) to integrin alphavbeta3 is involved in IGF-
1 signaling. J Biol Chem. 2009;284:24106-14. 
127. Guvakova MA, Adams JC, Boettiger D. Functional role of alpha-actinin, PI 3-kinase and 
MEK1/2 in insulin-like growth factor I receptor kinase regulated motility of human breast 
carcinoma cells. J Cell Sci. 2002;115:4149-65. 
128. Saikali Z, Setya H, Singh G, Persad S. Role of IGF-1/IGF-1R in regulation of invasion in 
DU145 prostate cancer cells. Cancer Cell Int. 2008;8:10. 
129. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and 
tumor invasion via PI 3-kinase/AKT signaling. Oncogene. 2003;22:974-82. 




inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and 
tumorigenicity. Cancer Gene Ther. 2003;10:823-32. 
131. Nakamura M, Miyamoto S, Maeda H, Ishii G, Hasebe T, Chiba T, Asaka M, Ochiai A. 
Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and 
facilitates insulin-like growth factor bioavailability. Biochem Biophys Res Commun. 
2005;333:1011-6. 
132. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, 
Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. 
Science. 1998;279:563-6. 
133. Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-
like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate 
cancer. J Natl Cancer Inst. 2002;94:1099-106. 
134. Stattin P, Bylund A, Rinaldi S, Biessy C, Dechaud H, Stenman UH, Egevad L, Riboli E, 
Hallmans G, Kaaks R. Plasma insulin-like growth factor-I, insulin-like growth factor-binding 
proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000;92:1910-7. 
135. Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, 
Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding 
protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate. 
2008;68:1477-86. 
136. Liao Y, Abel U, Grobholz R, Hermani A, Trojan L, Angel P, Mayer D. Up-regulation of 
insulin-like growth factor axis components in human primary prostate cancer correlates with 
tumor grade. Hum Pathol. 2005;36:1186-96. 




Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol 
Oncol. 2007;25:134-40. 
138. Chen W, Wang S, Tian T, Bai J, Hu Z, Xu Y, Dong J, Chen F, Wang X, Shen H. 
Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: 
evidence from 96 studies. Eur J Hum Genet. 2009. 
139. Isahaya E, Hara N, Nishiyama T, Hoshii T, Takizawa I, Takahashi K. Bone metabolic 
disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): impact 
of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis. Prostate. 
2009. 
140. Polo SE, Almouzni G. Histone metabolic pathways and chromatin assembly factors as 
proliferation markers. Cancer Lett. 2005;220:1-9. 
141. Vidanes GM, Bonilla CY, Toczyski DP. Complicated tails: histone modifications and the 
DNA damage response. Cell. 2005;121:973-6. 
142. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev 
Cancer. 2004;4:793-805. 
143. Kaiser C, James SR. Acetylation of insulin receptor substrate-1 is permissive for tyrosine 
phosphorylation. BMC Biol. 2004;2:23. 
144. Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and 
more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51. 
145. Giandomenico V, Simonsson M, Gronroos E, Ericsson J. Coactivator-dependent 
acetylation stabilizes members of the SREBP family of transcription factors. Mol Cell Biol. 
2003;23:2587-99. 




H, Kessler BM, Sinclair DA. Acetylation of the C terminus of Ku70 by CBP and PCAF controls 
Bax-mediated apoptosis. Mol Cell. 2004;13:627-38. 
147. Schemies J, Uciechowska U, Sippl W, Jung M. NAD(+)-dependent histone deacetylases 
(sirtuins) as novel therapeutic targets. Med Res Rev. 2009. 
148. Arts J, King P, Marien A, Floren W, Belien A, Janssen L, Pilatte I, Roux B, Decrane L, 
Gilissen R, Hickson I, Vreys V, Cox E, Bol K, Talloen W, Goris I, Andries L, Du Jardin M, 
Janicot M, Page M, van Emelen K, Angibaud P. JNJ-26481585, a Novel "Second-Generation" 
Oral Histone Deacetylase Inhibitor, Shows Broad-Spectrum Preclinical Antitumoral Activity. 
Clin Cancer Res. 2009. 
149. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and 
overview of recent clinical trials. Drugs. 2009;69:1911-34. 
150. Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and 
extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis 
in human leukemia cells. Mol Cancer Ther. 2003;2:1273-84. 
151. Sonnemann J, Gange J, Kumar KS, Muller C, Bader P, Beck JF. Histone deacetylase 
inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) to induce apoptosis in carcinoma cell lines. Invest New Drugs. 2005;23:99-109. 
152. VanOosten RL, Earel JK, Jr., Griffith TS. Histone deacetylase inhibitors enhance Ad5-
TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. 
Apoptosis. 2007;12:561-71. 
153. Ahn MY, Jung JH, Na YJ, Kim HS. A natural histone deacetylase inhibitor, Psammaplin 





154. Kang MR, Kang JS, Han SB, Kim JH, Kim DM, Lee K, Lee CW, Lee KH, Lee CH, Han 
G, Kim HM, Park SK. A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, 
induces cell cycle arrest and apoptosis in colon cancer cells. Biochem Pharmacol. 2009;78:486-
94. 
155. Mayo C, Lloreta J, Real FX, Mayol X. In vitro differentiation of HT-29 M6 mucus-
secreting colon cancer cells involves a trychostatin A and p27(KIP1)-inducible transcriptional 
program of gene expression. J Cell Physiol. 2007;212:42-50. 
156. Rocchi P, Tonelli R, Camerin C, Purgato S, Fronza R, Bianucci F, Guerra F, Pession A, 
Ferreri AM. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC 
inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells. Oncol Rep. 
2005;13:1139-44. 
157. Wang LG, Liu XM, Fang Y, Dai W, Chiao FB, Puccio GM, Feng J, Liu D, Chiao JW. De-
repression of the p21 promoter in prostate cancer cells by an isothiocyanate via inhibition of 
HDACs and c-Myc. Int J Oncol. 2008;33:375-80. 
158. Joung KE, Min KN, An JY, Kim DK, Kong G, Sheen YY. Potent in vivo anti-breast 
cancer activity of IN-2001, a novel inhibitor of histone deacetylase, in MMTV/c-Neu mice. 
Cancer Res. 2006;66:5394-402. 
159. Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A, Bellahcene A, Verdin 
E, Castronovo V. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through 
a Sp1-dependent, p53-independent mechanism. Oncogene. 2009;28:243-56. 
160. Sowa Y, Orita T, Hiranabe-Minamikawa S, Nakano K, Mizuno T, Nomura H, Sakai T. 




Ann N Y Acad Sci. 1999;886:195-9. 
161. Zhang HS, Gavin M, Dahiya A, Postigo AA, Ma D, Luo RX, Harbour JW, Dean DC. Exit 
from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-
Rb-hSWI/SNF and Rb-hSWI/SNF. Cell. 2000;101:79-89. 
162. Lee S, Park JR, Seo MS, Roh KH, Park SB, Hwang JW, Sun B, Seo K, Lee YS, Kang SK, 
Jung JW, Kang KS. Histone deacetylase inhibitors decrease proliferation potential and 
multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif. 
2009;42:711-20. 
163. Lin KT, Yeh SH, Chen DS, Chen PJ, Jou YS. Epigenetic activation of alpha4, beta2 and 
beta6 integrins involved in cell migration in trichostatin A-treated Hep3B cells. J Biomed Sci. 
2005;12:803-13. 
164. Kim SO, Choi BT, Choi IW, Cheong J, Kim GY, Kwon TK, Kim ND, Choi YH. Anti-
invasive activity of histone deacetylase inhibitors via the induction of Egr-1 and the modulation 
of tight junction-related proteins in human hepatocarcinoma cells. BMB Rep. 2009;42:655-60. 
165. Koshikawa N, Hayashi JI, Nakagawara A, Takenaga K. ROS-generating mitochondrial 
DNA mutation upregulates hypoxia-inducible factor-1alpha gene transcription via PI3K-
AKT/PKC/HDAC pathway. J Biol Chem. 2009. 
166. Williams RJ. Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced 
angiogenesis. Expert Opin Investig Drugs. 2001;10:1571-3. 
167. Yang QC, Zeng BF, Shi ZM, Dong Y, Jiang ZM, Huang J, Lv YM, Yang CX, Liu YW. 
Inhibition of hypoxia-induced angiogenesis by trichostatin A via suppression of HIF-1a activity 
in human osteosarcoma. J Exp Clin Cancer Res. 2006;25:593-9. 




FK228 inhibits tumor angiogenesis. Int J Cancer. 2002;97:290-6. 
169. Iacopino F, Urbano R, Graziani G, Muzi A, Navarra P, Sica G. Valproic acid activity in 
androgen-sensitive and -insensitive human prostate cancer cells. Int J Oncol. 2008;32:1293-303. 
170. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL. Histone 
deacetylases are required for androgen receptor function in hormone-sensitive and castrate-
resistant prostate cancer. Cancer Res. 2009;69:958-66. 
171. Lee YH, Hong SW, Jun W, Cho HY, Kim HC, Jung MG, Wong J, Kim HI, Kim CH, Yoon 
HG. Anti-histone acetyltransferase activity from allspice extracts inhibits androgen receptor-
dependent prostate cancer cell growth. Biosci Biotechnol Biochem. 2007;71:2712-9. 
172. Mottet D, Castronovo V. Histone deacetylases: target enzymes for cancer therapy. Clin 
Exp Metastasis. 2008;25:183-9. 
173. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek 
S, Denkert C, Dietel M, Kristiansen G. Histone deacetylases 1, 2 and 3 are highly expressed in 
prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical 
prostatectomy. Br J Cancer. 2008;98:604-10. 
174. Molife LR, Attard G, Fong PC, Karavasilis V, Reid AH, Patterson S, Riggs CE, Jr., 
Higano C, Stadler WM, McCulloch W, Dearnaley D, Parker C, de Bono JS. Phase II, two-stage, 
single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-
resistant prostate cancer (CRPC). Ann Oncol. 2009. 
175. Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, 
Chiappori A, Sullivan D, Daud A. Phase I trial of vorinostat and doxorubicin in solid tumours: 
histone deacetylase 2 expression as a predictive marker. Br J Cancer. 2009;101:1044-50. 




radiation response by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys. 2005;62:223-
9. 
177. Kolonel LN, Hankin JH, Whittemore AS, Wu AH, Gallagher RP, Wilkens LR, John EM, 
Howe GR, Dreon DM, West DW, Paffenbarger RS, Jr. Vegetables, fruits, legumes and prostate 
cancer: a multiethnic case-control study. Cancer Epidemiol Biomarkers Prev. 2000;9:795-804. 
178. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of 
carotenoids and retinol in relation to risk of prostate cancer. J Natl Cancer Inst. 1995;87:1767-76. 
179. Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak MN, Khachik F, Li YW, Banerjee M, 
Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP, Jr. Phase II randomized clinical trial 
of lycopene supplementation before radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 
2001;10:861-8. 
180. Hsing AW, Chokkalingam AP, Gao YT, Madigan MP, Deng J, Gridley G, Fraumeni JF, Jr. 
Allium vegetables and risk of prostate cancer: a population-based study. J Natl Cancer Inst. 
2002;94:1648-51. 
181. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone 
consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 
2003;12:665-8. 
182. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of 
human prostate cancer by oral administration of green tea catechins in volunteers with high-
grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle 
study. Cancer Res. 2006;66:1234-40. 
183. McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols 




endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth 
factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila Pa). 2009;2:673-82. 
184. Ip C, Ganther HE. Combination of blocking agents and suppressing agents in cancer 
prevention. Carcinogenesis. 1991;12:365-7. 
185. Wattenberg LW. Chemoprevention of cancer. Cancer Res. 1985;45:1-8. 
186. Surh Y. Molecular mechanisms of chemopreventive effects of selected dietary and 
medicinal phenolic substances. Mutat Res. 1999;428:305-27. 
187. Nair S, Xu C, Shen G, Hebbar V, Gopalakrishnan A, Hu R, Jain MR, Lin W, Keum YS, 
Liew C, Chan JY, Kong AN. Pharmacogenomics of phenolic antioxidant butylated 
hydroxyanisole (BHA) in the small intestine and liver of Nrf2 knockout and C57BL/6J mice. 
Pharm Res. 2006;23:2621-37. 
188. Shen G, Xu C, Hu R, Jain MR, Gopalkrishnan A, Nair S, Huang MT, Chan JY, Kong AN. 
Modulation of nuclear factor E2-related factor 2-mediated gene expression in mice liver and 
small intestine by cancer chemopreventive agent curcumin. Mol Cancer Ther. 2006;5:39-51. 
189. Shen G, Xu C, Hu R, Jain MR, Nair S, Lin W, Yang CS, Chan JY, Kong AN. Comparison 
of (-)-epigallocatechin-3-gallate elicited liver and small intestine gene expression profiles 
between C57BL/6J mice and C57BL/6J/Nrf2 (-/-) mice. Pharm Res. 2005;22:1805-20. 
190. Dorai T, Gehani N, Katz A. Therapeutic potential of curcumin in human prostate cancer. 
II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes 
the protein. Mol Urol. 2000;4:1-6. 
191. Korutla L, Kumar R. Inhibitory effect of curcumin on epidermal growth factor receptor 
kinase activity in A431 cells. Biochim Biophys Acta. 1994;1224:597-600. 




and also depletes p185neu. Clin Cancer Res. 1999;5:1884-91. 
193. Deeb D, Jiang H, Gao X, Al-Holou S, Danyluk AL, Dulchavsky SA, Gautam SC. 
Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] 
sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing 
ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the 
prosurvival AKT signaling pathway. J Pharmacol Exp Ther. 2007;321:616-25. 
194. Deeb D, Jiang H, Gao X, Hafner MS, Wong H, Divine G, Chapman RA, Dulchavsky SA, 
Gautam SC. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-
inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of 
IkappaBalpha phosphorylation. Mol Cancer Ther. 2004;3:803-12. 
195. Deeb DD, Jiang H, Gao X, Divine G, Dulchavsky SA, Gautam SC. Chemosensitization 
of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J Exp 
Ther Oncol. 2005;5:81-91. 
196. Sah NK, Munshi A, Kurland JF, McDonnell TJ, Su B, Meyn RE. Translation inhibitors 
sensitize prostate cancer cells to apoptosis induced by tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL) by activating c-Jun N-terminal kinase. J Biol Chem. 2003;278:20593-
602. 
197. Shankar S, Chen Q, Sarva K, Siddiqui I, Srivastava RK. Curcumin enhances the 
apoptosis-inducing potential of TRAIL in prostate cancer cells: molecular mechanisms of 
apoptosis, migration and angiogenesis. J Mol Signal. 2007;2:10. 
198. Shankar S, Ganapathy S, Chen Q, Srivastava RK. Curcumin sensitizes TRAIL-resistant 





199. Sah JF, Balasubramanian S, Eckert RL, Rorke EA. Epigallocatechin-3-gallate inhibits 
epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 
and AKT kinases. J Biol Chem. 2004;279:12755-62. 
200. Klein RD, Fischer SM. Black tea polyphenols inhibit IGF-I-induced signaling through 
AKT in normal prostate epithelial cells and Du145 prostate carcinoma cells. Carcinogenesis. 
2002;23:217-21. 
201. Thomas F, Patel S, Holly JM, Persad R, Bahl A, Perks CM. Dihydrotestosterone 
sensitises LNCaP cells to death induced by epigallocatechin-3-Gallate (EGCG) or an IGF-I 
receptor inhibitor. Prostate. 2009;69:219-24. 
202. Shimizu M, Shirakami Y, Sakai H, Yasuda Y, Kubota M, Adachi S, Tsurumi H, Hara Y, 
Moriwaki H. (-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR 
axis in human colorectal cancer cells. Chem Biol Interact. 2010;185:247-52. 
203. Rhode J, Fogoros S, Zick S, Wahl H, Griffith KA, Huang J, Liu JR. Ginger inhibits cell 
growth and modulates angiogenic factors in ovarian cancer cells. BMC Complement Altern Med. 
2007;7:44. 
204. Gao JL, Shi JM, Lee SM, Zhang QW, Wang YT. Angiogenic pathway inhibition of 
Corydalis yanhusuo and berberine in human umbilical vein endothelial cells. Oncol Res. 
2009;17:519-26. 
205. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res. 
2005;15:36-42. 
206. Gopalakrishnan A, Xu CJ, Nair SS, Chen C, Hebbar V, Kong AN. Modulation of 
activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells. 




207. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-
Jun and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 
2000;19:2056-68. 
208. Hu E, Mueller E, Oliviero S, Papaioannou VE, Johnson R, Spiegelman BM. Targeted 
disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene 
expression stimulated by growth factors or oncogenes. EMBO J. 1994;13:3094-103. 
209. Passegue E, Jochum W, Schorpp-Kistner M, Mohle-Steinlein U, Wagner EF. Chronic 
myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the 
myeloid lineage. Cell. 2001;104:21-32. 
210. Zenz R, Scheuch H, Martin P, Frank C, Eferl R, Kenner L, Sibilia M, Wagner EF. c-Jun 
regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell. 
2003;4:879-89. 
211. Chang HL, Wu YC, Su JH, Yeh YT, Yuan SS. Protoapigenone, a novel flavonoid, induces 
apoptosis in human prostate cancer cells through activation of p38 mitogen-activated protein 
kinase and c-Jun NH2-terminal kinase 1/2. J Pharmacol Exp Ther. 2008;325:841-9. 
212. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE. 
2006;2006:re13. 
213. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat Rev Immunol. 
2002;2:725-34. 
214. Divya CS, Pillai MR. Antitumor action of curcumin in human papillomavirus associated 
cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, 
and modulation of apoptosis. Mol Carcinog. 2006;45:320-32. 




inhibition of tumor necrosis factor (TNF)-mediated adhesion of monocytes to endothelial cells 
by suppression of cell surface expression of adhesion molecules and of nuclear factor-kappaB 
activation. Biochem Pharmacol. 1998;55:775-83. 
216. Hsieh TC. Antiproliferative effects of resveratrol and the mediating role of resveratrol 
targeting protein NQO2 in androgen receptor-positive, hormone-non-responsive CWR22Rv1 
cells. Anticancer Res. 2009;29:3011-7. 
217. Manna SK, Mukhopadhyay A, Aggarwal BB. Resveratrol suppresses TNF-induced 
activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: 
potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. 
2000;164:6509-19. 
218. Afaq F, Adhami VM, Ahmad N, Mukhtar H. Inhibition of ultraviolet B-mediated 
activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea 
Constituent (-)-epigallocatechin-3-gallate. Oncogene. 2003;22:1035-44. 
219. Davis JN, Kucuk O, Sarkar FH. Genistein inhibits NF-kappa B activation in prostate 
cancer cells. Nutr Cancer. 1999;35:167-74. 
220. Singh S, Natarajan K, Aggarwal BB. Capsaicin (8-methyl-N-vanillyl-6-nonenamide) is a 
potent inhibitor of nuclear transcription factor-kappa B activation by diverse agents. J Immunol. 
1996;157:4412-20. 
221. McEleny K, Coffey R, Morrissey C, Fitzpatrick JM, Watson RW. Caffeic acid phenethyl 
ester-induced PC-3 cell apoptosis is caspase-dependent and mediated through the loss of 
inhibitors of apoptosis proteins. BJU Int. 2004;94:402-6. 
222. Saito S, Yamaguchi H, Higashimoto Y, Chao C, Xu Y, Fornace AJ, Jr., Appella E, 




modifications in response to stress. J Biol Chem. 2003;278:37536-44. 
223. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM, Castellon 
EA. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate 
cancer-derived cell lines. J Androl. 2007;28:282-93. 
224. Chinni SR, Li Y, Upadhyay S, Koppolu PK, Sarkar FH. Indole-3-carbinol (I3C) induced 
cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene. 
2001;20:2927-36. 
225. Gupta S, Hussain T, Mukhtar H. Molecular pathway for (-)-epigallocatechin-3-gallate-
induced cell cycle arrest and apoptosis of human prostate carcinoma cells. Arch Biochem 
Biophys. 2003;410:177-85. 
226. Hsieh TC, Wu JM. Targeting CWR22Rv1 prostate cancer cell proliferation and gene 
expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer 
Res. 2009;29:4025-32. 
227. Shankar S, Srivastava RK. Involvement of Bcl-2 family members, phosphatidylinositol 
3'-kinase/AKT and mitochondrial p53 in curcumin (diferulolylmethane)-induced apoptosis in 
prostate cancer. Int J Oncol. 2007;30:905-18. 
228. Ye R, Bodero A, Zhou BB, Khanna KK, Lavin MF, Lees-Miller SP. The plant 
isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner. J Biol Chem. 
2001;276:4828-33. 
229. He Z, Ma WY, Hashimoto T, Bode AM, Yang CS, Dong Z. Induction of apoptosis by 
caffeine is mediated by the p53, Bax, and caspase 3 pathways. Cancer Res. 2003;63:4396-401. 
230. She QB, Bode AM, Ma WY, Chen NY, Dong Z. Resveratrol-induced activation of p53 




Cancer Res. 2001;61:1604-10. 
231. Singh S, Upadhyay AK, Ajay AK, Bhat MK. p53 regulates ERK activation in carboplatin 
induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. FEBS Lett. 
2007;581:289-95. 
232. Narayanan BA, Narayanan NK, Re GG, Nixon DW. Differential expression of genes 
induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int J Cancer. 
2003;104:204-12. 
233. Hastak K, Gupta S, Ahmad N, Agarwal MK, Agarwal ML, Mukhtar H. Role of p53 and 
NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene. 
2003;22:4851-9. 
234. Bode AM, Dong Z. Targeting signal transduction pathways by chemopreventive agents. 
Mutat Res. 2004;555:33-51. 
235. Hsieh TC, Wu JM. Differential effects on growth, cell cycle arrest, and induction of 
apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res. 1999;249:109-15. 
236. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of 
resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 
2004;24:2783-840. 
237. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RW. Resveratrol sensitizes 
androgen independent prostate cancer cells to death-receptor mediated apoptosis through 
multiple mechanisms. Prostate. 2007;67:1641-53. 
238. Shankar S, Siddiqui I, Srivastava RK. Molecular mechanisms of resveratrol (3,4,5-
trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) 




239. Aziz MH, Nihal M, Fu VX, Jarrard DF, Ahmad N. Resveratrol-caused apoptosis of 
human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3'-
kinase/AKT pathway and Bcl-2 family proteins. Mol Cancer Ther. 2006;5:1335-41. 
240. Siddiqui IA, Zaman N, Aziz MH, Reagan-Shaw SR, Sarfaraz S, Adhami VM, Ahmad N, 
Raisuddin S, Mukhtar H. Inhibition of CWR22Rnu1 tumor growth and PSA secretion in athymic 
nude mice by green and black teas. Carcinogenesis. 2006;27:833-9. 
241. Hastak K, Agarwal MK, Mukhtar H, Agarwal ML. Ablation of either p21 or Bax prevents 
p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J. 
2005;19:789-91. 
242. Lin L, Hutzen B, Ball S, Foust E, Sobo M, Deangelis S, Pandit B, Friedman L, Li C, Li 
PK, Fuchs J, Lin J. New curcumin analogues exhibit enhanced growth-suppressive activity and 
inhibit AKT and signal transducer and activator of transcription 3 phosphorylation in breast and 
prostate cancer cells. Cancer Sci. 2009;100:1719-27. 
243. Wolff GL, Kodell RL, Moore SR, Cooney CA. Maternal epigenetics and methyl 
supplements affect agouti gene expression in Avy/a mice. FASEB J. 1998;12:949-57. 
244. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for 
diagnosis and treatment. J Natl Cancer Inst. 2005;97:103-15. 
245. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, 
Bova GS, De Marzo AM, Isaacs WB, Nelson WG. Hypermethylation of CpG islands in primary 
and metastatic human prostate cancer. Cancer Res. 2004;64:1975-86. 
246. Pandey M, Shukla S, Gupta S. Promoter demethylation and chromatin remodeling by 





247. Nakagawa K, Okuda S, Miyazawa T. Dose-dependent incorporation of tea catechins, (-)-
epigallocatechin-3-gallate and (-)-epigallocatechin, into human plasma. Biosci Biotechnol 
Biochem. 1997;61:1981-5. 
248. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, Welsh W, Yang CS. Tea polyphenol (-)-
epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced 
genes in cancer cell lines. Cancer Res. 2003;63:7563-70. 
249. Lee WJ, Shim JY, Zhu BT. Mechanisms for the inhibition of DNA methyltransferases by 
tea catechins and bioflavonoids. Mol Pharmacol. 2005;68:1018-30. 
250. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol. 2004;14:R546-
51. 
251. Dashwood RH, Ho E. Dietary histone deacetylase inhibitors: from cells to mice to man. 
Semin Cancer Biol. 2007;17:363-9. 
252. Myzak MC, Tong P, Dashwood WM, Dashwood RH, Ho E. Sulforaphane retards the 
growth of human PC-3 xenografts and inhibits HDAC activity in human subjects. Exp Biol Med 
(Maywood). 2007;232:227-34. 
253. Kim SH, Kang HJ, Na H, Lee MO. Trichostatin A enhances acetylation as well as protein 
stability of ERalpha through induction of p300 protein. Breast Cancer Res. 2010;12:R22. 
254. Thompson PR, Wang D, Wang L, Fulco M, Pediconi N, Zhang D, An W, Ge Q, Roeder 
RG, Wong J, Levrero M, Sartorelli V, Cotter RJ, Cole PA. Regulation of the p300 HAT domain 
via a novel activation loop. Nat Struct Mol Biol. 2004;11:308-15. 
255. Ait-Si-Ali S, Carlisi D, Ramirez S, Upegui-Gonzalez LC, Duquet A, Robin P, Rudkin B, 
Harel-Bellan A, Trouche D. Phosphorylation by p44 MAP Kinase/ERK1 stimulates CBP histone 




256. Choi BH, Kim CG, Bae YS, Lim Y, Lee YH, Shin SY. p21 Waf1/Cip1 expression by 
curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer 
Res. 2008;68:1369-77. 
257. Deligezer U, Yaman F, Darendeliler E, Dizdar Y, Holdenrieder S, Kovancilar M, Dalay N. 
Post-treatment circulating plasma BMP6 mRNA and H3K27 methylation levels discriminate 
metastatic prostate cancer from localized disease. Clin Chim Acta. 2010. 
258. Xiang Y, Zhu Z, Han G, Lin H, Xu L, Chen CD. JMJD3 is a histone H3K27 demethylase. 
Cell Res. 2007;17:850-7. 
259. Vainio H, Weiderpass E. Fruit and vegetables in cancer prevention. Nutr Cancer. 
2006;54:111-42. 
260. Fang M, Chen D, Yang CS. Dietary polyphenols may affect DNA methylation. J Nutr. 
2007;137:223S-8S. 
261. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, Belanger C, 
LaMotte F, Gaziano JM, Ridker PM, Willett W, Peto R. Lack of effect of long-term 
supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular 
disease. N Engl J Med. 1996;334:1145-9. 
262. Zhou JR, Yu L, Zhong Y, Blackburn GL. Soy phytochemicals and tea bioactive 
components synergistically inhibit androgen-sensitive human prostate tumors in mice. J Nutr. 
2003;133:516-21. 
263. van Breda SG, van Agen E, van Sanden S, Burzykowski T, Kienhuis AS, Kleinjans JC, 
van Delft JH. Vegetables affect the expression of genes involved in anticarcinogenic processes in 
the colonic mucosa of C57BL/6 female mice. J Nutr. 2005;135:1879-88. 




Vegetables affect the expression of genes involved in carcinogenic and anticarcinogenic 
processes in the lungs of female C57BL/6 mice. J Nutr. 2005;135:2546-52. 
265. Mantena SK, Sharma SD, Katiyar SK. Berberine, a natural product, induces G1-phase 
cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol 
Cancer Ther. 2006;5:296-308. 
266. Capodice JL, Gorroochurn P, Cammack AS, Eric G, McKiernan JM, Benson MC, Stone 
BA, Katz AE. Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of a 
phase I clinical trial. J Soc Integr Oncol. 2009;7:43-51. 
267. Rafailov S, Cammack S, Stone BA, Katz AE. The role of Zyflamend, an herbal anti-
inflammatory, as a potential chemopreventive agent against prostate cancer: a case report. Integr 
Cancer Ther. 2007;6:74-6. 
268. Bemis DL, Capodice JL, Anastasiadis AG, Katz AE, Buttyan R. Zyflamend, a unique 
herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate 
cancer cells that lack COX-2 expression. Nutr Cancer. 2005;52:202-12. 
269. Yang P, Cartwright C, Chan D, Vijjeswarapu M, Ding J, Newman RA. Zyflamend-
mediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb 
protein phosphorylation. Cancer Biol Ther. 2007;6:228-36. 
270. Sandur SK, Ahn KS, Ichikawa H, Sethi G, Shishodia S, Newman RA, Aggarwal BB. 
Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and 
potentiates apoptosis through down-regulation of NF-kappa B activation and NF-kappa B-
regulated gene products. Nutr Cancer. 2007;57:78-87. 
271. Shankar S, Srivastava RK. Bax and Bak genes are essential for maximum apoptotic 




from turmeric, Curcuma longa. Carcinogenesis. 2007;28:1277-86. 
272. Chen S, Ruan Q, Bedner E, Deptala A, Wang X, Hsieh TC, Traganos F, Darzynkiewicz Z. 
Effects of the flavonoid baicalin and its metabolite baicalein on androgen receptor expression, 
cell cycle progression and apoptosis of prostate cancer cell lines. Cell Prolif. 2001;34:293-304. 
273. Wang BF, Wang JS, Lu JF, Kao TH, Chen BH. Antiproliferation effect and mechanism of 
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Zyflamend, a mixture containing extracts of ten common herbs, has been shown to cause 
regression of early stages of prostate cancer in clinical trials. The current experiments were 
designed to investigate its effects on advanced prostate cancer. Zyflamend® inhibited growth of 
human CWR22Rv1 prostate cancer cells by increasing the expression of the cell cycle regulators 
p21 and p27 through a p53-independent mechanism. Overexpression of p21 by Zyflamend® was 
associated with a suppression of class I and II histone deacetylases (HDACs) and an induction of 
CBP/p300 histone acetyl transferase activity by up regulating Erk-1/-2 and Elk-1. These effects 
were not observed with the individual herbal extracts. Our results suggest the extracts of this 
herbal combination inhibits castrate-resistant prostate cancer cell growth epigenetically by 






Prostate cancer (PrC) is currently the most commonly diagnosed solid malignancy and 
has become the second leading cause of cancer-related deaths in men in most Western developed 
countries (1). Metastatic PrC is defined as the spread of PrC cells to secondary sites (i.e., bone, 
lung, etc). Once tumors become metastatic, they are very difficult to treat, and prognosis is poor 
with a 31% 5-year survival rate (2). For the most part, PrC is temporarily responsive to hormone 
deprivation therapy as prostate epithelial cells are dependent on androgens for growth. While 
treatment with hormone deprivation results in tumor regression and clinical stabilization, the 
disease eventually relapses, with invariable fatal results within two years. Therefore, a critical 
barrier in treating advanced PrC is finding effective treatments for castrate-resistant forms of the 
disease. The CWR22Rv1 PrC cell line was chosen for the experiments because it represents a 
very late stage of PrC (3). These cells can grow in the presence or absence of androgens, produce 
prostate specific antigen (PSA) and express a functional androgen receptor (3) and, as such, these 
cells are considered to be a castrate-resistant cell line. Similarly, PrC in patients whose disease 
has relapsed following androgen ablation therapy expresses androgen receptors and produces 
PSA.  
The use of herbs, botanicals and their bioactive components have been shown to be 
effective in many tumor cells lines in vitro and in vivo by inhibiting cell and tumor growth. The 
use of herbal extracts in combination potentiates their actions, resulting in significant activity 
when any single agent has no effect (4-7). Zyflamend®, a polyherbal preparation derived from 
the extracts of ten common herbs, appears to provide clinical improvement to patients diagnosed 




(8). In addition, Zyflamend® has been shown to reduce proliferation in a variety of PrC cell lines 
by modulating genes that impact the cell cycle and apoptosis (9-11). Of particular interest to our 
laboratory is the effect of Zyflamend® on castrate-resistant PrC.  
In this study, we investigated the epigenetic effects of Zyflamend® on expression of the 
cell cycle regulator p21 and concomitant inhibition of cell proliferation. Expression of p21 is 
regulated, in part, by histone acetylation as mediated by histone deacetylases and histone acetyl 
transferases. This work was designed to explore some of the molecular mechanisms behind 
epigenetic regulation and the anti-carcinogenic effects of Zyflamend®. 
2.2 Materials and Methods 
2.2.1 Zyflamend® 
Zyflamend® (New Chapter, Brattleboro, VT) is derived from the extracts of ten different 
commonly consumed herbs (w/w): holy basil (12.8%), turmeric (14.1%), ginger (12.8%), green 
tea (12.8%), rosemary (19.2%), hu zhang (10.2%), barberry (5.1%), oregano (5.1%), baikal 
skullcap (2.5%), and Chinese goldthread (5.1%). 
2.2.2 Cell Culture  
Human prostate cell lines, RWPE-1, LNCaP, PC3 and CWR22Rv1, were purchased from 
American Type Culture Collection (Rockville, MD). RWPE-1 cells were maintained in complete 
medium containing keratinocyte serum free medium supplemented with bovine pituitary extract 
(BPE) (0.05 mg/ml) and human recombinant epidermal growth factor (hEGF) (5 ng/ml). LNCaP, 




bovine serum (FBS) under an atmosphere of 5% CO2 at 37oC. Cells were harvested with the 
addition of 0.25% trypsin with 0.02% EDTA during the exponential growth phase. For the 
experimental treatments, cells were cultured in RPMI 1640 media supplemented with 0.05% 
fetal bovine serum containing Zyflamend® or individual herbal extracts (ginger, rosemary, 
turmeric, Chinese goldthread, holy basil, hu zhang, barberry, green tea and baikal skullcap) (each 
supplied by New Chapter, Inc, Brattleboro, VT) reconstituted in dimethyl sulfoxide (DMSO) for 
cell proliferation assay, mRNA extraction and protein isolation. For inhibitor experiments, 
CWR22Rv1 cells were pretreated with U0126 (Erk inhibitor) (Cell Signaling Technology, Inc., 
Danvers, MA) at a dose of 2 μM for 30 minutes and subsequently treated with Zyflamend® (200 
μg/mL) for 24 hr. For histone deacetylase (HDAC) experiments, trichostatin A (TSA) (a general 
HDAC inhibitor) was added alone at various concentrations (0, 0.1, 0.5, 1.0 μM) or in 
combination with Zyflamend® (200 μg/mL) for 24 hours. In all experiments, 0.1% DMSO was 
used as the vehicle control.  
2.2.3 Cell Proliferation  
The MTT assay [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] 
(Andwin Scientific, Addison, IL) was used to assess relative cell growth and viability, following 
the manufacturer‟s instructions (Promega, Madison, WI). Cells (1×104 cells of RWPE-1, 
LNCaP, and CWR22Rv1, and 5×103 cells of PC3) were plated in 96-well plates in a volume of 
100 μl culture medium. The culture medium contained various concentrations of Zyflamend® 
(0, 40, 80, 100, 150, 200 μg/mL) or individual herbal extracts (10.2 μg/ml ginger, 15.4 μg/ml 
rosemary, 11.3 μg/ml turmeric, 4.1 μg/ml Chinese goldthread, 10.2 μg/ml holy basil, 8.2 μg/ml 




those doses in 200 μg/ml Zyflamend®). Cell proliferation was determined at 0, 24, 48, 72, 96 hr 
post incubation. At each time point, a mixture of MTT:complete medium (1:10, v/v) was added 
and incubated at 37℃ for 4 hr in a CO2 incubator (5%). Absorbance (at 540 nm) was measured 
on a SpectraCount microplate photometer (Perkin Elmer Inc, Waltham, MA). 
2.2.4 BrdU incorporation Assay 
Cells (1×104 cells of CWR22Rv1) were plated in 96-well plates and treated with various 
concentrations (0, 100, 150 and 200 μg/ml) of Zyflamend® for 48 hr and followed by a BrdU 
incorporation assay to assess relative DNA synthesis following the manufacturer‟s instructions 
(EMD Biosciences, Inc., Darmstadt, Germany). After Zyflamend® treatment, cells were treated 
with BrdU for 4 hr and the BrdU incorporation was measured on a FluoroCount microplate 
photometer (Perkin Elmer Inc, Waltham, MA) at a 340 nm excitation and a 460 nm emission. 
2.2.5 Down regulation of p21 by small interfering RNA  
CWR22Rv1 (1.5×105 cells per well in 6-well plates, in serum-free RPMI 1640 media) 
were transfected with validated p21 small interfering RNA (siRNA) or Stealth™ siRNA 
negative control (Invitrogen, Carlsbad, CA) (100 pmole each) using  Lipofectamine 2000™ 
transfection reagent (Invitrogen, Carlsbad, CA) following the manufacturer‟s instruction. Six 
hrs post transfection, cells were cultured with RPMI 1640 media containing 10% FBS overnight. 
After recovery, media was replaced with 0.05% FBS media containing vehicle or Zyflamend® 
(200 μg/ml) for 24 hr at 37 ℃. The total RNA was harvested for quantitative real-time 





2.2.6 Overexpression of p21  
pRc/CMV-p21 (Addgene Inc., Cambridge, MA), containing full length wild-type p21 
cDNA, was used to overexpress p21. CWR22Rv1 cells (1.5×105 cells per well in 6-well plates) 
were plated overnight. pRc/CMV-p21 or pRc/CMV (empty vector) were transfected using 
Lipofectamine 2000™ reagent in serum-free RPMI 1640 media. Transfected cells were selected 
by treatment for two weeks with neomycin (50 μg/ml) and subjected to the MTT cell 
proliferation assay. p21 protein expression in the transfected cells was examined by western blot. 
2.2.7 RNA isolation and quantitative RT-PCR 
Total RNA was isolated from CWR22Rv1 cells using Trizol reagent (Invitrogen, 
Carlsbad, CA) followed by chloroform extraction. The aqueous phase was precipitated in 100% 
isopropanol and the pellet was washed in 75% ethanol prior to re-suspension in RNase-free water. 
Contaminating DNA was removed from RNA samples using Turbo DNA free™ kit (Ambion, Inc. 
Austin, TX) and then the concentration of total RNA was measured using NanoDrop 1000™ 
(Thermo Scientifc Wilmington, DE). Total RNA (2 μg) from each sample was mixed with 
MultiScribe™ Reverse Transcriptase, RNase Inhibitor, dNTP Mixture, random hexamers, RT 
buffer, MgCl2 solution and incubated at 25℃ for 10 min, 48℃ for 30 min and 95℃ for 5 min to 
reverse transcribe to cDNA using TaqMan® reagent kit (Applied Biosystems, Carlsbad, CA).   
cDNA samples were used for quantitative RT-PCR (ABI Prism® 7300 Real-Time PCR System, 
Applied Biosystems, Carlsbad, CA). cDNA (0.7μl) was used as a template for qPCR 
amplification with primer sets (2.5 μM) of p21 sense, 5‟-TGGAGACTCTCAGGGTCGAAAA-3‟ 
and antisense, 5‟- CCGGCGTTTGGAGTGGTA-3‟, p27 sense, 5‟-




HDAC1 sense, 5‟-ACCGGGCAACGTTACGAAT-3‟ and antisense, 5‟-
CTATCAAAGGACACGCCAAGTG-3‟, H DAC2 sense, 5‟-
TCATTGGAAAATTGACAGCATAGT-3‟ and antisense, 5‟-
CATGGTGATGGTGTTGAAGAAG-3‟, HDAC3 sense, 5‟- TTGAGTTCTGCTCGCGTTACA-
3‟ and antisense, 5‟-CCCAGTTAATGGCAATATCACAGAT-3‟, HDA4 sense, 5‟-
AATCTGAACCACTGCATTTCCA-3‟ and antisense, 5‟-
GGTGGTTATAGGAGGTCGACACT-3‟, HDAC5 sense, 5‟-
TTGGAGACGTGGAGTACCTTACAG-„3 and antisense 5‟-
GACTAGGACCACATCAGGTGAGAAC-3‟, HDAC6 sense, 5‟-
TGGCTATTGCATGTTCAACCA-3‟ and antisense 5‟-GTCGAAGGTGAACTGTGTTCCT-3‟, 
HDAC7 sense, 5‟-CTGCATTGGAGGAATGAAGCT-3‟ and antisense 5‟-
CTGGCACAGCGGATGTTTG-3‟, were examined. Amplification was performed using a 
standard thermocycle  program beginning with an initial temperature at 94°C for 1 min followed 
by 30 cycles of 94°C for 15 sec, 50°C for 30 sec and 72°C for 2 min. Each sample was examined 
in triplicate and the amounts of PCR product were normalized with 36B4, 5‟-
TGCATCAGTACCCCATTCTATCA-3‟ and 5‟-AAGGTGTAATCCGTCTCCACAGA-3‟ as 
the internal control.  
2.2.8 Protein degradation   
CWR22Rv1 cells were cultured with RPMI 1640 medium containing Zyflamend® (200 
μg/ml) for 24 hr to induce p21 expression. Cells were then cultured ±Zyflamend® for an 
additional 24 hr. In addition, cells were treated with Zyflamend® (200 μg/ml) for 24 hr prior to 




hr in the continued presence or absence of Zyflamend® (200 μg/ml) and harvested for protein 
analysis. 
2.2.9 Western blotting   
CWR22Rv1 cells were lysed in the presence of cell lysis buffer (Cell Signaling 
Technology®, Inc. Danver, MA). Protein content of the lysates was quantified by BCA protein 
assay kit (Pierce Biotechnology, Inc., Rockford, IL). Lysates (20 μg) were fractioned by 8~12% 
SDS-PAGE and transferred to a polyvinylidine diflouride (PVDF) membrane by electroblotting. 
The membranes were blocked using 5% nonfat dry milk in 0.1% Tris-buffered saline-Tween-20 
(TBST) for 1 hour at room temperature and incubated in TBST containing primary antibodies 
overnight at 4°C. The membrane was incubated with anti-mouse or anti-rabbit secondary 
antibody conjugated with horseradish peroxidase (HRP) (Cell Signaling Technology®, Inc. 
Danver, MA). Protein expression was detected with a Pierce ECL Western Blotting detection 
system. Each membrane was exposed to Hyperfilm Film (GE Healthcare, Piscataway, NJ). 
Antibodies of p21, p27, p53, cyclin D1, cyclin E, HDAC1-7, Erk, phospho-Erk, Elk-1 (Cell 
Signaling Technology®, Inc. Danver, MA), phosphor-Elk-1 (GenScript USA, Inc. Piscataway, 
NJ) were used. Actin (with anti-β-actin antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, 
CA)) was used as the control. 
2.2.10 HDAC activity assay 
CWR22Rv1 cells were lysed in the presence of cold lysis buffer (10 mM Tris-HCl, pH 
7.5, 10 mM NaCl, 15 mM Mg2Cl2, 250 mM sucrose, 0.5% NP-40, and 0.1 mM EGTA). Nuclei 




NaCl, and 3 mM Mg2Cl2) and resuspended in extraction buffer (50 mM HEPES, pH 7.5, 420 
mM NaCl, 0.5 mM EDTA, 0.1 mM EGTA, and 10% glycerol). The nuclei suspension was 
sonicated on ice for 30 seconds and then the supernatant was stored at -80°C. An aliquot (30 
μg/10 μl) of the nuclear extracts was used for HDAC activity assay as per manufacturer‟s 
instructions (Cayman Chemical, Ann Arbor, MI). The assay was measured using an excitation 
wavelength of 340 nm and an emission wavelength of 460 nm (FluoroCount, Perkin Elmer Inc, 
Waltham, MA). 
2.2.11 Statistic analysis 
The results are presented as mean ± SEM and the mRNA results are presented as mean ± 
SD. The results were analyzed by two-way ANOVA. Differences were considered significant at 
p<0.05 versus control.  
2.3 Results 
2.3.1 Prostate cancer cell growth and DNA synthesis were inhibited by Zyflamend® 
Zyflamend® inhibited growth in all PrC cell lines tested in a time and concentration-
dependent manner. At the end of 96 hr treatment, Zyflamend® inhibited cell growth in RWPE-1 
cells by 80%, LNCaP cells by 60%, PC3 cells by 50% and CWR22Rv1 cells by 75% (Fig.2.1A). 
To further confirm the reduction of cell proliferation by Zyflamend®, BrdU assay was used for 
determining DNA synthesis during the cell cycle. After treatment with Zyflamend® (48 hr), 
BrdU incorporation in CWR22Rv1 cells was reduced in a concentration-dependent manner 




2.3.2 Zyflamend®-mediated induction of cell cycle inhibitors p21 and p27, mRNA and 
protein 
In CWR22Rv1 cells, Zyflamend® treatment (24 hr) induced mRNA levels for the cell 
cycle inhibitors p21 and p27 (Fig. 2.2A). Concomitantly, protein levels of p21 and p27 were 
increased by 4-fold and 2-fold, respectively, with Zyflamend® treatment compared to controls 
(Fig. 2.2B). While p21 protein expression increased in the presence of Zyflamend®, p53 
expression appears to be initially down regulated but these effects did not influence p21 (Fig. 
2.2C). In addition, cyclin E was down-regulated with no change in cyclin D1 expression (data 
not shown). Changes in p21 protein levels were determined and relative changes in expression, 
turnover, or both were investigated.   In the presence of Zyflamend® (24 hr), p21 protein 
expression was increased (lane 1 versus lane 2) (Fig. 2.2D). When Zyflamend® was removed 
(after 24 hr exposure), p21 levels did not change (lane 2 versus lane 4); however, when 
Zyflamend® was maintained for an additional 24 hr, protein level of p21 continued to increase 
(lane 2 versus lane 3), indicating Zyflamend® continuously induced p21 protein synthesis and/or 
prevented p21 protein degradation. To investigate p21 protein protection from degradation by 
Zyflamend®, cycloheximide (an inhibitor of protein synthesis) was added to the cells after 24-hr 
treatment with Zyflamend®; however, changes in p21 protein levels were not different in the 
















Figure 2.1 The effects of Zyflamend® on cell proliferation were determined using MTT or BrdU 
incorporation assays. A, RWPE-1, LNCaP, PC3 and CWR22Rv1 cells were treated 
±Zyflamend® (0, 100, 150 and 200 ug/ml) over 24, 48, 72 and 96 hr. B, CWR22Rv1 cells were 
treated with Zyflamend® for 48 hr prior to the BrdU incorporation  assay. Data are presented as 








Figure 2.2 Effects of Zyflamend® on p21 expression using CWR22Rv1 cells. A, p21 and p27 
mRNA levels (*p<0.05, ** p<0.005) were detected using qRT-PCR after 24 hr Zyflamend® 
treatment. B, p21 and p27 protein levels (24 hr treatment of Zyflamend®) using immunoblotting. 
C, protein levels of p21, p53, and cyclin E. D, p21 levels were detected in cells treated 
±Zyflamend® after 24 hrs (lane 1: control; lane 2: +Zyflamend®); after 24 hr Zyflamend® 
treatment, cells were treated ±Zyflamend® for another 24 hr (lane 3: +Zyflamend®; lane 4: -
Zyflamend®).  E, CWR22Rv1 cells were treated with Zyflamend® for 24 hr prior to adding 
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2.3.3 p21 silencing induces cell growth  
To link the molecular effects with biological outcomes, changes in p21 expression with 
cell growth were determined. CWR22Rv1 cells were transfected with siRNA against p21 in the 
presence or absence of Zyflamend®. Zyflamend® increased p21 mRNA expression in mock 
(p<0.005) and in negative control siRNA transfections (p<0.05) (Fig. 2.3A) with concomitant 
reductions in cell number (Fig. 2.3B). Transfection of p21 siRNA reduced p21 mRNA in the 
absence or presence of Zyflamend® (Fig. 2.3A). Comparing the mock/negative control groups to 
the p21 siRNA group in the presence of Zyflamend® (closed bars), there was a reduction in p21 
mRNA levels with p21 siRNA treatment (Fig. 2.3A) and a concomitant increase in cell number 
(Fig. 2.3B).  However, in cells not treated with Zyflamend® (open bars), cell numbers did not 
change following p21 siRNA treatment (Fig. 2.3B) despite reduced p21 expression below the 
baseline.  
2.3.4 p21 overexpression reduced cell growth  
To mimic the effect of Zyflamend®-induced p21, p21was overexpressed in CWR22Rv1 cells 
and confirmed by western blot (Fig. 2.3C). p21 protein levels were increased in cells with the 
p21 overexpression construct (lane 3) and in the presence of Zyflamend® (lane 2). The 
expression of p21 was further enhanced in the p21 stably transfected cells with the additon of 
Zyflamed® (lane 4).  Both p21 overexpression and the presence of Zyflamend® reduced cell 
proliferation over time (p<0.0005). The reduction of cell proliferation by p21 overexpression was 
potentiated in the presence of Zyflamend® (p<0.00005, Fig 2.3D). These results were supported, 
in part, by the fact that Zyflamend® increases p21 promoter activity (data not shown) using a full 
length human p21 promoter (2.4kb) luciferase reporter construct, consistent with increases in 







Figure 2.3 Effects of p21 on cell growth ±Zyflamend® using p21 silencing and p21 
overexpression. A, p21 mRNA levels, and B, cell proliferation, were determined in the presence 
or absence of Zyflamend® (24 or 96 hrs, respectively) in cells transfected with mock (reagent 
only), negative (scramble SiRNA) and p21 SiRNA. Data are presented as the mean ± SD.  
C, p21 protein levels in cells transfected with vector or pRc/CMV-p21 treated ±Zyflamend® for 
24 hr. D, Effects of Zyflamend® on cell proliferation in p21 or vector stably transfected cells 
using MTT assay. Data are presented as the mean ± SEM.  *p<0.05, **p<0.005, †p<0.0005, 
















2.3.5 p21 overexpression associated with cell growth reduction was significantly 
enhanced by Zyflamend®, but not individual herbs 
Of interest was whether any of the individual herbal extracts had the same effect as the 
combined herbal extracts (i.e., Zyflamend®) (Fig. 2.4). We evaluated the effects of each herbal 
extract on p21 mRNA expression and cell proliferation using the same concentrations found in 
Zyflamend®. Individual herbal extracts or Zyflamend® were added to CWR22Rv1 cells for 24 
and 48 hrs. Extracts of five herbs (barberry, goldthread, skullcap, green tea and ginger) 
significantly reduced p21 mRNA levels and three herbs (turmeric, hu zang and holy basil) 
significantly increased p21 mRNA levels; the extract from rosemery had no effect on p21 mRNA 
expression. Nevertheless, Zyflamend® had the most robust effect on increasing p21 mRNA 
levels (p=0.0004) (Fig. 2.4A) and was the only treatment that reduce cell proliferation (Fig. 
2.4B). 
2.3.6 Zyflamend®-mediates inhibition of HDACs 
Because regulation of p21 expression has been linked to HDAC activity, the effects of 
Zyflamend® on class I and class II HDACs were investigated using CWR22Rv1 cells. In the 
presence of Zyflamend®, mRNA expression of all HDACs tested (HDAC1-7) was reduced by 
30-80% (Fig. 2.5A). The reduction of HDAC protein levels was confirmed by western blot, and 
treatment with TSA (general HDAC inhibitor) was used as a control (Fig. 2.5B). Zyflamend®  
reduced protein levels (i.e., lane 1 versus lane 5) for HDAC1, HDAC2, HDAC3, and HDAC4, 
but not with HDAC5 or HDAC7. Treatment of CWR22Rv1 cells with TSA was shown to inhibit 
HDAC3 and HDAC4 expression in a dose-dependent manner (Fig. 2.5B). Concomitantly, 




affect the structure of chromatin by removing acetyl groups from histones, thereby reducing 
transcriptional expression, histone acetylation was examined. Histone 3 acetylation was 
increased in the presence of TSA, Zyflamend® and the combination of TSA plus Zyflamend® 
(lane 1, lane 5 and lane 8) (Fig. 2.5D). Induction of p21 protein expression accompanied these 
changes, suggesting coordinated modulation of both events. 
In addition, the effects of individual herbal extracts on HDAC expression were explored 
(Fig. 2.5E). Only Chinese goldthread and baikal skullcap appeared to mimic the down-regulation 
observed with Zyflamend® with regards to all HDACs tested. Extracts of rosemary, hu zang, 
holy basil, turmeric, green tea, barberry and ginger were unable to duplicate the effects observed 
with Zyflamend®.  
2.3.7 Zyflamend®-induced p21 expression and induction of acetyl CBP/p300 via the 
MAPK pathway  
To determine the involvement of mitogen-activated protein (MAP) kinases on p21 
protein expression, we used the Erk inhibitor U0126 ± Zyflamend®. U0126 reduced 
Zyflamend®-induced p21expression (Fig. 2.6A). One target of particular interest was CBP/p300, 
transcriptional coactivators with histone acetyl transferase activity, and the down-stream target 
proteins of Erk and Elk-1. Zyflamend® increased the levels of phosphorylated Erk and Elk-1, 








Figure 2.4 Effects of individual herbal extracts versus Zyflamend® on p21 mRNA expression 
and cell proliferation using CWR22Rv1 cells. A, Cells were treated with Zyflamend® or 
individual herbs at doses equivalent to those in Zyflamend® for 24 hr, and p21 mRNA was 
quantified by RT-PCR and normalized to control (* p<0.05). B, Cells were treated with 
Zyflamend® or individual herbal extracts for 48 hr and cell proliferation was measured by MTT 
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Figure 2.5 Class I and class II histone deacetylases mRNA, protein and activity were determined 
±Zyflamend® in CWR22Rv1 cells. A, HDACs mRNA levels after treatment with Zyflamend® 
for 24 hr. B, HDAC proteins levels ±Zyflamend®, ±TSA after 24 hr treatment. C, Effects of 
Zyflamend® on nuclear HDAC activity (nM/min/ug protein). D, Acetyl histone 3 (AcH3), 
histone 3 and p21 protein levels ±Zyflamend®, ±TSA after 24 hr. E. Effects of individual herbal 















Figure 2.6 Effects of Zyflamend® on the mitogen-activated protein kinase (MAPK) pathway and 
p21 expression. A, Effect of Zyflamend® on p21 protein expression in the presence or absence 
of the Erk inbibitor U0126 (2 uM).  B, Effects of Zyflamend® (0-60 min treatment) on protein 
expression of p-Erk, p-Elk-1 and acetyl-CBP/p300. C. A model of epigenetic regulation by 
Zyflamend® on p21 expression by activation of histone acetyl transferase (CBP/p300) through 
















2.4    Discussion 
The use of herbs and botanicals and their bioactive components are effective inhibiting 
growth, angiogenesis, metastasis and inducing apoptosis in many tumor lines. Many of their 
molecular mechanisms of action have been characterized in vitro (12, 5, 13). In addition, the use 
of herbal extracts in combination appears to potentiate each other‟s actions, resulting in 
significant activity whereas single agents may have greatly reduced effects (7, 14). 
Zyflamend® is derived from the extracts of ten different herbs, each with reported 
medicinal properties. Individuals diagnosed with HGPIN are at increased risk for developing PrC 
(15). When this polyherbal preparation was used in a Phase I clinical trial with patients 
diagnosed with HGPIN, reductions in PSA and re-diagnosis to benign forms of prostate tissue 
were reported (8, 16). Based on this data, we investigated the effects of Zyflamend® in a cell 
model of castrate-resistant PrC with a particular interest in identifying molecular mechanisms of 
action.  
To understand the doses used in this study, we chose a maximum dose of Zyflamend® 
based on the levels of curcumoids (~7% w/w in turmeric (17)) found in the poly-mixture. This 
level of curcumoids would be equivalent to the identifiable range of human plasma 
concentrations for Zyflamend® at these physiologically relevant concentrations inhibited PrC 
cell growth in concentration- and time-dependent manners. These effects were observed in 
RWPE-1 cells (immortalized prostate epithelial cells that represent an early stage of the disease, 
i.e., PIN (18)), and in tumor cell lines representing androgen-dependent (LNCaP), androgen-
independent (PC3), and castrate-resistant (CWR22Rv1) forms of the disease. Similar results with 




previous interest of investigating castrate-resistant PrC (19), we focused our attention on those 
underlying molecular mechanisms responsible for these effects using CWR22Rv1 cells. 
Zyflamend® increased cell cycle regulators p21 and p27, duplicating previous results of 
Zyflamend® on p21 expression (9, 11). P21 and p27 are common targets for bioactive 
phytonutrients (7, 20). Zyflamend® consistently enhanced mRNA and protein levels in dose- 
and time-dependent manners. These effects were always biologically correlated with reductions 
in cell proliferation. Increases in p21 protein levels were due to increases in transcription and not 
a reduction in protein stability. Transcriptional expression of p21 can be regulated by p53-
dependent (21-23) and/or p53-independent (24-31) mechanisms. We observed that Zyflamend®-
mediated increases in p21 were not accompanied by concomitant changes in p53 expression. We 
also observed reductions in the expression of cyclin E, a protein inhibited by p21 and involved in 
regulating the transition of the G1/S phase of the cell cycle. In addition to these effects, 
Zyflamend® has been reported to modify other cell cycle regulators, including retinoblastoma 
protein (phosphorylation) and cyclin D1 in PC3 cells (11). 
To confirm that Zyflamend® was attenuating cell proliferation, in part, by up-regulating 
p21 expression, we used siRNA technology to silence p21 and stably transfected cells for over 
expression. Overexpression of p21 significantly inhibited proliferation, duplicating those effects 
observed with Zyflamend®. Knocking down p21 mRNA levels in the absence of Zyflamend® 
had no effect on cell proliferation, suggesting the basal level of p21 was not acting in a 
regulatory manner. However, knocking down Zyflamend®-induced p21 mRNA levels increased 
cell proliferation, reaffirming that the effects of Zyflamend® are, in part, mediated by p21 




an added reduction in cell proliferation, suggesting multiple mechanisms may be involved. This 
makes sense since Zyflamend® is comprised of 10 different herbal extracts. 
Induction of p21 expression by the individual herbal extracts was quite variable. 
However, cell proliferation was unaffected by any of the herbal extracts when used individually 
at concentrations present in the Zyflamend® preparation; only the combination proved to be 
effective. Levels of each extract when used individually could have been below the 
physiologically active threshold, accounting for the lack of effects on cell proliferation (as 
discussed in Ref (5)). 
Post-translational modification of histones, in particular the removal or addition of acetyl 
groups on ε-N-acetyl lysine residues, play an important role in epigenetic regulation of 
transcription (32). Acetylation of the N-terminal tails of histones “relaxes” the chromatin making 
it more accessible for binding by coactivating factors. The result is an increase in gene 
expression. In contrast, deacetylation results in a more compact chromatin and transcriptional 
repression. Regulation of acetylation is a balance between histone acetyl transferases and histone 
deacetylases (HDACs) (33). HDACs in particular are important in cancer biology, by promoting 
proliferation, angiogenesis, migration/metastasis, resistance to chemotherapy, and inhibiting 
apoptosis and differentiation (as reviewed in Ref (34)). Identification of HDAC inhibitors is 
therefore a new therapeutic approach to treat cancer (35). 
Epigenetic regulation via acetylation is important in regulating tumor suppressor genes, 
such as p21 (36). Zyflamend® increased acetylation of histone 3, in part, by down regulating 
mRNA levels of class I and class II HDACs (HDAC1-7), reducing protein expression of HDAC1, 




be particularly specific for the repression of p21 expression (37, 36, 38). Hyper-acetylation of 
Sp1 binding sites in the proximal promoter is a key regulator of p21 expression (36) and HDAC4 
has been shown to regulate expression through a Sp1-dependent, p53-independent pathway (37). 
In contrast to Zyflamend®, when cells were treated with the individual herbs, only 
goldthread and skullcap reduced HDAC expression, but interestingly p21 expression was down 
regulated in the presence of either of these herbal extracts. There is increasing evidence that 
many bioactive phytochemicals may function as histone deacetylases inhibitors, but these results 
typically are generated with concentrations many times higher than what was used here (39). 
Up regulation of p21 expression also is coordinately regulated by CBP/p300. CBP/p300 
proteins are transcriptional coactivators with histone acetyltransferase activity that is involved in 
the regulation of p21 expression through the Sp1 binding sites (40-41). The histone 
acetyltransferase activity of CBP/p300 is increased by phosphorylation and is regulated upstream 
by Erk-1/-2 and its downstream regulator, Elk-1 (42). MAP kinase-dependent phosphorylation of 
Elk-1 results in interaction with p300 and increased histone acetyltransferase activity (43). In a 
time-dependent manner, Zyflamend® increased the expression of pErk and pElk-1, followed by 
the acetylated form of CBP/p300 (44). MAP kinase involvement was confirmed using the Erk-
1/-2 inhibitor U0126 which resulted in the down regulation of pErk in a time dependent manner 
(data not shown) and inhibition of Zyflamend®-induced p21 expression. Stimulation of p21 
expression via up regulation of the Erk pathway has been observed by others and these effects 





In summary, Zyflamend® is composed of ten concentrated herbal extracts. It has been 
used successfully in a Phase I clinical trial (8), suggesting it may be helpful for patients 
diagnosed with PIN, which is related to development of PrC. These studies suggest it also may 
have utility in addressing advanced forms of PrC. The concentrations used in this study were of 
importance and carefully considered. When compared to the multi-herbal preparation, the use of 
the herbal extracts in isolation could not duplicate the overall effects of Zyflamend®, and this 
may be related to those concentrations used. Zyflamend inhibited tumor cell growth in vitro, in 
part, by up-regulating the tumor suppressor protein p21. The epigenetic regulation of p21 by 
Zyflamend® can be summarized in Figure 2.6 C. Increased expression of p21 was coordinately 
regulated by activation of the histone acetyltransferase CBP/p300 through up regulation of pErk 
signaling and through concomitant down regulation of class I and class II HDACs. These effects 
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Zyflamend® Reduces the Expression of Androgen Receptor and 
Insulin-Like Growth Factor Receptor, Biomarkers of Cancer 






Prostate cancer is the most commonly diagnosed solid malignancy and tumor cells 
eventually transform to castrate-resistant or androgen-independent relapse through the proposed 
activation of the androgen receptor via insulin-like growth factor receptor (IGF-1R) signaling 
involving phospho-AKT (pAKT). In this study, a mixture of medicinal herbal extracts, 
Zyflamend®, was used as an adjuvant treatment in a model of castrate-resistant prostate cancer, 
CWR22Rv1 cells. We found that Zyflamend® reduced androgen receptor and IGF-1R 
expression along with a reduction of IGF-1-mediated proliferation of CWR22Rv1 cells. To 
investigate the involvement of pAKT in the downstream signaling of IGF-1, IGF-1 activated 
AKT phosphorylation; however, the induction of pAKT was not associated with androgen 
receptor expression. Further, constitutive active form of AKT had no effect on nuclear expression 
of androgen receptor, indicating that upregulation of pAKT did not promote androgen receptor 
expression or nuclear translocation in castrate-resistant CWR22Rv1 cells. Conversely, 
Zyflamend® reduced androgen receptor expression following IGF-1 stimulation and in cells 
over-expressing pAKT. These results demonstrated that Zyflamend® inhibited IGF-1-stimulated 
cell growth, IGF-1R expression and androgen receptor expression and its nuclear localization, 
but these effects were not mediated through PI3K/pAKT signaling. In addition to an inhibition of 
androgen receptor and its growth promoting effects by Zyflamend®, it was found that 
Zyflamend® influenced indices of proliferation and apoptosis by inducing caspase 3 activity, 
PARP cleavage, and inhibiting Bcl-2 expression and the proliferative biomarker Ki67. In 
conclusion, Zyflamend® inhibited IGF-1R and androgen receptor expression in a PI3K/pAKT 
independent manner. Furthermore, some of Zyflamend‟s effects involve a concomitant decrease 





Prostate cancer is the most commonly diagnosed solid malignancy. In the last few years, 
prostate cancer has become the second leading cause of cancer-related deaths in men in the 
United States (1-2). The advanced forms of prostate cancer metastasize to distant organs, most 
commonly bone, and eventually become castrate-resistant or androgen-independent following 
androgen deprivation (commonly referred to as androgen deprivation or hormone ablation 
therapy) (3). This advanced stage of the disease is very difficult to treat and is invariably fatal.  
Zyflamend® is a poly herbal preparation consisting of the supercritical CO2 fluid extracts 
of ten different medicinal herbs shown to have anti-neoplastic activity. In phase I clinical trials, 
Zyflamend® has demonstrated efficacy in patients with high-grade prostatic intraepithelial 
neoplasia (HG-PIN), a premalignant form of the disease (4), and has inhibited the growth of 
androgen-dependent, androgen-independent and castrate-resistant prostate cancer cells in vitro 
and in vivo via multiple mechanisms (5-6). These latter results suggest that Zyflamend® could 
potentially have efficacy in metastatic forms of this disease, a possible adjuvant to hormone 
deprivation therapy. The mechanisms of prostate cancer cell resistance to androgen 
withdrawal have been investigated and one mechanism that is repeatedly mentioned as a 
potential target is reactivation of androgen signaling in the absence of androgens  (7). 
Amplification of androgen receptor expression (8) and activation of androgen signaling, in 
the absence or presence of very low levels of androgens, may involve crosstalk with other 
signaling pathways (9-10). For example, androgen receptor signaling can be activated via 
crosstalk between, insulin-like growth factor-1 (IGF-1)/ insulin-like growth factor-1 receptor 
(IGF-1R) signaling. Levels of IGF-1 are significantly higher in metastatic prostate cancer 




activate the androgen receptor in the presence of low levels of androgens (12).Similarly, the 
expression of IGF-1R is increased in patients with progressive forms of prostatic neoplasia (13), 
demonstrating a correlation of IGF-1/IGF-1R and prostate cancer progression. The mechanisms 
of IGF-1/IGF-1R on androgen receptor activation have linked IGF-1/IGF-1R signaling to 
increased androgen receptor activity through phosphatidylinositol 3-kinase (PI3K)/AKT 
phosphorylation (12, 14). The PI3K/AKT pathway is reported to activate androgen receptor 
signaling via the dissociation of a suppressor-androgen receptor complex, thus allowing 
androgen receptor to bind to the promoter regions of target genes such as prostate specific 
antigen (PSA) (15-16) and cell proliferative promoting growth factors such as IGF-1 (17), 
forming a positive feedback of androgen receptor and IGF-1 signaling. However, this pathway 
has yet to be studied in a model of castrate-resistant prostate cancer using cells that are more in-
line with the human disease, those that express an active androgen receptor, secrete human PSA 
and can grow in an androgen-deprived environment. 
In this study, we used a combination of herbal extracts, Zyflamend®, as an adjuvant 
therapy in an experimental model of castrate-resistance using a the human prostate cancer cell 
line, CWR22Rv1. Zyflamend® has been found to inhibit androgen receptor expression in an 
androgen-dependent prostate cancer cell line, LNCaP (5), but the mechanisms were not 
investigated. In this study, we found that Zyflamend® reduced protein levels of IGF-1R and 
androgen receptor in CWR22Rv1 cells and investigated whether crosstalk between these 





3.2. Materials and Methods 
3.2.1 Cell Culture  
Human prostate cancer cell line, CWR22Rv1, was purchased from American Type 
Culture Collection (Rockville, MD). CWR22Rv1 cells were maintained in RPMI 1640 media 
supplemented with 10% fetal bovine serum under an atmosphere of 5% CO2 at 37
o
C. Cells were 
harvested with the addition of 0.25% trypsin with 0.02% EDTA during the exponential growth 
phase. For the experimental treatments, cells were cultured in RPMI 1640 media supplemented 
with 0.05% fetal bovine serum containing Zyflamend® ( New Chapter, Inc, Brattleboro, VT) 
reconstituted in dimethyl sulfoxide (DMSO) for cell proliferation assay, mRNA extraction and 
protein isolation. In all experiments, 0.1% DMSO was used as the vehicle control. CWR22Rv1 
cells are hormone independent and represent a very late stage of prostate cancer following 
hormone ablation. On the other hand, CWR22Rv1 cells produce PSA and express a functional 
androgen receptor. These cells can grow in the presence or absence of androgens and are 
considered to be a castrate-resistant cell line (18). CWR22Rv1 cells were chosen for most of the 
experiments because prostate cancer cells in most patients who relapse following androgen 
ablation therapy express androgen receptor and produce PSA. 
3.2.2 Cell Proliferation  
MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] (Andwin 
Scientific, Addison, IL) is cleaved by metabolically active cells to form a formazan, 
chromaphore product that absorbs at 540 nm. The MTT assay was used to assess relative cell 
growth and viability, following the manufacturer‟s instructions (Promega, Madison, WI). Cells 
(1×10
4 
cells of CWR22Rv1) were plated in 96-well plates in a volume of 100 ul culture medium. 




growth-like factor-1 (100 ng/ ml). 0.1% of DMSO was used as the controls. For PI3K inhibitor 
experiments, cells were treated wortmannin (1.0 μM). Cell proliferation was determined at 0, 24, 
48, 72, 96 hr post incubation. At each time point, a mixture of MTT:complete medium (1:10, 
v/v) was added and incubated at 37
 o
C for 4 hr in a CO2 incubator (5%). The absorbance was 
measured on a SpectraCount microplate photometer (Perkin Elmer Inc, Waltham, MA). 
3.2.3 Induction of pAKT by Adenovirus infection  
CWR22Rv1 cells (1.5×10
5
 cells per well in 6-well plates) were plated overnight prior to 
adenovirus infection. The myrAkt1 adenovirus N-terminally myristoylation signal-attached Akt 
(myr-Akt) expresses constitutive active AKT1 protein described previously (19). CWR22Rv1 
cells in RPMI 1640 media containing 10% FBS were infected with the myrAKT1 adenovirus 
for 6 hr, after which time the cells were cultured overnight in RPMI 1640 media containing 
0.5% FBS while β-Gal constructed adenovirus was used as the control. Infected cells were pre-
treated with vehicle or Zyflamend® (200 ug/ml) for 24 hr at 37 
o
C.  Protein expression of 
pAKT (serine 473), AKT and androgen receptor was examined by western blot.  
3.2.4 Western blotting   
CWR22Rv1 cells were lysed in the presence of cell lysis buffer (Cell Signaling 
Technology®, Inc. Danver, MA). Protein concentrations of the lysates were quantified by BCA 
protein assay kit (Pierce Biotechnology, Inc., Rockford, IL). Lysates (15 ug) were fractioned by 
8~12% SDS-PAGE and transferred to a polyvinylidine diflouride (PVDF) membrane by 
electroblotting.  The membranes were blocked using 5% nonfat dry milk in 0.1% Tris buffered 
saline-Tween-20 (TBST) for 1 hour and were incubated with primary antibodies overnight at 4°C. 




horseadish peroxidase (HRP) (Cell Signaling Technology®, Inc. Danver, MA). Protein 
expression was detected with a Pierce ECL Western Blotting detection system. Each membrane 
was exposed to Hyperfilm Film (GE Healthcare, Piscataway, NJ). Antibodies of AR, phospho-
ser473-AKT, AKT, cleaved caspase 3, poly (ADP-ribose) polymerase, p65 (Cell Signaling 
Technology®, Inc. Danver, MA), IGF-1Rα and Ki67 (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA) were used. β-actin with anti-β-actin antibody (Santa Cruz Biotechnology, Inc., Santa 
Cruz, CA) was used as the control. 
3.2.5 Immunofluorescence staining 
CWR22Rv1 cells were seeded on the cover slips supplemented in RPMI 1640 media with 
10% FBS under an atmosphere of 5% CO2 at 37
o
C overnight.  Before the treatment, CWR22Rv1 
cells were maintained in RPMI 1640 media with 0.5% FBS. For the observation of androgen 
receptor translocation, the cells were pretreated with Zyflamend® (200 ug/ml) for 24 hr.  After 
the treatment, the cells were fixed using 2% paraformaldehyde for 15 min, followed by blocking 
with 10% goat serum (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) for 1hr, and anti-
androgen receptor antibody (1 μg) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) overnight at 
4 
 o
C. Alexa Fluor® 488 goat anti-rabbit IgG was used as secondary antibody. 
3.2.6 Caspase 3/7 activity assay 
CWR22Rv1 cells were lysed in cell lysis buffer after treated with Zyflamend®. Fifty μg 
of cell lysates were used for the Caspase 3/7 Assay (Promega, Madison, WI).  Briefly, 50 μg of 
cell lysates in 50 μl lysis buffer were mixed with 50 μl of caspase 3/7 reagent and incubated in 
dark for 1 hr at room temperature. Caspase 3/7 activity was measured on a FluoroCount 




emission.   
3.2.7 Protein degradation   
CWR22Rv1 cells were cultured with RPMI 1640 medium containing Zyflamend® (200 
μg/ml) for 24 hr prior to adding cycloheximide (10 μM) to terminate protein synthesis for an 
additional 0, 0.5, 1, 1.5, 2, 4 hr in the continued presence or absence of Zyflamend® (200 μg/ml) 
and harvested for protein analysis. 
3.2.8 RNA isolation and quantitative RT-PCR 
Total RNA was isolated from CWR22Rv1 cells using Trizol reagent (Invitrogen, 
Carlsbad, CA) followed by chloroform extraction. The aqueous phase was precipitated in 100% 
isopropanol and the pellet was washed in 75% ethanol prior to re-suspension in RNase-free water. 
Contaminating DNA was removed from RNA samples using Turbo DNA free™ kit (Ambion, Inc. 
Austin, TX) and then the concentration of total RNA was measured using NanoDrop 1000™ 
(Thermo Scientific Wilmington, DE). Total RNA (2 μg) from each sample was mixed with 
MultiScribe™ Reverse Transcriptase, RNase Inhibitor, dNTP Mixture, random hexamers, RT 
buffer, MgCl2 solution and incubated at 25℃ for 10 min, 48℃ for 30 min and 95℃ for 5 min to 
reverse transcribe to cDNA using TaqMan® reagent kit (Applied Biosystems, Carlsbad, CA).   
cDNA samples were used for quantitative RT-PCR (ABI Prism® 7300 Real-Time PCR System, 
Applied Biosystems, Carlsbad, CA). cDNA (0.7μl) was used as a template for qPCR 
amplification with primer sets (2.5 μM) of androgen receptor sense, 5‟- 
CCTGGCTTCCGCAACTTACAC-3‟ and antisense 5‟- GGACTTGTGCATGCGGTACTCA-3‟, 
and prostatic specific antigen sense, 5‟ - ACCAGAGGAGTTCTTGACCCCAAA-3‟ and 




using a standard thermocycle  program beginning with an initial temperature at 94°C for 1 min 
followed by 30 cycles of 94°C for 15 sec, 50°C for 30 sec and 72°C for 2 min. Each sample was 
examined in triplicate and the amounts of PCR product were normalized with 36B4, 5‟-
TGCATCAGTACCCCATTCTATCA-3‟ and 5‟-AAGGTGTAATCCGTCTCCACAGA-3‟ as the 
internal control.  
3.2.9 Statistical  analysis 
The results are presented as mean ± SD and multiple comparisons are analyzed by a two-
way ANOVA. Differences were considered significant at p<0.05.  
3.3. Result 
3.3.1 Effect of Zyflamend® on the growth of castrate-resistant prostate cancer 
CWR22Rv1 cells  
Zyflamend® inhibited growth of castrate-resistant prostate cancer cells, CWR22Rv1 cells, 
in a time-dependent manner. After 48 hr treatment, Zyflamend® significantly inhibited cell 
growth by 38% (p<0.005), and cell growth was further reduced by 70% (p<0.005) after a 96 hr 
treatment (Figure 3.1).  
3.3.2 Zyflamend® and androgen receptor and prostate specific antigen expression 
Androgen receptor in CWR22Rv1 cells was detected via immunofluorescent imaging 
following 24 hr treatment of Zyflamend®. The green fluorescent stain corresponds to protein 
intensity.  Zyflamend® reduced androgen receptor intensity as measured via immunofluorescent 
staining (Figure 3.2A). This result was confirmed with western blot analysis (Figure 3.2A). 




greater than 65%. However, androgen receptor degradation was not promoted by Zyflamend® 
(Figure 3.2 C) when protein synthesis was blocked by cycloheximide.  
3.3.3 Zyflamend® and its effect on cell proliferation in the presence or absence of 
IGF-1   
CWR22Rv1 cells were treated with IGF-1 (10 and 100 ng/ml) with and without 
Zyflamend® (200 µg/ml) for up to 96 hrs. IGF-1 increased cell proliferation in a dose-dependent 
manner and these effects were significantly attenuated in the presence of Zyflamend® (Figure 
3.3B). These results were consistent with a reduction in the protein levels of IGF-1R (Figure 
3.3C).  Cultured cell morphology was monitored over 96 hr following treatment with vehicle 
(control), IGF-1, Zyflamend® and a combination of IGF-1 and Zyflamend® (Figure 3.3D).  
IGF-1 increased cell density compared to the control cells after 24 hr treatment.  Conversely, 
cells started to shrink, round-up, and detach with treatment of Zyflamend® at 24 hr compared to 
the control and IGF-1-treated cells (Figure 3.3E). This affect of Zyflamend® was delayed by 
IGF-1, but by 48 hr cells exposed to the combination of IGF-1 and Zyflamend® were similar to 













Figure 3.1 The effect of Zyflamend on cell proliferation. CWR22Rv1 cells were treated with 
Zyflamend® (200 μg/ ml) for 0-96 hr and cell proliferation was compared to control using MTT 
assay. Values are means±SEM (n=8/group). Differences were considered significant at p<0.05 as 


































Figure 3.2 Effect of Zyflamend® on androgen receptor (AR) and prostate specific antigen (PSA) 
expression. A. Zyflamend® (200 μg/ml) was added to the cells for 24 hr and the expression of 
AR was detected using immunofluorescent staining and protein expression via western blot 
analysis. B. Expression of mRNA levels of AR and PSA were detected using RT-PCR following 
24 hr-treatment of Zyflamend® (200 μg/ml). Values are means±SEM (n=3/group) and 
considered significant at p<0.05 as compared to the control. C. AR synthesis was blocked using 
cycloheximide for 4 hrs with or without Zyflamend® and levels of AR were monitored via 























Figure 3.3 Effect of Zyflamend® on IGF-1R expression and cell proliferation in the presence or 
absence of IGF-1. A. This figure presents the signaling model where IGF-1/IGF-1R potentially 
promotes cell growth via pathways dependent upon or independent of androgen receptor. B. Cell 
proliferation (0-96 hr) in the presence or absence of IGF-1 (10 and 100 ng/ml) and Zyflamend 
(200 μg/ml). Values are means±SEM (n=8/group) and considered significant at p<0.05 as 
compared to control. C. IGF-1R expression levels (protein) following 24 hr treatment of 
Zyflamend® (200µg/ml). D. Effect of IGF-1 on morphological changes in CWR22Rv1 cells in 
the presence or absence of Zyflamend® after treatment for 96 hrs. E. Enlarged images of 

























control 10 ng/ml IGF-1 100 ng/ml IGF-1
Zyflamend 10 ng/ml IGF-1 + Zyflamend 100 ng/ml IGF-1 + Zyflamend
C 
* * 




* * * 
* * 





















3.3.4 Effect of IGF-1 and Zyflamend® on pAKT, IGF-1R and androgen receptor 
expression  
To investigate whether IGF-1/IGF-1R signaling regulates androgen receptor expression 
and/or nuclear translocation via pAKT, CWR22Rv1 cells were treated with IGF-1 (10 and 100 
ng /ml) for 10 min to stimulate AKT phosphorylation (Figure 3.4 A). To determine if these 
effects influenced the expression of IGF-1R and androgen receptor in the presence or absence of 
Zyflamend®, cells were pre-treated with IGF-1 (100 ng/ml) for 10 min, followed by treatment of 
±Zyflamend® for up to 24 hr. As demonstrated previously, pre-treatment of cells with of IGF-1 
increased pAKT expression, with no effect on IGF-1R and androgen receptor expression. 
Zyflamend®, on the other hand, reduced IGR-1R receptor expression (as reported previously), 
but increased phosphorylation levels at serine 473 on AKT were not associated with an induction 
ofandrogen receptor expression. These results question the link between pAKT and androgen 
receptor expression (Figure 3.4B).      
To confirm that IGF-1/IGF-1R signaling was not influencing androgen receptor 
expression and nuclear translocation, cells were pretreated in the absence or presence of IGF-1 
(100 ng/ml, 10 min)  followed by Zyflamend® (200 ng/ml) for 24 hr and the levels of androgen 
receptor (cytosol and nucleus) were determined via immuno-fluorescent staining (Figure 3.4 C).  
Cellular and nuclear levels of androgen receptor were unaffected by preincubating cells with 
IGF-1, suggesting that IGF-1 signaling did not affect nuclear translocation. On the other hand, 










Figure 3.4 Effect of IGF-1 and Zyflamend® on pAKT, IGF-1R and androgen receptor (AR) 
expression. A. Effect of IGF-1 (10 and 100 ng/ml) on expression levels of pAKT.  B. Effect of 
IGF-1 (pretreatment of 100 ng/ml for 10 min) in the presence or absence of Zyflamend® (0-24 
hr). IGF-1Rα, AR, AKT and phospho-ser473 AKT were valued using immunebloting. C. 
CWR22Rv1 cells were treated with Zyflamend for 24 hr prior to treatment with IGF-1 (100 
ng/ml). Expression of AR was evaluated using immuno-fluorescent staining. Nuclear AR 
intensity was quantified with DAPI staining. Values are means±SEM (n=250/group) and 











3.3.5 Effect of overexpression of pAKT via adenovirus infection on androgen receptor 
expression and translocation   
To investigate the effect of AKT phosphorylation on androgen receptor expression and 
nuclear translocation, overexpression of pAKT via myrAkt1 adenovirus was used. Increasing the 
levels of the adenovirus resulted in increased levels of AKT and pAKT, but had no effect on 
androgen receptor expression (Figure 3.5A).  Zyflamend® treatment of adenovirus-infected cells 
inhibited androgen receptor expression and these results were not associated with pAKT levels. 
These results suggest that although Zyflamend® reduces the expression of androgen receptor 
(cellular and nuclear) and IGF-1R, these effects are not mediated via changes in pAKT.   
3.3.6 Inhibition of PI3 kinase with wortmannin in the presence or absence of 
Zyflamend®  
Wortmannin (1.0 µM), a PI3 kinase inhibitor, and Zyflamend® (200 ug/ml) inhibited cell 
proliferation in a time dependent manner. Wortmannin reduced cell growth by 57% after 96 hr 
treatment (Figure 3.6A). LY294002, another PI3 kinase inhibitor, showed the same reductions in 
cell growth over the time period (data not shown), indicating PI3K inhibition reduces 
CWR22Rv1 cell growth and these effects were similar to or greater than those observed with 
Zyflamend® (Figure 3.6B). . However, the inhibitory effect of wortmannin on the PI3 kinase 
pathway did not reduce androgen receptor expression (Figure 3.6 C). 
3.3.7 Effects of Zyflamend® on biomarkers of apoptosis and proliferation  
Zyflamend® (200 ug/ml) reduced the levels of pro-caspase 3 in a dose-dependent manner 
(Figure 3.7 A) and concomitantly increased caspase 3 activity (Figure 3.7 B). Cleavage of PARP, 




Expression of the proliferative marker, Ki67 and the anti-apoptotic protein, Bcl-2, were inhibited 
by Zyflamend® treatment  (Figure 3.7 C), suggesting Zyflamend® affects tumor cell number by 












Figure 3.5 Androgen receptor expressions in CWR22Rv1 cells infected with the adenovirus 
myrAKT1 in the absence or presence of Zyflamend®.  A. CWR22Rv1 cells were infected with 
adeno-myrAKT1 at uncreasing doses while β-Gal was used as the control. Total AKT, phospho-
serine473-AKT, androgen receptor and β-actin were detected via western blot analysis. B. 
Androgen receptor levels in the nuclear fraction of CWR22Rv1 cells following infection with 
adeno-myrAKT1. C. Protein expression of androgen receptor and pAKT in CWR22Rv1 cells co- 

























Figure 3.6  Effect of Zyflamend® (200 μg/ ml) and the PI3K inhibitor, wortmannin (1.0 μM), on 
cell proliferation and the expressions of pAKT and androgen receptor. Values are means±SEM 
(n=8/group) and considered significant at p<0.05 as compared to control.  A. CWR22Rv1 cells 
were treated with Zyflamend® or the PI3K inhibitor, wortmannin and cell proliferation was 
evaluated from 0-96 hr. Values are mean±SEM (n=8/group) and groups are considered 
significant at p<0.0 5. B and C. Protein expressions of pAKT and androgen receptor were 

















Figure 3.7 Effect of Zyflamend® on levels of pro-caspase-3,caspase 3/7 activity, PARP cleavage 
and expressions of Bcl-2 and Ki67 in CWR22Rv1 cells.  A. Protein levels of pro-caspase 3 were 
determined after 24 hr treatment with Zyflamend® (0-200 ug/ml). B. Caspase3/7 activity after 24 
hr treatment with Zyflamend® (200 ug/ml). Values are means±SEM (n=3/group) and considered 
significant at p<0.05.  C. Protein levels of cleaved PARP, Ki67, and Bcl-2 were determined after 






Prostate cancer relapse following androgen deprivation therapy is of particular 
concern with more advanced forms of the disease, particularly in those patients with 
metastatic prostate cancer. Prostate cancer cells are dependent upon androgens for growth 
and androgen deprivation results in regression. However, the cancer inevitably relapses and 
up regulation of the androgen receptor is a huge concern in controlling castrate-resistant 
relapse (20), as such; amplification of androgen receptor signaling has been identified as a 
potential target (7, 17), where identification of compounds that can antagonize this pathway, 
with few side effects, is paramount.  
One of these compounds could be Zyflamend®. We previously demonstrated that 
Zyflamend® can inhibit CWR22Rv1 cell proliferation via multiple mechanisms, most 
notably epigenetically through histone acetylation. This study confirmed that Zyflamend® 
inhibits proliferation by down-regulating the proliferative marker, Ki67 (consistent with our 
earlier findings that Zyflamend® inhibited BrdU incorporation), and modifying indices of 
apoptosis (increasing caspase 3 activity and PARP cleavage and reducing Bcl-2 expression).     
 Amplification of androgen receptor signaling includes overexpression of androgen 
receptor, induction of androgen receptor activity (8), or crosstalk with other receptor pathways 
such as IGF-1/IGF-1R (12, 21). Several mechanisms involving the activation of the IGF-
1/IGF-1R/AKT signaling pathway on androgen receptor regulation have been proposed. One 
pathway involves the androgen receptor regulator Foxo1. IGF-1 activates IGF-1R and its 
downstream kinases, PI3K and AKT. Activated AKT (pAKT) translocates to the nucleus and 




dissociates from the androgen receptor, allowing it to activate target genes that can promote 
cell growth (15). It has also been proposed that IGF-1 enhances nuclear translocation of 
androgen receptor and activation of co-regulators in the absence of androgens, possibly 
through the action of a variety of kinases, including AKT (17), and that transcriptional 
activity of androgen receptor can be regulated by AKT-mediated phosphorylation (22). On 
the other hand, there is contradictory evidence with regards to the role IGF-1/IGF-1R on 
androgen receptor signaling (23). 
In this study, we observed that Zyflamend® concomitantly inhibited the expression 
of IGF-1R and androgen receptor and its nuclear translocation. Based on the reports in the 
literature, it seemed logical that these effects could be coordinately mediated via the 
PI3K/AKT pathway. When CWR22Rv1 cells were treated with the PI3 kinase inhibitors, 
wortmannin and LY294002 inhibited cell proliferation to the same extent as Zyflamend®; 
however, expression of androgen receptor was not changed. 
In an effort to clarify the role of PI3K/AKT in this process, we observed that IGF-1 
increased pAKT levels; however, it had no effect on androgen receptor levels, total or 
nuclear, when evaluated by immuno-fluorescent staining. In contrast, Zyflamend® treatment 
significantly reduced androgen receptor levels, independent of IGF-1.  This regulation 
appears to be at the transcriptional and translational levels as protein stability was 
unaffected. Furthermore, Zyflamend® did not down-regulate pAKT despite inhibiting the 
expression of IGF-1R and AR; and in fact, in some instances pAKT levels appeared to be 
increased in the presence of Zyflamend®. It is possible that overexpression of pAKT could 




phosphorylation-dependent (involving AKT), targeting the androgen receptor for 
degradation by proteasomes (24). This hypothesis seems plausible given the fact that over-
expression of pAKT (by infecting CWR22Rv1 cells with the adenovirus myrAKT) was 
inversely correlated with androgen receptor expression, but the levels of androgen receptor 
were unaffected by wortmannin despite reducing pAKT levels, the downstream target of 
PI3K. Similarly, pAKT failed to alter the levels of androgen receptor in androgen-
independent LNCaP-AI cells (derived from androgen-dependent LNCaP cells), or following 
knocked down of AKT1 by siRNA (25). 
Androgen receptor is critical to castrate-resistance/androgen-independence in more 
advanced forms of prostate cancer. Mutations in the androgen receptor are associated with 
castrate-resistance and appear to have gains of function that enhance the activation of androgen 
receptor (26-27). CWR22Rv1 cells have two isoforms and one mutant at 874 (substitution of 
tyrosine for histidine) (28), enhancing androgen receptor activity and resisting the effects of   
androgen deprivation. One is a 114-kDa protein and other one is a 75~80-kDa protein.  The 114-
kDa protein has a duplication of exon 3 encoding zinc finger domain of the androgen receptor 
DNA-binding site and the truncated protein lacks the ligand-binding domain (LBD), referred to 
as ARΔLBD, in COOH-terminus (18). These two isoforms don‟t exist in the parental cell line, 
CWR22 cells. These two isoforms are constitutively expressed, where the smaller isoform 
remains active in a hormone-deprived environment.  It is possible that these changes could have 
influenced how pAKT regulates and IGF-1/IGF-1R influences androgen receptor signaling. 
 




castrate-resistant relapse following hormone deprivation. It has been postulated that upregulation 
of IGF-1/IGF-1R signaling contributes to this process. Zyflamend® appears to antagonize these 
events by inhibiting the expression of IGF-1R and androgen receptor, resulting in significant 
reductions in nuclear localization. Whether these effects are mediated, in part, by PI3K/AKT 
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Effects of a Combination of Herbal Extracts on Multiple Prostate 







Prostate cancer (PrC) is the second deadliest cancer of males in the USA. Hormone 
ablation therapy (HAT), a major therapy for metastatic forms of the disease, results in tumor 
regression; unfortunately, residual cells re-grow in the absence of androgens (castrate-resistant), 
and the disease is invariably fatal within 2 years. Diet is not an appropriate primary therapy 
following metastasis or for refractory forms of the disease; however, diet may be effective as an 
adjuvant to HAT, potentially extending the latency period and delaying relapse and/or inhibiting 
refractory growth. Zyflamend® is a combination of extracts from multiple herbs, each with 
reported anti-cancer properties. There is evidence that this combination is far more effective than 
any herb in isolation. We and others have demonstrated that Zyflamend® can inhibit growth of 
various PrC cell lines, but no studies have investigated its potential use in vivo using a model of 
metastatic PrC. In this study, the inhibitory effect of Zyflamend® was examined using androgen-
dependent and castrate resistant tumors in a mouse model that mimics the phases of this terminal 
stage of the disease. At human equivalent doses, Zyflamend® potentiated the effects of HAT in 
initiating tumor regression, where the time needed to reduce tumor size was almost cut in half 
and the response of the tumors to intervention was less variable.  Zyflamend® reduced the 
expression of a number of biomarkers linked to PrC progression including pAKT, prostate 
specific antigen (PSA), histone deacetylases and androgen receptor. In summary, this is the first 
paper to report that a combination of herbal extracts when provided at human equivalent doses 
can potentiate the effects of hormone deprivation therapy on the regression of PrC and inhibit the 






Prostate cancer (PrC) is the most commonly diagnosed solid malignancy and has become 
the second leading cause of cancer-related deaths in men in most Western developed countries 
(1). Once tumors become metastatic, they are very difficult to treat, and prognosis is poor with a 
5-year survival rate of 31% (2). For the most part, PrC is temporarily responsive to hormone 
deprivation therapy as prostate epithelial cells are dependent on androgens for growth.  
Metastatic PrC can be divided into four distinct phases, all of which play an important 
role in determining the inevitable outcome of this disease (Figure 4.1). Phase I involves initial 
tumor growth following metastasis (i.e., bone). This is an androgen-dependent process 
characterized by continued increases in levels of prostate specific antigen (PSA). Phase II 
involves hormone ablation therapy (HAT; also referred to as hormone deprivation therapy) 
followed by tumor regression (characterized by reductions in PSA levels).  Although more than 
95% of patients will respond to HAT and enter into a stabilization phase (Phase III), most find 
their PrC will eventually relapse and become hormone refractory (Phase IV). This castrate-
resistant phase of the disease is invariably fatal with treatments that delay death by only a few 
months. If we can delay tumor relapse, inhibit growth of androgen-dependent and refractory 
tumors, and understand some of the mechanisms related to disease progression, we might be able 








Figure 4.1 The theoretical phases of metastatic prostate cancer with androgen ablation therapy 
(HAT). 
 
A preclinical experimental model mimicking this disease process has been developed 
using CWR22 cells. These androgen-dependent PrC tumor cells, when used in a xenograph 
mouse model, will grow into solid tumors in the presence of testosterone. These tumors will 
regress following testosterone ablation and eventually relapse into a refractory cell line  
(CWR22R cells) generating castrate-resistant tumors (3). CWR22Rv1 cells are a stable 
immortalized cell line that is derived from the CWR22R lineage.  These cells are considered 
castrate-resistant because they can grow in the absence of androgens despite having a functional 
androgen receptor (4). Our previous work has demonstrated that diet can potentiate the effects of 





Currently, the use of medicinal herbs and their bioactive compounds have been shown to 
have beneficial effects on reducing models of PrC. Combinations of herbs and bioactive 
phytochemicals have been shown to be more effective than when used individually and it has 
been argued that these combinations are more clinically relevant because of their synergistic 
effects (6-7). Zyflamend® is one such combination.  Zyflamend®, a polyherbal preparation 
derived from the extracts of ten common herbs, appears to provide clinical improvement to 
patients diagnosed with high grade prostatic intraepithelial neoplasia (HGPIN), a preneoplastic 
form of PrC (8). In addition, Zyflamend® has been shown to reduce proliferation in a variety of 
PrC cell lines by modulating genes that impact the cell cycle and apoptosis (9-11) at 
concentrations believed to be physiologically relevant where the individual herbs had no effect 
(Huang 2010).  
Using castrate-resistant CWR22Rv1 cells we have demonstrated that Zyflamend® 
inhibits cell growth using physiologically relevant concentrations and these effects can be 
attributed to reductions in androgen receptor expression and increases in the cell cycle inhibitor 
p21 as regulated by histone acetylation (Huang 2010).  However, no studies have used this 
experimental model (in vivo) to test the impact of bioactive herbals as the disease progresses 
from androgen-dependent to androgen-independent tumor growth. As such, this study will 
investigate the effects of Zyflamend® on androgen-dependent and castrate-resistant tumor 
growth in vivo and determine if there is preclinical value when used in conjunction with hormone 






One of the animal models to study the natural responses of prostate cancer cells to 
hormone deprivation is the use of CWR22 PrC cells, derived from a primary tumor, which was 
established by Pretlow‟s group in 1993. CWR22 PrC cells are highly androgen dependent and 
cells regress after androgen removal and then relapse to transform an androgen-independent line, 
CWR22R. Relapse of tumor is in 30-50% of the animals within 3-10 months of castration (3). 
CW22RRv1 cells are castrate-resistant cells derived from relapsed CWR22 cells. CWR22Rv1 
cells can survive in the absence of androgen but still response to androgen due to their isoforms 
of androgen recpetors (4) while these two isoforms don‟t exist in parental CWR22 cells. CWR22 
cell line and its derivative, CWR22Rv1 cells, serve a good model to study the progression of 
prostate cancer to refractory.  
Currently, the use of medicinal herbs and their bioactive compounds have been shown to 
have the beneficial effects on reducing prostate cancer progression and incidence. A combination 
of medicinal herbs is believed to have synergistic anticancer effects. In a CWR22Rv1 athymic 
nude mouse model, green tea polyphenols (GTPs) and EGCG postponed the tumor by 100% (54 
days) and 33% (36 days) versus control (26 days), indicating the use of combination of 
phytochemicals inhibited prostate cancer cell growth, synergistically (12). These results showed 
that green tea polyphenols is more effective than single green tea bioactive compound, EGCG. 
Further, Zyflamend®, a polyherbal preparation derived from the extracts of ten common herbs, 
appears to provide clinical improvement to patients diagnosed with high grade prostatic 
intraepithelial neoplasia (HGPIN), a preneoplastic form of the disease (8). In addition, 
Zyflamend® has been shown to reduce proliferation in a variety of PrC cell lines by modulating 
genes that impact the cell cycle and apoptosis (9-11). To understand the effects of Zyflamend® 




used and represented the different stages following hormone ablation therapy. 
4.2 Materials and Methods 
4.2.1 Supplement 
Zyflamend® (New Chapter, Inc.,  Brattleboro, VT)  is a combination of the extracts of 
ten herbs commonly used in food preparations (ginger, rosemary, turmeric, Chinese goldthread, 
holy basil, hu zhang, barberry, oregano, green tea and basil skullcap) (Table 4.1) (10) .  
4.2.2 Cell lines  
Human prostate cancer cell line, CWR22Rv1, was purchased from American Type 
Culture Collection (Rockville, MD). CWR22Rv1 cells are a castrate-resistant cell line that were 
maintained in RPMI 1640 media supplemented with 10% fetal bovine serum under an 
atmosphere of 5% CO2 at 37
o
C. CWR22 cells (originally provided by Dr. Thomas Pretlow, Case 
Western Reserve University, Cleveland, OH) are an androgen-dependent human prostate cancer 
cell line that is propagated through donor mice (serial transplanted tumors) that are sensitive to 
androgen withdrawal, and thus, share greater similarity with primary prostatic tumors than 













Chinese Goldthread 5.1 
Holy Basil 12.8 
Hu Zhang 10.2 
Barberry 5.1 
Oregano 5.1 
Green Tea 12.8 











Five-week old castrated athymic male (nu/nu) nude mice (Harlan Sprague Dawley, Inc., 
Indianapolis, IN) were housed in wired cages with free access to water and fresh food and in a 
temperature-controlled room with 14 h periods of light and 10 h periods of darkness. The health 
of the animals was monitored daily. All animal manipulations were approved by the University 
of Tennessee Institutional Animal Care and Use Committee and were conducted in accordance 
with the Guide for the Care and Use of Laboratory Animals (1996, NRC).  
4.2.4 Diets 
The background diets used in this study were based on the composition of a typical 
Western diet with the following energy distribution: carbohydrate at 50%, fat at 34%, and protein 
at 16%.  These diets were based on a modified version of the US17 diet (Research Diets, New 
Brunswick, NJ; diet # D05010801). The lipid composition was also designed to mimic that of the 
Western diet, ~15% monounsaturated fats, ~13% saturated fats and 6-7% polyunsaturated fatty 
acids (PUFA) where the PUFA distribution included 6% linoleic acid (LA), 0.7% alpha-linolenic 
acid (ALA), 0.09% long chain n-3 PUFA (eicosapentaenoic acid, EPA, plus docosahexaenoic 
acid, DHA), and 0.09% arachidonic acid (AA). The human equivalent doses of these PUFA for 
the murine diets were derived from human daily intakes of 15 g, 1.33 g,  200 mg and 200 mg for 
LA, ALA, EPA+DHA and AA,  respectively, as shown in table 4.2. Human equivalent dose of  
Zyflamend®, which is ~2 one-gram capsules/d (13) or 0.32 % (g/100 g mouse diet),  was used in 
the diet to maximize our ability to translate the results. When extrapolated based on differences 
in metabolic activity, the level of Zyflamend® is equivalent to a daily dose of 16 mg/day/mouse. 
We chose extrapolations using metabolic activity based on data evaluating interspecies 










Table 4.2 The dietary compositions in control diet and in Zyflamend® diet 
Compositions Control Zyflamend® 
 
gm kcal gm kcal 
Protein 17.4 15.8 17.4 15.8 
CHO 54.7 49.7 54.7 49.7 










    Casien 150 600 150 600 
L-Cystine 3 12 3 12 
Corn starch 295 1180 295 1180 
Maltodextin 10 75 300 75 300 
Sucrose 100 400 100 400 
Cellulose 50 0 50 0 
Cocoa butter, deodorized 33 297 33 297 
Linseed oil, RBD 3.95 35.55 3.95 35.55 
Paml oil, bleached, deorderized 42 378 42 378 
Safflower oil 23 207 23 207 
Sunflower oil 21.6 194.4 21.6 194.4 
Olive oil 0.79 7.11 0.79 7.11 
Zyflamend (dry weight) 0 0 0.53 0 
ARASCO (0.04g AA/ g) 8.75 78.75 8.75 78.75 
DHASCO (0.04g DHA/ g) 8.75 78.75 8.75 78.75 
Alpha linolenic acid, estyl ester 0 0 0 0 
Oleic acid, estyl ester 5.9 53.1 5.9 53.1 
t-BHQ 0.03 0 0.03 0 
Mineral mix S10026 10 0 10 0 
Calcium phoshate, dibasic 13 0 13 0 
Calcium carboate 5.5 0 5.5 0 
Potassium citrate 16.5 0 16.5 0 
Vitamin mix V13401 10 40 10 40 
Choline bitartrate 2 0 2 0 
Alpha Vitamin E acetate 0.13 0 0.13 0 
Total 877.9 3861.66 877.9 3861.66 
 
Fatty Acids (%) mole 
Total amount 100   100 
 Total saturated fatty acid (SFA) 37.9 
 
37.7 
 Total monounsaturated fatty acid (MUFA) 41.4 
 
41.4 
 Total polyunsaturated fatty acid (PUFA) 20.7 
 
20.9 
 Total n-6 PUFA 18.6 
 
18.8 
 Total n-3PUFA 2.1  2.1 
 Ratio PUFA/SFA 0.6 
 
0.6 
 Ratio PUFA/MUFA 0.5 
 
0.5 








4.2.5 Fatty acid analysis for diets 
Fatty acid analysis of the diets was performed as described previously (15) with the 
following modifications. Samples of powdered diets (100 mg), suspended in 0.9% saline with an 
internal control (1, 2-diheptadecanoyl-sn-glycerol-3-phosphorylcholine (Matreya LLC, Pleasant 
Gap, PA), were extracted with chloroform/methanol (1:2 v/v) followed by extraction (x2) with 
chloroform. Lipids were saponified with 0.5N NaOH/MeOH at 86C for 15 minutes, followed 
by trans-methylation with BF3 in MEOH (Thermo Fisher Scientific, Morris Plains, NJ) at 86C 
for 10 minutes. The preparation was neutralized with 0.7 N HCl in MeOH followed by the 
addition of saline. The fatty acid methyl esters were extracted with hexane and measured using a 
Hewlett Packard HP 5890 Series II Gas Chromatograph (Agilent Technologies, Inc. Santa Clara 
CA) with flame ionization detector and a DB23 fused silica capillary column (0.25 mm i.d. x 
0.25 µm film; J&W Scientific, Folsom, CA), with hydrogen as the carrier gas. Fatty acids were 
identified when compared to standards (NuChek Prep, Elysian, MN). 
4.2.6 Design of Xenograft Experiments  
4.2.6.1 Androgen-dependent CWR22Rv1 tumor growth 
CWR22 prostate cancer cells were grown in donor mice (five-week old castrated athymic 
male (nu/nu) nude mice) prior to transplantation into the experimental mice. Following growth of 
xenograft tumors, the tissues were homogenized with BD Matrigel™ Basement Membrane 
Matrix (BD Biosciences, San Jose, CA) and subcutaneously inoculated into the right flank of the 
animals while a sustained-release testosterone pellet was implanted subcutaneously. One week 
after transplantation the animals were divided into two dietary groups, ±Zyflamend 




days (Figure 4.2A). Food intake, body weights, tumor size and wet weight, and serum PSA levels 
were measured at the end of the experiment. 
4.2.6.2 Androgen-dependent CWR22 tumor growth following hormone deprivation 
CWR22 prostate cancer cells were maintained in ten donor mice (five-week old castrated 
athymic male (nu/nu) nude mice) prior to transplantation into sixty experimental mice as 
described above. Sixty mice involved in the experiment were randomly divided into two groups, 
30 for the control group and 30 for the Zyflamend® group. Tumors were allowed to grow in the 
presence of a slow-releasing testosterone pellet. When the tumors reached a size of 1.0 cm in 
diameter, the testosterone pellet was removed and mice were put on their respective diets (30 
mice/group; two dietary groups, ±Zyflamend®) as shown in figure 4.2B. Additional identical 
experiment was repeated and ten animals were used in each group. This experiment was 
terminated at day 4 following testosterone pellet removal and xenograft tissues and blood 
samples were collected for analysis.  The composition of the diets is described in Table 4.2. 
Regression of the tumors was monitored following the removal of testosterone after the animals 
were placed on diet. Food intake, body weights, tumor size and serum PSA levels were measured.  
4.2.6.3 Castrate-resistant CWR22Rv1 tumor growth: 
CWR22Rv1 cells (1 × 10
6
) were suspended in serum-free RPMI 1640 medium mixed 
with BD Matrigel™ Basement Membrane Matrix (BD Biosciences, San Jose, CA) at a ratio of 
1:1 (v/v) and subcutaneously inoculated into the right flank of the animals. After tumor cells 
were injected, the animals were maintained on the background diet for 8 days to avoid dietary 
interference with initial tumor growth and cell survival, where upon 30 animals were randomly 




Measurements of tumor size were initiated at day 0 and monitored every other day. Tumor 
volume was calculated using a formula of [0.5×length×width
2
] (16). Food intake and body 
weights were measured every day. Serum PSA levels and tumor wet weights were measured at 
the end of the study.  Tumors did not grow in two animals in the control group and one animal in 














Figure 4.2 Dietary designs on androgen-dependent CWR22 xenograft model and castrate-
resistant CWR22Rv1 xenograft model. A. CWR22 prostate cancer cells and testosterone pellets 
were transplanted into the athymic male (nu/nu) nude mice prior to switch to the experimental 
diet. Following transplantation (1 week), twenty mice were randomly placed into two groups 
(n=10/group), as indicated as day 0, and the study was terminated at day 16 when the length of 





xenograft model following testosterone pellets removal. CWR22 prostate cancer cells and 
testosterone pellets were transplanted into the athymic male (nu/nu) nude mice prior and the 
tumors were allowed to grow to a length of 1.0- 1.5 cm.  The mice were then randomly placed 
into two dietary groups (n=30 /group), ±Zyflamend®. Additional identical experiment was 
repeated and ten animals were used in each group. This experiment was terminated at day 4. C. 
Dietary design using a castrate-resistant CWR22Rv1 xenograft model. CWR22Rv1 prostate 
cancer cells were transplanted into the athymic male (nu/nu) nude mice.  After 8 days, the mice 
were randomly placed into two dietary groups ±Zyflamend® (n=10 /group). The study was 





4.2.7 RNA isolation and quantitative RT-PCR 
 
Total RNA was isolated from CWR22 xenograft tissues using Trizol reagent (Invitrogen, 
Carlsbad, CA) followed by chloroform extraction. The aqueous phase was precipitated in 100% 
isopropanol and the pellet was washed in 75% ethanol prior to re-suspension in RNase-free water. 
Contaminating DNA was removed from RNA samples using Turbo DNA free™ kit (Ambion, Inc. 
Austin, TX) and then the concentration of total RNA was measured using NanoDrop 1000™ 
(Thermo Scientifc Wilmington, DE). Total RNA (2 μg) from each sample was mixed with 
MultiScribe™ Reverse Transcriptase, RNase Inhibitor, dNTP Mixture, random hexamers, RT 
buffer, MgCl2 solution and incubated at 25℃ for 10 min, 48℃ for 30 min and 95℃ for 5 min to 
reverse transcribe to cDNA using TaqMan® reagent kit (Applied Biosystems, Carlsbad, CA).   
cDNA samples were used for quantitative RT-PCR (ABI Prism® 7300 Real-Time PCR System, 
Applied Biosystems, Carlsbad, CA). cDNA (0.7μl) was used as a template for qPCR 
amplification with primer sets (2.5 μM) of androgen receptor sense, 5‟- 
CCTGGCTTCCGCAACTTACAC-3‟ and antisense 5‟- GGACTTGTGCATGCGGTACTCA-3‟, 
and prostatic specific antigen sense, 5‟ - ACCAGAGGAGTTCTTGACCCCAAA-3‟ and 
antisense 5‟- CCCCAGAATCACCCGAGCAG-3‟ were examined. Amplification was performed 
using a standard thermocycle  program beginning with an initial temperature at 94°C for 1 min 
followed by 30 cycles of 94°C for 15 sec, 50°C for 30 sec and 72°C for 2 min. Each sample was 
examined in triplicate and the amounts of PCR product were normalized with 36B4, 5‟-
TGCATCAGTACCCCATTCTATCA-3‟ and 5‟-AAGGTGTAATCCGTCTCCACAGA-3‟ as 




4.2.8 Western blotting   
Xenograft tissues (20 mg) were lysed in the presence of cell lysis buffer (Cell Signaling 
Technology®, Inc. Danver, MA). Protein content of the lysates were quantified by BCA protein 
assay kit (Pierce Biotechnology, Inc., Rockford, IL). Lysates (20 ug) were fractioned by 8~12% 
SDS-PAGE and transferred to a polyvinylidine diflouride (PVDF) membrane by electroblotting.  
The membranes were blocked using 5% nonfat dry milk in 0.1% tris buffered saline-Tween-20 
(TBST) for 1 hour and were incubated in TBST containing primary antibodies overnight at 4°C. 
The membrane was incubated with anti-mouse or anti-rabbit secondary antibody conjugated with 
horseradish peroxidase (HRP) (Cell Signaling Technology®, Inc. Danver, MA). Protein 
expression was detected with a Pierce ECL Western Blotting detection system. Each membrane 
was exposed to Hyperfilm Film (GE Healthcare, Piscataway, NJ). Antibodies of AR, phosphor-
AKT, AKT (Cell Signaling Technology®, Inc. Danver, MA), IGF-1R and COX2 (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA) were used. β-actin (with anti-β-actin antibody (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA)) was used as the control. 
4.2.9 Serum PSA measurement 
Serum PSA levels were measured using PSA ELISA kit (MP Biomedicals, Solon, OH) as 
per manufacturer‟s instructions. Briefly, blood was harvested and serum was isolated by 
centrifugation (13,000 x g at 4 °C for 20 min). PSA concentration was calculated based on 






4.2.10 Statistic analysis 
The results are presented as mean ± SEM and are analyzed by a two-way ANOVA when 
multiple comparisons were made. Differences were considered significant at p<0.05.  
4.3 Result 
4.3.1 Effects of hormone ablation on select biomarkers  
The impact of hormone deprivation on select biomarkers of PrC was compared in a 
xenograph model using CWR22-derived tumors prior to and after the removal of a testosterone 
pellet in castrated athymic nude mice. Following testosterone removal, protein levels of 
androgen receptor, pAKT (the activated form of AKT), insulin-like growth factor -1 receptor 
(IGF-1R) and cyclooxygenase-2 (COX-2) were reduced by 85%, 60%, 46% and 49%, 











Figure 4.3 Protein expression of androgen receptor (AR) and phospho- AKT (pAKT) in CWR22-











Figure 4.4 IGF-1R and COX2 expression (protein) from CWR22-derived tumors from mice on 







































4.3.2 Effects of Zyflamend® on the growth of CWR22 xenograft tumors  
CWR22 cells were transplanted into the flank of athymic nude mice in the presence of 
testosterone (a slow-releasing pellet inserted subcutaneously) and tumor growth was monitored 
in mice fed diets devoid of or containing Zyflamend®. After 16 days on diet, tumor size was 
significantly smaller (>50%) in those animals consuming Zyflamend® (Figure 4.5).  There were 
no differences in body weights and food intake (Table 4.3). Circulating PSA levels were 
positively correlated with tumor size, where reductions (~40%) in tumor weight (wet weight) and 
PSA levels (ng/ml) mimicked the reductions (~50%) in tumor size.  Expression of PSA mRNA 
was significantly reduced in tumors from mice fed Zyflamend® compared to mice fed the 
control diet; however, androgen receptor expression (protein and mRNA) was unaffected by diet 





Table 4.3 Tumor sizes and biological indices from CWR22-derived tumors from mice on the 
Control and Zyflamend®-supplemented diets. 




Relative tumor size (100%) 4.08±0.82 2.03±0.35 0.042 
Tumor wet weight (g) 0.25±0.05 0.153±0.03 0.132 
Food intake (g/d) 4.79±0.08 4.96±0.06 0.324 
Body weight (g) 33.3±0.88  35.24±01.11 0.967 









Figure 4.5 Tumor growth of CWR22cells inserted into the flank of nude (nu/nu) mice. The tumor 
size was measured and calculated using a formula of 0.5×length×width
2
 and presented as a ratio 


































4.3.3 Effects of Zyflamend® on the growth of CWR22 xenograft tumors following 
hormone ablation 
CWR22 cells were transplanted into the flank of athymic nude mice in the presence of 
testosterone and allowed to grow. When the tumors reached the appropriate diameter (1.0-1.5 cm) 
the testosterone pellet was removed, the animals were placed on their respective diets 
(±Zyflamend®) and tumor regression was monitored. Figure 4.6A represents the change in 
tumor size for each animal in each group following hormone deprivation. Within the first 4 days, 
tumors appeared to continue to grow in the control-fed animals prior to regression (Figure 4.6C), 
while tumor size in the Zyflamend®-fed group was reduced, after which time, tumor size 
continued to decline in both groups where Zyflamend® had a significantly greater effect 
compared to controls (within the first 20 days). The variability of response to hormone ablation 
was significantly smaller with Zyflamend® (Figure 4.6B). The length of time to reduce tumor 
size by an average of 50% in the Zyflamend® and control groups was 11days and 19 days, 
respectively (p<0.05) (Figure 4.6C). In addition, PSA levels (ng/ml) were correlated with tumor 
size (Figure 4.6D) and this was reflected in a reduction of PSA mRNA expression, but the 
changes in mRNA and protein levels of androgen receptor were not significant (Figure 4.7).   
Expression of IGF-1R was reduced post- versus pre-hormone ablation (Figure 4.4), but 
Zyflamend did not reduce IGF-1R expression further (Figure 4.4). Histone deacetylase 5 (HDAC 
5) expression (mRNA) was lower in the Zyflamend® group compared to expression in tumors 
from the control group (Fig. 7). Food intake among dietary groups were not different (Table 4.4), 
but the animals in the Zyflamend® group lost less weight compared to those on the control diet 








Figure 4.6 The impact of hormone deprivation on CWR22-derived tumors from mice on Control 
or Zyflamend®-supplemented diets. A. Relative tumor sizes in each individual animal over 100 
days. B. Mean variances of relative tumor size for each dietary group over 100 days.. C. Changes 
in mean tumor volume for the first 20 days following hormone deprivation (mean±SEM). D. 








































































































Figure 4.7 Expression of androgen receptor (AR) and PSA from CWR22-derived tumors from 
mice on diets from mice on Control or Zyflamend®-supplemented diets at day 4 following 
hormone deprivation. A. AR and PSA RNA expression levels of xenograft tissues were detected 








































Figure 4.8 mRNA expression of class I and II histone deacetylases (HDACs) from CWR22-
derived tumors from mice on diets from mice on Control or Zyflamend®-supplemented diets at 





Table 4.4 Tumor sizes and biological indices from CWR22-derived tumors at day 4 compared to 
day 0 following testosterone pellets removal in mice fed Control or Zyflamend®-containing diets. 
    
  Control diet Zyflamend® diet p-value 
Relative tumor size compared to day 0 
(100%)* 
1.27±0.09 0.50±0.04  <0.001 
Food intake (g/d) 6.0±0.46 6.1±0.44 0.638 
Weight change (g)  -1.0±0.13  -0.5±0.15 0.001 
PSA (ng/ml) 81.0±11.16 58.8±8.12 0.187 




4.3.4 Effect of Zyflamend® on androgen-independent growth of CWR22Rv1 
xenograft tumor 
Castrate-resistant CWR22Rv1 cells were transplanted into the flank of castrated athymic 
nude mice (in the absence of testosterone). After 8 days, the mice were switched to diets devoid 
of or containing Zyflamend® and tumor growth was monitored. After 12 days on their respective 
diets, tumor size was significantly smaller (46%) in those animals consuming Zyflamend® as 
tumor growth began to diverge within the first 2 days on the experimental diets (Figure 7.9A). 
Food intake and weight gain were not significantly different among dietary groups (Table 4.5). 
PSA levels (ng/ml) were low and could not be detected in 13/14 animals on the Zyflamend® diet, 
while almost half of the control animals (6/13) had measurable amounts of PSA (Table 4.5). 
Androgen receptor expression (protein) was significantly reduced in the xenograph tumors from 
mice fed Zyflamend® compared to tumors from mice fed the control diet (Figure 7.9B). HDAC 
4 expression (protein) was lower in Zyflamend®-treated tumors compared to tumors from the 















Figure 4.9 Growth of CWR22Rv1-derived tumors from mice on Control or Zyflamend®-
supplemented diets.  A. Tumor size was calculated using the formula 0.5×length×width
2
. B. 
Androgen receptor expression (protein) in CWR22Rv1-derived tumors. C. Expression (protein) 
of histone deacetylases 1 and 4 (HDAC 1 & 4) from CWR22Rv1-derived tumors from mice on 




































































































Table 4.5 Tumor sizes and biological indices from CWR22Rv1-derived tumors from mice on the 
Control and Zyflamend®-supplemented diets.  
 





Animal number 13 14  
Tumor size (cm
3
) 0.24±0.04 0.13±0.03 0.033 
Tumor wet weight (g) 0.18±0.02 0.12±0.03 0.074 
Food intake (g/d) 2.95±0.05 3.10±0.03 0.098 
Final body weight (g) 25.31±0.37 25.19±0.49 0.609 
Weight gain (g) 2.28±0.19 2.91±0.27 0.062 
PSA (ng/ml) 6/13* 1/14*  







There are only a few preclinical experimental models of PrC and most of those do not 
address the progression of metastatic PrC. This paper reaffirms the proof of concept that 
metastatic PrC can be divided into four phases, where each phase may respond differently to 
therapeutic intervention with unique regulatory mechanisms (5).  Furthermore, we propose that a 
mouse model of metastatic PrC may provide a unique opportunity to study the impact of diet as 
an adjuvant to standard therapies, in this case, hormone ablation.  
Metastatic PrC travels to lung, liver and primarily bone. Following diagnosis, hormone 
deprivation therapy is commonly prescribed because prostate epithelial cells are dependent upon 
androgens for growth. This therapy results in tumor regression and stabilization for several years, 
after which time the residual cells appear to become refractory, resulting in castrate-resistant 
regrowth. Unfortunately, this relapse is invariably fatal within two years with few therapeutic 
strategies.  
The experimental model used in this study follows a similar pattern. CWR22 cells are an 
androgen-dependent human prostate tumor cell line that mimics this process (3). When inserted 
subcutaneously in athymic nude mice, these cells grow into a solid tumor, and following 
androgen withdrawal the tumors shrink. However, relapse can occur within a year in the absence 
of androgens and the cells from the relapsed tumor, CWR22R, are classified as castrate resistant. 
An immortalized cell line derived from these relapsed cells, CWR22Rv1 cells, has been used as 
a model of castrate-resistant PrC because they produce human PSA, contain an active androgen 




a model of metastatic PrC in the presence or absence of testosterone and is an extension of our 
previous work with this cell model in vitro and dietary intervention on metastatic PrC (5). 
Zyflamend® is derived from the extracts of ten different herbs and each has been 
reported to have medicinal properties in vitro (18-19, 7) and therapeutic value in humans. 
Individuals diagnosed with HGPIN are at increased risk for developing PrC (20). When this 
polyherbal preparation was used in a Phase I clinical trial with patients diagnosed with HGPIN, 
reductions in PSA and re-diagnosis to benign forms of prostate tissue were reported in 60% of 
the participants (8, 13). Based on this data, we investigated the effects of Zyflamend® in our 
model of castrate-resistant PrC. The oral dose of Zyflamend® for these in vivo studies was 
calculated to be ~600 mg/kg body weight (0.32% of diet, w/w). Allometric scaling for a human 
dose was based on the equivalent of ~two 1 g soft gel capsules of Zyflamend per day (based on 
energy for allometric scaling between species) (14). To give an idea how this dose may relate to 
individual doses of phytochemicals typically used, if one were to estimate the levels of 
curcumoids from Zyflamend®, it would be equivalent to ~2 mg/kg body weight per mouse per 
day (Zyflamend® contains ~0.35% curcumoids, w/w). These levels are well below typical levels 
of curcumin supplemented to the diets of rodents (200-1000 mg/kg body weight) (19). We used 
these conservative values in an effort to provide human relevance to our data. 
We investigated the effects of Zyflamend® on androgen-dependent and castrate-resistant 
PrC tumor growth and explored its interaction with androgen deprivation. We focused our 
attention on several key biomarkers that have been related to metastatic PrC, vis, PSA and 




CWR22 cells represent those androgen-dependent metastatic tumor cells at the initial 
phase of tumor growth prior to hormone ablation treatment.  Zyflamend® significantly inhibited 
tumor growth. This was somewhat surprising because dietary long chain n-3 polyunsaturated 
fatty acids (i.e., eicosapentaenoic acid, EPA), which are noted to be antitumorigenic, had no 
significant effect in this model at this phase of the disease process (5). We and others have 
shown that Zyflamend® inhibits growth of other androgen-dependent PrC cells in vitro (i.e., 
LNCaP cells) at doses considered physiologically relevant (review earlier chapters of this 
dissertation) (9). These previous effects were related to increases in biomarkers of apoptosis 
(caspase-3 activity and PARP cleavage) along with increased expression of the cell cycle 
inhibitor p21 (9). While we did not look at p21 expression in these tumors, we previously 
reported that Zyflamend® robustly increases p21 expression via epigenetic regulation in 
CWR22Rv1 cells. 
Of interest is the ability to use diet to potentiate the impact of standard therapies, in this 
case, hormone derivation. The use of Zyflamend® in conjunction with the removal of 
testosterone potentiated tumor regression where the time needed to reduce tumor size was almost 
cut in half  (11 days versus 19 days) and the response of the tumors to intervention was more 
immediate with Zyflamend® and less variable. The reduction in tumor size correlated with 
circulating PSA levels, an important biomarker for prostate epithelial cells and tumor growth. 
Although androgen receptor expression (mRNA) declined following hormone deprivation, we 
did not observe a significant reduction with dietary Zyflamend®, but PSA expression in those 
tumors was significantly reduced. The lack of a significant effect on androgen receptor 
expression with Zyflamend post-HAT could be due the fact that androgen receptor expression 




Furthermore, pAKT expression, a reported regulator of androgen activation (21) was also 
significantly down-regulated (by ~60%) when testosterone was removed (independent of 
Zyflamend®).  
This data and the data previously published with dietary EPA (5) are the first evidence to 
suggest that diet could be used in conjunction with hormone ablation to potentiate its effects. 
This could have an impact on potentially extending the subsequent latency phase prior to relapse, 
a key objective for increased survival (5). In humans, the latency period associated with hormone 
ablation therapy lasts approximately two years (22). Refractory growth is typically treated with 
chemotherapy in an effort to prolong survival by several months.  It has been suggested that 
reactivation of androgen receptor in the absence of androgens may be one of the underlying 
mechanisms associated with this relapse (23).  
Zyflamend® inhibited growth of CWR22Rv1-derived tumors by 46% within 12 days on 
diet. These cells represent a model of castrate-resistant tumor relapse. These results are 
consistent with data that shows Zyflamend® inhibits the growth of CWR22Rv1 cells in vitro 
(review earlier chapters of this dissertation), and with other androgen-independent PrC cells (i.e., 
PC3 cells) (11). The latter effect was associated with reductions in 12-lipoxygenase expression 
and phosphorylation of the cell cycle regulator retinoblastoma protein (Rb) (11).  
The effects in the current study were associated with significant reductions in androgen 
receptor expression (protein). Similarly, using CWR22Rv1 cells in vitro androgen receptor 
expression and nuclear localization was significantly reduced following Zyflamend® treatment, 
further supporting our in vivo results. In addition to the reduction of androgen receptor, the 




Zyflamend® is a general HDAC inhibitor (class I and II) in CWR22Rv1 cells in vitro and here 
we show that Zyflamend® inhibits HDAC expression in xenograph tumors (Fig. 4.7 and 4.8). 
Inhibition of HDACs has been shown to inhibit androgen receptor and PSA expression in both 
hormone sensitive and insensitive PrC cells and thus could be likely mechanisms behind our 
effects (24). 
In summary, we used a preclinical model of metastatic PrC by which the impact of diet 
can be investigated prior to or following hormone ablation therapy. Zyflamend®, a mixture of 
polyherbal extracts, inhibited androgen-dependent (CWR22 cells) and castrate-resistant tumor 
growth (CWR22Rv1 cells) in vivo using levels in the diet consistent with those recommended for 
humans. PSA levels correlated with tumor growth (or regression) and expression was reduced 
when Zyflamend® was added to the diet in all phases of the disease. Similarly, androgen 
receptor expression was inhibited following hormone deprivation and in castrate-resistant tumors, 
and these effects could be mediated by down-regulation of pAKT and HDAC expression. The 
mechanisms of action for Zyflamend® have been clearly elucidated in vitro (review earlier 
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Summary and Conclusions 
Advanced prostate cancer is aggressive and is the second leading cause of death from 
cancer in males in the United State. Malignant prostate cancer cells metastasize to adjacent and 
more distant tissues, such as bone. The characteristics of advanced prostate cancer can be 
outlined by four phases. The cells in the first phase are androgen-sensitive. Their growth is 
dependent upon the presence of androgens. Typically, the resultant tumors undergo regression 
following hormone ablation/deprivation therapy (Phase II), followed by an extended remission 
phase (Phase III). This remission phase usually lasts 3 to 5 years and eventually relapses (Phase 
IV). The relapsed cells grow in the absence of androgens and appear to be more aggressive with 
typical survival times limited to 1-2 years. Therefore, a critical barrier in treating advanced 
prostate cancer is finding effective treatments for castrate-resistant forms of the disease.  
In this study, CWR22 cells and relapsed CWR22 cells (in the form of CWR22Rv1 cells) 
were chosen for the experiments because they represent those transitions associated with 
advanced prostate cancer. CWR22 cells only grow in the athymic nude mice supplied with 
testosterone and produce prostate specific antigen (PSA). After removal of testosterone, CWR22 
cells regress and eventually relapse. These relapsed cells are referred to as CWR22R cells. They 
are castrate resistant, but still respond to androgens and can produce PSA. Similarly, prostate 
cancer cells in patients whose disease has relapsed following androgen ablation therapy express 
androgen receptors and produce PSA. 
The use of herbs, botanicals and their bioactive components have been shown to be 




Zyflamend®, a polyherbal preparation derived from the extracts of ten herbs, appears to provide 
clinical improvement to patients diagnosed with high grade prostatic intraepithelial neoplasia 
(HGPIN), a preneoplastic form of the disease. Our findings suggest that Zyflamend® reduced 
cell proliferation in a variety of PrC cell lines, including RWPE-1 (representing premalignant 
cells), LNCaP (androgen-dependent), PC3 (androgen-dependent) and CWR22Rv1 (castrate-
resistant) cells.  
In the androgen-dependent phase of the disease (Phase I), Zyflamend® significantly 
inhibited growth of CWR22-derived tumors. Then, Zyflamend® potentiated the effects of 
hormone ablation (Phase II), reducing expression of PSA and HDAC5, important therapeutic 
targets. In an effort to address the issue of castrate-resistant relapse (Phase IV), CWR22Rv1 cells 
were used under in vivo conditions where mechanisms were extensively explored under in vitro 
conditions. Zyflamend® significantly inhibited CWR22Rv1-derived tumor growth. In vitro 
experiments demonstrated that the antitumorigenic effects of Zyflamend® were mediated, in part, 
by significantly enhancing the cell cycle inhibitors p21 and p27. These effects were mediated 
epigenetically via hyperacetylation of histones. Universal inhibition of histone deacetylases was 
responsible for these effects and these results were, in part, recapitulated in vivo (reductions in 
HDAC1 and 4 expressions).  
Important to castrate-resistant relapse is the reactivation of the androgen receptor, 
possibly through the upregulation of IGF-1/IGF-1R signaling, and finding therapies that can 
target this process is a priority. Zyflamend® inhibited the expression of IGF-1R and IGF-1-
stimulated cell proliferation.  Levels of androgen receptor in CWR22Rv1 cells were reduced, 




mediated by PI3K/AKT signaling through crosstalk between IGF-1R and androgen receptor; 
however, a definitive link could not be made.  
The effects of Zyflamend are multifactoral and this is probably why it is so effective at 
the doses used. It inhibits tumor cell proliferation as evidenced by BrdU incorporation, inhibition 
of the expression of Ki67, fatty acid synthase and its upstream regulator SREBP-1c, and  it 
increases markers of programmed cell death (increasing caspase 3 and PARP cleavage and 
reducing Bcl-2 expression). Furthermore, because epigenetic regulation of cancer is an 
environmentally driven process, finding therapeutic interventions that target acetylation and 
methylation processes are a priority. Zyflamend® appears to be a universal HDAC inhibitor. As 
such, the results in vitro and in vivo provide a logical rationale for the use of Zyflamend® in 
clinical trials because it appears to be effects at physiologically relevant concentrations, it has 
multiple mechanisms, in addition to its efficacy in multiple phases of a model of advanced 
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